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ABSTRACT 
Eissler, Christie L. Ph.D., Purdue University, December 2013. Characterization of the 
specificity and functions of the protein phosphatase Cdc14. Major Professor: Mark C. 
Hall. 
 
Protein phosphorylation is perhaps the most ubiquitous posttranslational 
modification in eukaryotes and recent studies suggest that upwards of 75% of human 
proteins are phosphorylated.  Many proteins are phosphorylated at multiple sites, often 
controlled by multiple kinases and phosphatases.  Multisite phosphorylation can 
differentially affect the functional and regulatory cellular outcomes.  For example, 
dephosphorylation of a protein at a particular site may inhibit nuclear localization of a 
protein while dephosphorylation of a different site may be necessary for enzymatic 
activation of a protein. Thus, multisite protein phosphorylation can complicate our 
understanding of the biological significance and the functional consequences of protein 
phosphorylation.  A clearer understanding of the functional consequences associated 
with an individual proteins phosphorylation status requires methods that can 
quantitatively monitor each phosphorylation site on a protein independent of one 
another.   
Here, I present a general method for quantitatively studying multisite protein 
phosphorylation.   I demonstrate that label-free selected reaction monitoring (SRM) 
mass spectrometry is comparable to conventional assays for measuring reaction rates 
and steady-state kinetic parameters of phosphatases and kinases.  Furthermore, I 
demonstrate that this method can be employed to measure the activity of an enzyme 
towards multiple substrates in a single reaction, suggesting that this approach is a useful 
tool for studying substrate specificity of kinases and phosphatases.  I also demonstrate 
xiv 
that this method can be used to simultaneously measure relative rates of 
dephosphorylation at individual phosphorylation sites on intact protein substrates in the 
context of a whole cell extract. 
Failure to properly regulate protein phosphorylation during the cell cycle 
compromises genome integrity and can lead to cancer and other disease states. The 
protein phosphatase Cdc14 has been implicated in the general reversal of cyclin 
dependent kinase (Cdk) phosphorylation at the end of cell division. However, the 
molecular mechanisms responsible for ordered Cdk substrate dephosphorylation are 
poorly understood. The protein Fin1 is a multisite phosphorylated protein and is a 
known substrate of Cdk and Cdc14.  The SRM assay affords one the ability to examine 
the dephosphorylation of individual phosphorylation sites on an intact protein substrate, 
a task that cannot be accomplished using a conventional phosphatase assay.  Therefore, 
using the SRM assay, I examined the dephosphorylation of Fin1 in response to Cdc14 
treatment.  This approach to studying protein dephosphorylation revealed that Cdc14 
differentially dephosphorylates Fin1 such that the three phosphoserine sites that were 
monitored were readily dephosphorylated while the phosphothreonine site was 
resistant to Cdc14 activity.  Importantly, these results suggested that Cdc14 may 
specifically reverse only a subset of Cdk-dependent phosphorylation events.  These 
findings sparked an investigation into the specificity of Cdc14 and eventually lead to the 
identification of the first experimentally defined consensus sequence for Cdc14. 
Using our experimentally defined consensus sequence for Cdc14, we searched 
the yeast proteome for potential Cdc14 substrates.  From this list, I identified the 
protein Yen1, a Holliday junction (HJ) resolvase, as a potential Cdc14 substrate. HJs are 
DNA intermediates that form during homologous recombination (HR) in response to 
repair of DNA double strand breaks. Yen1 has been shown to resolve HJs in a cell cycle 
and phosphorylation dependent manner; however, the protein kinase and phosphatase 
responsible for modulating the resolvase activity of Yen1 in vivo were previously 
unidentified. Here I demonstrate that Yen1 is indeed a bona fide physiological Cdc14 
substrate and that dephosphorylation of distinct clusters of Cdk sites on Yen1 by Cdc14 
xv 
is important for 1) modulating the nucleocytoplasmic localization of Yen1 and 2) 
triggering enzymatic activation of Yen1.  I show that dephosphorylation of Yen1 is 
essential for its biological function in recombination based repair of DNA damage. These 
findings suggest that Cdc14 plays a previously unknown role in DNA repair and 
maintenance of genome stability
1 
CHAPTER 1. NEW INSIGHTS INTO THE SPECIFICITY AND FUNCTIONS OF THE PROTEIN 
PHOSPHATASE CDC14 
1.1 Protein kinases and phosphatases 
Reversible phosphorylation is a common cellular mechanism for regulating 
protein function and the physiological pathways in which they act.   Phosphorylation is 
controlled by the opposing catalytic activities of protein kinases and protein 
phosphatases. Protein kinases catalyze the addition of phosphate to the hydroxyl group 
of specific Ser, Thr, or Tyr residues in their substrates and phosphatases catalyze the 
hydrolysis of phosphate from these residues. Changes in a protein’s phosphorylation 
state can regulate its function in diverse ways, including altering interactions with 
protein partners, enzymatic activity, intracellular localization, and stability. Protein 
phosphorylation is nature’s way of diversifying the proteome and providing a molecular 
switch for dynamic control of protein function. 
The actions of protein kinases and phosphatases are highly regulated, often both 
temporally and spatially. Furthermore, their activities must be precisely targeted to the 
appropriate substrates through molecular recognition mechanisms. Many studies have 
been conducted to understand both how the activities of protein kinases are regulated 
and the factors that govern their substrate selection.  For many protein kinases this has 
led to the identification of consensus sequences which can facilitate identification of 
their substrates.  In contrast to protein kinases, protein phosphatases were initially 
thought of as non-specific housekeeping proteins necessary only to reset the 
phosphorylation status of proteins to a basal state [14].  Recently, the 
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idea that protein phosphatases possess distinct substrate specificities comparable to 
kinases and are also subject to complex regulation has been gaining traction in the 
scientific community. Still, our understanding of how phosphatases modulate biological 
processes and signaling pathways is far behind that of kinases, and is in part hindered by 
our lack of knowledge of the direct substrates for many phosphatases.    
 Several decades of research have provided a wealth of knowledge defining how 
the sequential activation of numerous kinases directs the faithful execution of the cell 
division cycle, a process critically dependent on the precisely timed and ordered 
execution of many complex events, including genome duplication and chromosome 
segregation. Our current models of cell cycle control are centered around the activities 
of cyclin-dependent kinase (Cdk) complexes, distinct waves of which appear and 
disappear to control progression into and through the cell division program. However, 
only in recent years has it become clear that multiple protein phosphatases also play 
active and critical roles in regulating the cell cycle including reversing the effects of Cdk 
phosphorylation [15].  Very little is known about the biochemical mechanisms that 
dictate timing and substrate specificity of cell cycle phosphatase activities.  
  In this review I will highlight the protein phosphatases that contribute to reversal 
of Cdk phosphorylation during cell division.  I will first briefly discuss the factors that are 
known to contribute to substrate recognition by the protein phosphatases PP1 and 
PP2A and then focus on the protein phosphatase Cdc14.  I will describe recent research 
that has led to the identification of a consensus substrate sequence for Cdc14, speculate 






1.2 Cdk substrate phosphorylation and dephosphorylation contributes to cell cycle 
regulation 
The ordered phosphorylation of numerous substrates by sequential waves of 
Cdk complexes is essential to ensure unidirectional movement through the cell cycle 
and is required for faithful execution of the cell division program.  Cdk substrate 
phosphorylation regulates virtually all aspects of cell division, such as transcription, cell 
morphogenesis, organelle inheritance, DNA replication, chromosome segregation, 
centrosome duplication, spindle positioning and elongation, and entry of the cell into 
mitosis (for and excellent review of Cdk controlled processes in budding yeast, see [16]).  
Cdks exert their effects on the cell cycle via association with a cyclin subunit.  Upon 
formation of the cyclin-Cdk complex, Cdks are targeted to their substrates where they 
phosphorylate the consensus sequence S/T-P-X-K/R or the minimum consensus 
sequence S/T-P. A defined set of cyclin-Cdk complexes becomes active in late G1 and, 
through the ordered association of the Cdks with different cyclin subunits, Cdk activity 
continues to increase until a cell reaches metaphase. 
Late mitotic events such as chromosome segregation, spindle disassembly, 
cytokinesis and general reversal of the mitotic state thereby resetting the cell to a G1 
state are all dependent upon the orderly dephosphorylation of key proteins by the 
mitotic protein phosphatases.  The protein phosphatases Cdc14, PP1 and PP2A have all 
been linked to reversal of Cdk-dependent protein phosphorylation [17-22].  In recent 
years it has become clear that the mechanisms that drive ordered substrate 
dephosphorylation are likely to be as complex as the mechanisms that lead to protein 
phosphorylation.  It has also become clear that in some cases a protein is the substrate 




1.3 Mitotic protein phosphatases reverse Cdk-dependent phosphorylation 
 
1.3.1 PP1 and PP2A 
PP1 and PP2A are both members of the serine/threonine phosphoprotein 
phosphatase (PPP) family and, like other family members; they function as part of 
multimeric protein complexes [23].  The catalytic subunit of PP1 associates with a 
regulatory subunit which directs substrate specificity and subcellular localization [8, 24] 
(Figure 1-1A).  PP2A functions as a trimeric protein complex composed of a catalytic 
subunit, scaffolding subunit and a regulatory subunit (Figure1-1B).  The regulatory 
subunit of PP2A is responsible for substrate selection and localization [7, 8].  The binding 
of regulatory proteins is thought to generate distinct substrate binding platforms 
through which the phosphatase can selectively bind and dephosphorylate its substrates.  
In this model, substrate specificity is defined primarily by binding interfaces distal from 
the enzyme active site and the active site itself need not exquisitely distinguish between 
different types of phosphorylated sequences. Consistent with this notion, the catalytic 
subunits of both PP1 and PP2A exhibit little discrimination towards substrates in the 
absence of the regulatory subunits [8].  In some cases, substrate selection of PP1 and 
PP2A is influenced by phosphorylation of the regulatory subunits to allow the binding of 
one substrate while excluding another [7, 8]. 
Although it is understood that PP1 and PP2A are important for proper regulation 
of the cell cycle, exactly how they exert their forces is not thoroughly understood.  This 
is largely due to a lack of precise substrate knowledge.  Due to the complex regulatory 
and targeting mechanisms of PP1 and PP2A, identification of PP1 and PP2A substrates is 
typically done on a substrate by substrate basis.  To some extent, PP1 substrates can be 
identified in silico by the presence of an RVxF motif [24] [4].  However, this approach 
should be used with caution as the RVxF docking motif is also used by PP1 substrate-
targeting proteins, thus the distinction between the two based on the presence of the 
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docking motif is at present quite blurred [24].  Currently, a consensus sequence to 
signify that a protein is a PP2A substrate awaits identification [7]. 
 
1.3.2 Cdc14 
The protein phosphatase Cdc14 is a member of the dual specificity phosphatase 
(DSP) family, a subgroup of the larger protein tyrosine phosphatase (PTP) super family 
[25].  As a member of the DSP family, Cdc14 might be expected to possess catalytic 
activity towards phosphorylated serine, threonine and tyrosine amino acids.  Pioneering 
work on Cdc14 in the budding yeast Saccharomyces cerevisiae revealed that Cdc14 is 
essential for terminating Cdk activity at the end of mitosis and led to the initial model 
that Cdc14 might be responsible for the bulk of Cdk substrate dephosphorylation to 
promote mitotic exit and cytokinesis [17]. However, subsequent studies in a variety of 
other organisms suggest that Cdc14 is required neither for Cdk inactivation nor for bulk 
Cdk substrate dephosphorylation [26, 27]. The specific biological functions of Cdc14 
outside yeast model systems are still poorly characterized and the extent to which 
functions might be conserved across divergent eukaryotes remains unclear. 
In stark contrast to PP1 and PP2A, Cdc14 does not function as part of a 
multimeric complex.  Instead, Cdc14 is composed of multiple domains which contain 
important localization signals which, in combination with the catalytic domain, direct 
substrate specificity (Figure 1-1C)  [3].  In 2003 Gray and colleagues solved the crystal 
structure of human Cdc14B bound to a synthetic phosphopeptide [3].  This work shed 
some initial light on the structural characteristics of Cdc14 that drive the genetic and 
biochemical linkage between Cdc14 and Cdk [17] [18]. More recent work in the past two 
years has provided additional insight into Cdc14 substrate specificity that suggests these 
enzymes likely act on only a subset of Cdk substrates and may play specialized roles in 
the reversal of Cdk phosphorylation. 
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1.4 Molecular determinants of Cdc14 specificity 
Cdks phosphorylate serine or threonine immediately followed by proline (the +1 
position) [28]. The crystal structure of Cdc14 bound to the peptide substrate A(pS)PRRR 
revealed that at the interface of the A and B domains lies a small hydrophobic pocket 
immediately adjacent to the catalytic site [3]. Importantly, this hydrophobic pocket is 
organized to form optimal van der Waals contacts between the amino acid side chains 
of Cdc14 and substrates with a proline in the +1 position.  While Cdks will phosphorylate 
substrates with the minimal consensus sequence Ser/Thr-Pro, optimal Cdk substrates 
have been found to contain basic amino acids in the +2 to +4 position, depending on the 
type of Cdk.  In addition to revealing the hydrophobic pocket that provides +1 Pro 
specificity, the Cdc14B crystal structure also revealed an acidic grove leading to the 
catalytic site composed of highly conserved amino acids.  It was initially hypothesized 
that the acidic groove could contribute to Cdc14 substrate selectivity by making ionic 
contacts with the same basic residues downstream of the phosphorylated residue that 
are preferred by Cdks [3]. This would provide additional overlap in the kinase and 
phosphatase specificity.  However, no electron density was detected for the substrate 
basic amino acids in the crystal structure and only minimal effects on catalytic activity 
towards the co-crystallized model peptide substrate were observed upon replacement 
of the basic residues [3].  Furthermore, inspection of the amino acid sequences 
surrounding pSer and pThr sites of known budding yeast Cdc14 substrates reveals that 
more often than not, the known substrates contain at least one basic residue within the 
+3 to +5 positions.  These observations begged the question; if a protein is 
dephosphorylated by Cdc14 at multiple sites, does Cdc14 exhibit preference for one site 
over another? 
In order to answer such a question, we employed a mass spectrometry based 
assay that allows for the simultaneous and quantitative measurement of individual 
phosphorylation sites as an intact protein is dephosphorylated by Cdc14  [2]. The 
protein Fin1 is a known Cdk and Cdc14 substrate [29].  As discussed in chapter 2, using 
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our SRM assay to examine dephosphorylation of the individual phosphorylation sites on 
Fin1 by Cdc14, we found that Cdc14 does in fact exhibit a preference for some Cdk 
phosphorylation sites over others.  What was shocking about these findings however, 
was the observation that while Cdc14 was able to readily dephosphorylate Cdk-
dependent phosphoserine residues, Cdk-dependent phosphothreonine residues were 
resistant to Cdc14 activity [2].  In a more thorough investigation of these findings we 
found that not only is the serine specificity conserved amongst yeast and human Cdc14 
phosphatases, this specificity is due to spatial constraints in the phosphatase active site 
[2].  The active site of Cdc14 is highly conserved from yeast to humans and within the 
HCX5R motif that defines the active site lies an invariant alanine amino acid.  
Replacement of the phosphoserine with a phosphothreonine in the crystal structure of 
Cdc14 suggested that the serine selectivity is a result of a steric clash between the active 
site alanine side chain and the methyl group of the phosphothreonine substrate [2].  To 
test this idea, the active site alanine was mutated to a glycine thus providing more space 
in the active site of Cdc14 to accommodate the methyl group of a phosphothreonine 
substrate.  Importantly, we found that this mutation reduced the specificity of Cdc14 for 
phosphoserine substrates 100 fold, suggesting that the observed specificity is largely 
due to spatial restrictions in the active site of Cdc14 [2].  From these studies we 
concluded that Cdc14 is a phosphoserine-selective phosphatase, despite its evolutionary 
relationship to the PTP family.  The implications of these findings will be discussed 
below. 
Having identified the unique serine only specificity of Cdc14, we became intrigued 
in identifying other factors that direct Cdc14 substrate specificity. Using a synthetic 
peptide library to test the contribution of basic amino acids on Cdc14 catalysis we found 
that an absolute requirement for Cdc14 catalysis is that the substrate must contain a 
basic amino acid in the +3 position relative to the phosphoserine (see chapter 3).  We 
expanded on this specificity and found that additional basic residues in the +4 and +5 
positions further enhanced the catalytic activity of Cdc14.  To better understand the 
biochemical basis for the strong preference of Cdc14 for substrates with a +3 basic 
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residue, we used an optimal Cdc14 substrate peptide and performed docking and 
molecular dynamics (MD) simulations using the crystal structure of hCdc14B and a 
homology model of the budding yeast homologue (chapter 3).  We found that the strict 
specificity of Cdc14 for substrates containing a +3 basic residue is not due to ionic 
interactions between the substrate +3 amino acid and the acidic groove of Cdc14.  
Rather, it is due to the formation of cation-pi contacts between the side chain of the +3 
basic residue and a conserved pocket in the active site of Cdc14 adjacent to the 
hydrophobic pocket that accommodates the proline in the +1 position (chapter 3).  In 
light of our recent findings demonstrating that a +3 basic amino acid is required for 
Cdc14 catalysis and our previous characterization of Cdc14 as a serine only phosphatase 
[2], it has become clear that the active site of Cdc14 imposes strict requirements for 
substrate selection. 
 
1.5 Identification of Cdc14 substrates 
Despite the many studies that have been conducted to identify protein kinase 
substrates and how kinase substrate phosphorylation governs cell cycle regulation, 
knowledge about phosphatase substrates and how their dephosphorylation contributes 
to cell cycle regulation is significantly lacking compared to kinases.  To begin to fill this 
gap in knowledge, several studies have been conducted to identify Cdc14 substrates in 
both budding and fission yeast [30, 31].  One challenge associated with identifying 
phosphatase substrates is the transient nature of the interaction. In studies aimed to 
identify Cdc14 substrates, the transient nature of the phosphatase-substrate complex is 
compensated for by overexpression of a substrate trapping mutant of Cdc14.  
Dephosphorylation of proteins by members of the PTP family is dependent upon an 
active site cysteine residue.   Mutation of the active site cysteine to serine abolishes the 
catalytic activity of the phosphatase yet the phosphatase retains the ability to bind 
substrates [25].  The Cdc14 substrate trapping mutant thus allows for stable formation 
of the phosphatase-substrate complex which can be subsequently isolated from cells.  
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Though much information regarding proteins that may be Cdc14 substrates and proteins 
that may interact with Cdc14 for different reasons have been gained from studies using 
the substrate trapping approach, there are several caveats associated with substrate 
trapping mutants.  One caveat is the possibility that in addition to identifying Cdc14 
substrates, such an approach may also be identifying stable interaction partners of the 
substrate that is bound to the active site of Cdc14.  Thus, if a protein is identified as a 
substrate under such conditions, additional biochemical studies are necessary to 
validate that it is in fact a bona fide substrate.  An additional challenge associated with 
utilizing the substrate trapping approach to identify Cdc14 substrates is the possibility 
that one could be identifying a skewed set of substrates since for each molecule of 
enzyme only one substrate can be bound. It is possible that identified substrates will be 
limited to those in close proximity to the phosphatase, those with the highest binding 
affinity for the phosphatase or highly expressed substrates.  For this reason, it is possible 
that even if Cdc14 has a very high affinity for a substrate, if the substrate is present at a 
very low intracellular concentration, or phosphorylated at low stoichiometry, it may not 
be identified. 
 
1.6 Identification of a Cdc14 consensus sequence 
Though identifying Cdc14 substrates has traditionally been a daunting task, the 
recent work from our group characterizing Cdc14 enzyme specificity has established an 
optimal consensus substrate sequence [2, 32] Furthermore, we demonstrated that the 
stringent specificity of Cdc14 for substrates containing the consensus sequence pSer-
Pro-x-K/R-K/R or pSer-Pro-x-K/R-x-K/R (where x is any amino acid) can be exploited to 
identify novel, high efficiency Cdc14 substrates (chapter 3).  It is possible that in the 
future this consensus sequence could be a valuable tool to help weed out substrates 
from non substrates in large scale studies which utilize the substrate trapping approach. 
To date, in higher eukaryotes, only a handful of Cdc14 substrates have been 
identified.  Previously, we found that like its yeast counterpart, hCdc14A and B substrate 
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dephosphorylation is dependent upon the presence of basic residues [2].  These findings 
are in line with previous studies which have demonstrated that expression of either 
hCdc14A or hCdc14B in budding yeast is sufficient to compliment the cell cycle arrest of 
cdc14-1 and cdc14-3 cells [33, 34].  These results suggest that at least some aspects of 
Cdc14 selectivity are conserved between yeast and humans.  Currently, it is unclear if 
hCdc14A and hCdc14B are capable of recognizing the same substrates or if each 
homologue recognizes a distinct set of substrates.  Experimental evidence suggests that 
while some hCdc14A and B substrates may overlap, the two homologues likely also 
dephosphorylate distinct substrates [35].  In order to fully understand how Cdc14 
regulates mitotic events in higher eukaryotes, we need to first understand how it 
recognizes its substrates. Therefore, studies utilizing a synthetic peptide library to 
experimentally identify a Cdc14 consensus sequence in higher eukaryotes may prove to 
be very fruitful and could lead to a better understanding of the importance of Cdc14. 
 
1.7 Biological implications of Cdc14 specificity 
In budding yeast, it has long been thought that Cdc14 is the primary phosphatase 
responsible for reversing Cdk-dependent phosphorylation [17].  Our recent work in 
characterizing the enzymatic specificity of the budding yeast Cdc14 strongly argues that 
Cdc14 is responsible for reversing only a subset of Cdk-dependent phosphorylation 
events [2, 32]. While Cdks are known to phosphorylate substrates that contain the 
minimal consensus sequence of a serine or threonine followed by a proline [28], current 
studies suggest that these sites would be resistant to Cdc14 activity due to the lack of a 
basic amino acid downstream of the phosphorylated residue.  In recent studies we have 
demonstrated that Cdc14 fails to catalyze the dephosphorylation of threonine residues 
at both the peptide and protein level [2].  Furthermore, we have found that upon 
mutation of serine phosphosphorylation sites to threonine, Cdc14 fails to associate with 
its substrate suggesting that in vivo Cdc14 is selective for phosphoserine containing 
substrates [2, 32].  Taken together, these results strongly suggest that Cdk-dependent 
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threonine phosphorylation likely represents a subset of Cdk substrates that are not 
Cdc14 substrates.   
Such studies suggest that similar to higher eukaryotes, in budding yeast 
additional protein phosphatases may play a previously unappreciated role in reversing 
Cdk-dependent phosphorylation.  In recent years a role for PP2A in reversing Cdk-
dependent phosphorylation in budding yeast has begun to come to light.  A fine 
example of this is the protein Net1.  Net1 is a potent inhibitor of Cdc14 and is 
responsible for keeping Cdc14 sequestered in the nucleolus from G1 until anaphase [36, 
37].  At anaphase onset, Cdk phosphorylates Net1 thereby promoting dissociation of the 
Net1-Cdc14 complex [38] and subsequently leads to nuclear accumulation and 
activation of Cdc14.  Interestingly, Net1 is phosphorylated in metaphase, however; 
Cdc14 is not disengaged from Net1 until anaphase when the activity of PP2ACdc55 
becomes downregulated by separase activation [39].  These studies suggest that during 
metaphase, Cdk dependent phosphorylation of Net1 is directly reversed by PP2ACdc55, 
however; to date no biochemical assays have been conducted to demonstrate that Net1 
is a PP2A substrate.  Of the six sites on Net1 that must be phosphorylated by Cdk to 
disengage it from Cdc14, four sites are threonine residues and two are serine residues 
that lack +3 basic amino acids.  This likely prevents Cdc14 from dephosphorylating them 
and inhibiting its own release. We hope to test this in the future. Importantly, the 
findings of Queralt et. al suggest that one important function of the mitotic exit 
phosphatases may be to work together in a cooperative nature to promote the 
dephosphorylation of a specific set of proteins at a defined time. 
 
1.7.1 Cdc14 specificity may contribute to the ordering of late mitotic events 
Events such as chromosome segregation, spindle disassembly, cytokinesis and 
resetting the cell to a G1 state are all dependent upon reversal of Cdk-dependent 
phosphorylation events.  Importantly, proper segregation of genetic material to the next 
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generation is dependent upon the sequential completion of these events.  For example, 
if the spindle was to disassemble before the chromosomes segregated or if cytokinesis 
was to occur before chromosome segregation, this would lead to catastrophic failure of 
the cell cycle as a result of genome instability, damaged chromosomes or aneuploidy.  In 
budding yeast, Cdc14 clearly contributes to the ordered reversal of Cdk-dependent 
phosphorylation.  However, despite recent advances, the mechanisms responsible for 
driving the ordered dephosphorylation of Cdk substrates by Cdc14 are poorly 
understood.  Recently, Bouchoux and colleagues demonstrated that consistent with the 
need to sequentially dephosphorylate key proteins to promote chromosome 
segregation (such as Ask1), spindle stabilization (Fin1 and Sli15) and spindle disassembly 
(Cdh1), these proteins are dephosphorylated by Cdc14 in an order consistent with their 
expected roles [40].  In order to address mechanisms responsible for directing the 
ordered dephosphorylation of these substrates by Cdc14, Bouchoux et. al tested several 
models and concluded that Cdc14 targets specific substrates when the balance of Cdk to 
Cdc14 activity reaches a defined threshold [40].  The authors could not explain though 
why the threshold would be different for distinct sets of substrates. 
In light of our recent findings, we propose that the threshold of Cdk to Cdc14 
activity required for dephosphorylation is largely a function of the active site specificity 
of Cdc14. In this view, the threshold of Cdk to Cdc14 activity at which Cdc14 substrates 
are dephosphorylated is a reflection of the consensus sequence surrounding each 
phosphorylation site rather than a reflection of the protein as a whole.  This would allow 
Cdc14 to reverse critical phosphorylation sites even in the face of high Cdk activity. 
 
1.7.2 Regulation of nucleocytoplasmic distribution 
One mechanism by which eukaryotes are able to regulate the activity of proteins 
needed for gene transcription and cell cycle regulation is the dynamic 
compartmentalization of proteins between the nucleus and cytoplasm. Due to the 
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composition of the nuclear envelope, transport of proteins between the cytoplasm and 
nucleus is dependent upon the association of a proteins nuclear localization signal (NLS) 
with transport receptor importins such as importin-α [10, 11].  The prototypical classical 
NLS has been elucidated from studies on the SV40 large T antigen and, can be defined 
loosely as K (K/R) X (K/R) (Figure 1-2) [5].  NLS signals enriched with basic residues 
promotes the association of the NLS containing protein with importin α; however, this 
interaction has been shown to be disrupted by phosphorylation of the NLS containing 
protein either within or immediately adjacent to the NLS [10-12].  Due to their 
preference for serine and threonine residues with upstream basic residues, in budding 
yeast, Cdks have been linked to regulating the nucleocytoplasmic shuttling of several 
proteins [41-44]. Recently, Kosugi and colleagues undertook a study to identify proteins 
that contain Cdk-regulated NLSs [11].  In this study, many of the identified 
phosphorylation sites believed to be important for regulating the nucleocytoplasmic 
shuttling of proteins were serine-proline sites that contain a basic residue in the +3 and 
+4 position relative to the phosphoserine.   
In budding yeast, Cdc14 has been shown to modulate the intracellular location of 
the proteins Acm1 [41], Swi6 [45], Whi5 [46], Mcm3 [47], and Swi5 [17, 44].  
Interestingly, of the 34 proteins with a candidate Cdk-regulated NLS identified by Kosugi 
and colleagues, 12 were also identified in our recent screen of the yeast proteome for 
Cdc14 substrates.  Of the remaining 22 proteins identified by Kosugi and colleagues that 
were not identified in our list, 7 of the predicted Cdk-regulated NLSs are threonine sites. 
Recently, we demonstrated that nuclear accumulation of the protein Yen1 is dependent 
on Cdc14 dephosphorylation of two serine residues that encompass the NLS of Yen1 
(chapter 3).  In the work conducted by Kosugi and colleges, they demonstrate that Cdk-
dependent phosphorylation of Yen1 S679, Pds1 S71 and Acm1 S31 (and S48) inhibits 
nuclear accumulation of these proteins.  Interestingly, in our recent work with synthetic 
peptides derived from Cdc14 substrates, the peptides Yen1pS679, Pds1pS71 and 
Acm1pS31 have been found to be our best Cdc14 substrates.  Taken together, it seems 
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plausible that one important biological function of Cdc14, at least in budding yeast, may 
be to work with the protein localization machinery to regulate the intracellular 
localization of a defined set of substrates, specifically during mitosis. The regulated 
import of proteins into the nucleus may be an important mechanism for coordinating 
mitotic progression in organisms that maintain an intact nuclear envelope throughout 
mitosis (closed mitosis), as in budding yeast. This also implies an important function for 
nuclear import factors such as importin α in regulating mitosis. 
 
1.8 The Cdc14 consensus sequence can be used to identify novel substrates 
In higher eukaryotes, very little is known about the exact molecular function of 
Cdc14 though recent studies suggest that it does play a role in repairing damaged DNA 
[48-50].  In fission yeast, the Cdc14 ortholog, Clp1, is released from the nucleolus in 
response to genotoxic stress and, this release is important for full activation of the DNA 
damage checkpoint [51, 52].  Consistent with findings in fission yeast that Cdc14 plays a 
role in DNA damage response; recent work from our lab has identified the Holliday 
junction resolvase Yen1 as the first DNA repair substrate of Cdc14 (chapter 3).    We 
have found that dephosphorylation of Yen1 by Cdc14 is important for maintaining 
genome stability as failure to do so leads to an elevated rate of sister chromatid non-
disjunction (chapter 3).   
Although Yen1 represents the first experimentally verified Cdc14 substrate in the 
DNA damage response in budding yeast, it is likely not to be the only one.  In addition to 
Yen1, the proteins Rad9, Srs2 and Fun30, all of which are known to be important for 
DNA damage repair in budding yeast, were also identified in our screen of the yeast 
proteome for potential Cdc14 substrates (chapter 3).  In considering the work 
conducted in higher eukaryotes and recent work in budding and fission yeast, it seems 
possible that a conserved function of Cdc14 may be to contribute to the repair of 
damaged DNA.   
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Amongst the potential Cdc14 substrates identified using our experimentally 
determined consensus sequence were several proteins with known functions in 
cytokinesis.  The identification of cytokinesis proteins supports the known and 
conserved role of Cdc14 in cytokinesis [18, 53-56].  The recently identified Cdc14 
consensus sequence is a new tool that can be used to probe further into the biological 
function of Cdc14; however, it is important to note that while a role for Cdc14 in 
regulating a biological process may be conserved, its precise substrates that must be 
dephosphorylated may not be. 
 
1.9 Concluding remarks 
While defining the substrate specificity of Cdc14 in budding yeast has provided 
valuable insight into understanding how Cdc14 recognizes its substrates and has 
expanded our knowledge of the biological processes in which Cdc14 activity is important, 
our understanding of the roles and requirements for Cdc14 during the mitotic cell cycle 
is far from complete. Furthermore, there is a drastic lack of knowledge pertaining to 
how phosphatases in general contribute to cell cycle regulation.  One way in which we 
can increase our understanding of how phosphatases regulate the cell cycle is to 
conduct comprehensive studies to define or further define the specificity of the major 
mitotic phosphatases.  Such studies however will be a daunting task as many protein 
phosphatases require the association of regulatory subunits to direct substrate selection.  
It is important to point out that studies designed to examine dephosphorylation of 
phosphatase substrates at individual phosphorylation sites rather than global 
phosphorylation will be of most use.  A fine example of this is the discovery that Cdc14 
is a phosphoserine only phosphatase [2, 57].  Had we conducted our studies by 
examining global protein dephosphorylation, this paradigm changing finding would have 
been missed. 
Recent studies have indicated that overexpression of Cdc14b in humans leads to 
oncogenic transformation [58].  However, virtually nothing is known about the 
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specificity and the substrates of the human Cdc14 phosphatases and so the molecular 
mechanisms driving this transformation are poorly understood.  We have recently 
demonstrated that using a synthetic peptide library derived from a known budding 
yeast substrate, we were able to predict Cdc14 substrates in silico.  This approach is 
particularly useful in understanding the specificity of the Cdc14 phosphatases as unlike 
other phosphatases, to date, they are not known to require accessory proteins and 
there specificity is believed to be directed by protein sequences adjacent to the active 
site.  Such characteristics of Cdc14 lend themselves to in vitro studies as they reduce the 
possibility of promiscuity that is often observed with in vitro studies of other 
phosphatases. For these reasons, it is likely that such an approach could also be used to 







Figure 1-1 Phosphatase – substrate interactions of the mitotic protein phosphatases 
  
A) PP1 substrate (orange) recognition is facilitated by association of the catalytic subunit 
(purple) of PP1 with a regulatory subunit (green).  The association of PP1 with both substrates 
and regulators occurs through multiple low affinity interactions distil from the active site [4]. 
B)  The PP2A holoenzyme complex is composed of a catalytic subunit (purple), a scaffolding 
subunit (blue) and a regulatory subunit (green).  Substrate (orange) selection is dependent 
upon the regulatory subunit.  The regulatory subunit binds to the scaffolding subunit to expose 
an acidic region that is in close proximity to the shallow catalytic cleft thus forming a substrate 
binding groove [7, 8].  In addition to making contacts with the substrate binding groove, 
substrates can also interact with the regulatory subunit at regions distant to the active site 
[13].  C) Cdc14 is a multidomain protein and substrate selection is dependent upon the amino 
acids surrounding the active site.  Cdc14 is shown in purple and the substrate in orange. 
 
























K - (K/R) - x - (K/R) 
pS – P – (K/R/x) – (K/R) – (K/R/x) – (K/R/x) 
Figure 1-2 Comparison of NLS consensus sequence and Cdc14 consensus sequence 
A) The classical NLS that is recognized by importin α is defined by a lysine in position 1 
and basic residues in position 2 and 4 [5].  Phosphorylation of amino acids within the 
immediate vicinity of the classical NLS have been shown to disrupt nuclear localization 
[10].  B) Experimentally defined consensus sequence for Cdc14.  Substrate recognition is 
dependent upon a proline in the +1 position and a basic residue in the +3 position with 




CHAPTER 2. A GENERAL STRATEGY FOR STUDYING MULTI-SITE PROTEIN 
PHOSPHORYLATION BASED ON SELECTED REACTION MONITORING MASS 
SPECTROMETRY AND LABEL-FREE QUANTIFICATION  
2.1 Introduction 
The function of most proteins is regulated in some way by enzymatic post-
translational modifications (PTMs). A large number of covalent PTMs exist in nature and 
can affect many aspects of protein function including enzymatic activity, binding 
partners, stability, structure, and cellular localization. Most PTMs are reversible, and 
therefore allow dynamic control of protein function. Reversible phosphorylation of 
serine, threonine, and tyrosine, controlled by the opposing activities of kinases and 
phosphatases, is the most abundant and heavily studied regulatory PTM in eukaryotic 
cells. At least 75% of human proteins are phosphorylated in vivo [59]and many proteins 
are phosphorylated on multiple sites that can be subject to differential regulation [60], 
often by more than one kinase and/or phosphatase. As an example, more than 100 in 
vivo phosphorylation sites have been mapped on the human anaphase-promoting 
complex (APC), a large E3 ubiquitin ligase complex that regulates progression through 
mitosis [61] [59, 62]. Evidence suggests that the APC is regulated, both positively and 
negatively, by at least four different kinases [63-70]. This complexity makes functional 
studies of protein phosphorylation challenging. There is a need for improved methods 
for detection and quantification of individual PTM sites on multiply modified proteins.  
 Very few analytical methods employed to study phosphorylation, or PTMs in 
general, are effective at quantitatively detecting multiple sites independently on the 
This chapter has been reprinted from Analytical Biochemistry, Eissler,C.L., Bremmer, S. C., Martinez, J. S., 
Parker, L. L., Charbonneau, H., and Hall, M. C.  A general strategy for studying multisite protein 
phosphorylation using label free selected reaction monitoring mass spectrometry.  418(2011) 267-275 
with permission from Elsevier. 
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same protein. Mass spectrometry (MS) is one exception. Reduction of proteins to 
peptides is an effective way to separate the PTMs on a single protein into distinct 
molecules for mass spectral analysis. Tandem MS can provide the sequence of individual 
peptides and the exact location of any PTMs. Although the complexity of biological 
systems poses a constant challenge to the detection and quantification of target 
molecules, the development of affinity enrichment strategies, multi-dimensional 
chromatographic separations, improved instrument designs, and various other 
methodological advances are steadily allowing more comprehensive study of the 
proteome. Selected reaction monitoring (SRM) MS, which relies on the filtering 
capabilities of a triple quadrupole mass spectrometer, has become a popular method 
for direct detection of specific target proteins within complex biological samples. 
Because of its sensitivity and specificity, SRM is also a useful approach for the 
quantitative study of PTM regulation in living systems.  
 To fully understand regulation and function of PTMs it is necessary to measure 
their dynamic changes under different conditions and in response to physiological and 
environmental signals. A variety of methods exist for the absolute and relative 
quantification of proteins and PTMs from peptide-based mass spectral data [71, 72]. 
Most quantitative MS approaches employ some form of stable isotope dilution, which 
has the advantage of allowing simultaneous analysis and comparison of multiple 
samples or a single sample with an internal standard [73-75].  Use of stable isotopes is 
not essential for quantification, however, and a number of “label-free” approaches have 
also been developed [72]. Label-free quantification requires comparison of separate MS 
experiments, which necessitates exquisite care in sample preparation and the 
appropriate controls or standards to account for run to run signal variations. Although 
stable isotope-based methods are generally thought to be more accurate than label-free 
approaches [71], there are important advantages to label-free methods such as 
simplicity and general applicability. With label-free quantification there are no 
specialized reagents required, no extra chemical reaction and sample processing steps, 
and the methods are suitable for any experimental system. For these reasons, label-free 
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quantitative MS methods have important advantages for the study of PTMs and are 
becoming more common.  
 A variety of strategies have been developed for quantitative MS-based analysis 
of phosphorylation and other PTMs (for example [76-82]). The majority of these 
methods rely on stable isotope labeling or addition of specific standards for 
quantification. Some are limited to studies of synthetic peptide substrates or highly 
purified protein preparations or require phosphopeptide enrichment steps. We set out 
to establish a strategy that will be generally useful for the quantitative measurement of 
changes in phosphorylation on intact proteins. Our approach uses label-free 
quantification of phosphorylation stoichiometry [9, 79, 83] for simplicity, compatibility 
with all experimental systems, and practicality for studies of large numbers of 
phosphorylation sites. We used SRM MS of peptides generated by enzymatic digest 
because the sensitivity, specificity, and dynamic range of SRM [84] make it suitable for 
analysis of highly complex biological samples, and it is also capable of simultaneous 
monitoring of up to hundreds of target molecules in a single sample run. Related SRM 
MS methods were developed and used recently. In one case, changes in 
phosphorylation of the Pho4 transcription factor in budding yeast were measured [85], 
but without a rigorous quantification strategy. In another case, autophosphorylation 
sites on the Lyn tyrosine kinase in mouse xenograft tumors were monitored [83]. Our 
strategy is equally useful for studying phosphatases and kinases, and can be applied in 
vitro as an enzymatic assay, or in vivo to quantify changes in many phosphorylation sites 
in response to experimental variables. Among other potential applications, we predict it 
will be very useful for the exploration of kinase and phosphatase specificity. The general 
method is also suitable for studying other PTMs. 
 In this report we describe proof of principle experiments that validate this 
strategy. We demonstrate that SRM MS combined with label-free quantification is 
comparable to conventional assays for measuring reaction rates and steady-state kinetic 
parameters of phosphatases and kinases. We also demonstrate the utility of the method 
for simultaneously monitoring multiple phosphorylation sites on intact protein 
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substrates, including in a whole cell extract, and the potential to reveal different 
responses of individual sites to experimental variables. Possible experimental designs 
and practical aspects of applying this method to large-scale studies in complex biological 
mixtures and in vivo are discussed. 
 
2.2 Results and discussion 
Our goal was to establish an approach to measure the activities of kinases and 
phosphatases on their natural physiological substrates in a site-specific manner that 
could be applied to in vitro and in vivo studies with any experimental system. To 
facilitate use of the approach in complex mixtures such as cell extracts or to monitor 
activities in vivo we used SRM MS on a triple quadrupole mass spectrometer. We also 
chose a simple label-free method for determining PTM stoichiometry for quantification 
[9, 79, 83]. Although SRM has been used previously to measure enzymatic activities, its 
use in measuring kinase and phosphatase activities, or changes in phosphorylation 
stoichiometry under different experimental conditions, has been very limited. To our 
knowledge measurement of phosphatase and kinase activities by SRM MS, particularly 
with label-free quantification, has not been validated by comparison to conventional 
assays. We therefore set out initially to do so using a defined system with synthetic 
peptide substrates and purified enzyme preparations. 
 
2.2.1 Comparison of SRM MS to conventional assays for measuring kinetics of 
phosphatase and kinase activities 
Consistent with other SRM studies using triple quadrupole instruments, product 
detection in our phosphatase reactions was linear over a 10,000-fold concentration 
range with sub-femtomole sensitivity (Figure 2-1A). The dynamic range was limited only 
by the capacity of the HPLC column used and therefore may be even greater. The 
sensitivity was typical for our synthetic peptide substrates but varies substantially with 
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sequence. Precision of SRM measurements was tested by repeat analysis of single 
samples. Run to run variation was consistently less than 4 percent (Figure 2-1B). 
Satisfied with these basic properties of the SRM analysis we next compared initial 
dephosphorylation rates of several phosphopeptide substrates of the yeast Cdc14 
phosphatase measured using a malachite green dye-based colorimetric assay and our 
SRM method to determine if SRM MS is capable of accurate kinetic measurements. 
Individual completed reactions were split and products analyzed by the two methods 
(using a spectrophotometer and mass spectrometer) in parallel.   
 Figures 2-1 C-E show overlay plots of dephosphorylation versus time for three 
phosphopeptide substrates measured using the two independent methods. The plots 
and calculated rates of peptide dephosphorylation were very similar. In our experiments 
we used our previously described method to determine the percentage of peptide 
dephosphorylated at each time point from the substrate and product SRM signals [9] 
and converted this to moles of product formed using the known initial substrate 
concentration. Other approaches are also possible when absolute quantification of 
product is required, including use of stable isotope labeled product as an internal 
standard. 
 We also compared the ability of the conventional and SRM-based phosphatase 
assays to measure reaction velocity as a function of substrate concentration for 
determination of the steady-state kinetic parameters KM and kcat (Figure 2-2A). 
Consistent with the rate measurements, overlays of velocity versus substrate 
concentration plots generated from the independent methods were in close agreement 
and calculated KM and kcat values obtained by nonlinear regression analyses were very 
similar (Table 2-2). To demonstrate that the approach is equally useful for measuring 
kinase activity, we measured KM values for budding yeast Cdk1-catalyzed 
phosphorylation of an unmodified peptide containing a consensus Cdk phosphorylation 
sequence using conventional 32P incorporation compared to SRM MS (Figure 2-2B). 
Again, the plots and calculated KM values were very similar. These results demonstrate 
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that SRM MS can be used for the accurate measurement of phosphatase and kinase 
activities in vitro. 
Since the power of SRM MS lies in its ability to quantitatively measure many 
specific target molecules within a complex mixture, we next demonstrated the 
simultaneous measurement of a mixture of phosphopeptide substrates 
dephosphorylated by Cdc14 (Figure 2-3). The relative rates of dephosphorylation (with 
each peptide’s initial SRM signal normalized to 100%) of seven of our synthetic 
phosphopeptides were measured. Note that most conventional assays for phosphatase 
and kinase activity are not useful for analysis of substrate mixtures and provide only 
global data with multiply phosphorylated substrates because they do not distinguish 
between individual sites. Although the specificity of SRM is not necessarily required for 
measurement of synthetic peptide mixtures of this complexity (standard MS analyses 
will suffice, particularly with high resolution instruments), this approach would allow 
rapid screening of large peptide mixtures, which would be useful for characterizing 
enzyme specificity or identification of potential enzyme substrates. Similarly, the 
approach can be applied to analysis of many phosphorylation sites on intact protein 
substrates in a cell extract following post-reaction enzymatic digest without the need for 
affinity purification or fractionation steps. In these cases, the specificity and sensitivity 
of SRM MS is essential. 
 
2.2.2 Independent measurement of dephosphorylation rates at multiple 
phosphorylation sites on an intact protein substrate 
As an example of the utility of this approach, we simultaneously monitored 
multiple phosphorylation sites on an intact protein substrate of Cdc14, the yeast spindle 
stabilizing protein Fin1 [29]. Recombinant GST-Fin1 was phosphorylated in vitro by 
purified Cdk1 as described in Materials and Methods. Cdk phosphorylation sites are the 
preferred substrates of Cdc14 phosphatases [18, 86] and previous studies have 
demonstrated that Fin1 is regulated by both Cdk and Cdc14 [29]. Intact phosphorylated 
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GST-Fin1 was reacted with Cdc14 and prepared for MS analysis by protease digestion. 
The resulting peptide mixture was analyzed by SRM MS. We monitored both the 
unmodified and phosphorylated forms of 4 peptides containing consensus Cdk sites 
(S/T-P) that are known in vivo phosphorylation sites of biological importance [29, 87-89], 
as well as several additional peptides lacking Cdk1 sites that were used for 
normalization. Estimated initial phosphorylation stoichiometry was similar for each site 
and plotting relative phosphorylation of the individual Fin1 Cdk1 phosphorylation sites 
over time after Cdc14 addition revealed an unexpected difference in apparent 
dephosphorylation rates (Figures 2-4A). These results suggest that not all Fin1 Cdk 
phosphorylation sites are equivalent substrates for Cdc14 and that additional specificity 
determinants may exist. This type of observation can only be made using an assay 
capable of quantifying phosphorylation at individual sites and highlights the potential of 
our method to study kinase and phosphatase specificity using intact multiply-
phosphorylated and physiologically relevant protein substrates, including large protein 
complexes, and in the context of complex mixtures such as cell extracts. 
 
2.2.3 Measuring protein dephosphorylation in a complex mixture 
With an eye towards future implementation of this strategy for studies in vivo 
and in cell extracts, we analyzed our recombinant Fin1 phosphatase reaction products 
again after mixing them with a large excess of trypsin-digested yeast whole cell extract 
(Figure 2-4B). Even within the context of a cell extract, the SRM MS approach was 
specific enough (Figure 2-4C-D) that we could faithfully reproduce the relative 
dephosphorylation rates at all 4 Cdk1 phosphorylation sites (compare 2-4A and 2-4B). 
 
2.2.4 Protocol for an in vivo phosphatase assay 
In Figure 2-5 we outline a potential strategy for an in vivo phosphatase assay, 
using Cdc14 as an example, for which SRM MS could be used to simultaneously monitor 
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a large number of substrate sites under native physiological conditions. The yeast Cdc14 
phosphatase is kept inactive during the majority of the cell cycle by its competitive 
inhibitor, Net1 [90]. Since Cdk sites are preferred Cdc14 substrates , yeast cells can be 
arrested in early mitosis when Cdk activity is high, for example by chemical treatment 
with the microtubule depolymerizing agent nocodazole, or by expression of a non-
degradable securin (Pds1) mutant [91]. Dephosphorylation of Cdc14 substrates is then 
“initiated” by addition of galactose to the culture to ectopically express Cdc14 from the 
GAL1 promoter and aliquots of the culture collected over time. Extracts are made and 
proteins digested under denaturing conditions [92] and the phosphorylation status at a 
large number of specific phosphorylation sites of interest is monitored by LC-SRM MS. 
SRM methods can be developed based on existing phosphoproteomic data [88, 89, 93]. 
This approach would allow for relative rates of dephosphorylation of Cdk sites on many 
proteins to be determined. We expect that similar types of assays could be designed for 
a large number of kinases and phosphatases in many different model systems. A current 
challenge is the ability to detect modified peptides in cell extracts with the required 
sensitivity. Continued improvements in triple quadrupole instrumentation should make 
experiments like this more routine in the near future. 
 
2.2.5 Conclusions and considerations for use of the SRM MS phosphatase/kinase assay 
This method is not useful for discovery and mapping of phosphorylation sites. 
The sites must be known or mapped initially by standard MSMS methods. Like other MS 
analyses of PTMs, success of this method is dependent on generation of detectable 
peptides by protease digestion. Certain PTMs will inevitably be difficult to detect due to 
lack of conveniently located digestion sites. Although we have demonstrated previously 
that two modification sites on a peptide can be individually quantified using SRM MS [9], 
existence of several PTMs on a single peptide makes individual quantification difficult. 
Nonetheless, we conclude from our studies that combining SRM MS with label-free 
quantification methods provides a powerful, flexible, and accurate approach for the 
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study and characterization of phosphatases and kinases on natural protein substrates. 
Although we have focused here on reversible protein phosphorylation, this method is 
equally applicable, in principle, to the study of other PTMs. SRM MS also offers the 
potential for high throughput analysis of hundreds of modification sites simultaneously. 
Even with partially purified proteins or large protein complexes, the specificity of SRM is 
a significant advantage because it largely avoids complications of overlapping signals 
from other peptides of similar m/z. The use of label-free quantification allows the 
method to be used with any experimental system, improves sensitivity by eliminating 
additional chemical reaction or sample processing steps, and obviates the need for 




Table 2-1 SRM method parameters 
Phosphopeptide names begin with “p” and the phosphorylated amino acid is in parentheses. 
“SP” refers to synthetic peptides; Peptides with “Std” were internal standards used for 
normalization of recombinant protein data.  Trypsin digested samples were normalized using 
Std1 and Std3. Lys-C digested samples were normalized with Std2 and Std3. GluFib and AngII 
peptides were used for normalization in synthetic peptide experiments.  Data in Figure 3 were 
normalized with GluFib, SP10 and SP5. CE, collision energy. 
Peptide 
Name Peptide Sequence 
Precursor ion Transition 1 Transition 2 
m/z charge m/z charg ion CE m/z charg ion CE 
SP 1 VKGNELRSPSKRRSQI 464.4 4+ 543.1 3+ y14 15 585.8 3
+ y15 15 
pSP1 VKGNELR(S)PSKRRSQI 484.5 4+ 569.8 3+ y14 23 612.5 3
+ y15 23 
SP 2 TDYALRRSPIKTIQIS 621.2 3+ 822.4 2+ b14 22 865.2 2
+ a15 22 
pSP 2 TDYALRR(S)PIKTIQIS 647.9 3+ 603.4 2+ y10- 18 862.4 2
+ b14 18 
SP 3 MISPSKKRTIL 425.1 3+ 757.5 1+ y6 15 844.4 1
+ y7 15 
pSP 3 MI(S)PSKKRTIL 451.8 3+ 629.4 1+ y5 23 757.5 1
+ y6 23 
SP 4 DSKQLLSPGKQFRQI 619.9 3+ 875.5 1+ y7 25 972.4 1
+ y8 25 
pSP 4 DSKQLL(S)PGKQFRQI 646.6 3+ 875.5 1+ y7 25 972.4 1
+ y8 25 
SP 5 SSASLLSSPSRRSRPS 558.5 3+ 706.3 2+ y13- 25 741.9 2
+ y14- 20 
pSP 5 SSASLLS(S)PSRRSRPS 585.5 3+ 654.8 2+ y11 20 754.8 2
+ y13 25 
SP 6 TDVTPESSPEKLQFGS 861.4 2+ 1305.6 1+ Y12 26 905.5 1
+ y8 26 
pSP 6 TDVTPES(S)PEKLQFGS 901.4 2+ 1385.6 1+ Y12 28 1072.5 1
+ y9 28 
SP 7 NNTPSSSPLKGSESK 511.6 3+ 652.8 2+ y13 6 602.3 2
+ y12 6 
pSP 7 NNTPSS(S)PLKGSESK 538.3 3+ 692.8 2+ y13 7 642.3 2
+ y12 7 
SP 8 ARFKNGLMSPERIQQQ 476.5 4+ 586.3 3+ b15 4 543.6 3
+ b14 4 
pSP 8 ARFKNGLM(S)PERIQQQ 661.6 3+ 855.5 2+ b14 30 759.2 1
+ a7 30 
SP 9 FLKPPMRISPNKTDGMK 490.7 4+ 567.3 3+ Y15 5 524.6 3
+ y14 5 
pSP 9 FLKPPMRI(S)PNKTDGMK 510.8 4+ 777.9 2+ y13 14 588.3 3
+ b15 6 
SP 10 KKVVRKLSFHVYEDE 626.1 3+ 865.6 2+ b14 20 661.7 2
+ b11 20 
GluFib EGVNDNEEGFFSAR 786 2+ 1171 1+ y10 30 684 1
+ y6 30 
Ang II DRVYIHPF 523.8 2+ 647.2 1+ b5 15 NA NA NA NA 
Ser36 DNVFVRLSMSPLRTTSQK 699.3 3+ 975.3 2+ b17 30 884.3 2
+ y15 30 
pSer36 DNVFVRLSM(S)PLRTTSQK 726.0 3+ 924.4 2+ y15 30 843.9 1
+ b7 30 
Ser54 EFLKPPMRISPNK 519.9 3+ 1039.6 1+ y9 25 942.6 1
+ y8 25 
pSer54 EFLKPPMRI (S)PNK 546.4 3+ 1022.6 1+ y8 25 924.7 1
+ y9 25 
Thr68 HSIQVTPR 469.4 2+ 713.3 1+ y7 12 600.7 1
+ y15 12 
pThr68 HSIQV(T)PR 509.7 2+ 793.4 1+ y6 14 880.2 1
+ y7 17 
Ser117 IQNSDHITNIIFPTSPTK 676.2 3+ 777.5 1+ y7 20 1136.6 1
+ b10 20 
pS117 IQNSDHITNIIFPT(S)PTK 702.8 3+ 1023.3 1+ b9 20 1136.6 1
+ Y8 20 
Std1 DAPFENDLPR 587.3 2+ 890.3 1+ Y10 16 614.7 1
+ y9 16 
Std2 DAPFENDLPRAK 458.4 3+ 813.5 1+ y7 15 942.6 1
+ y8 15 
Std3 LNSMLANEGK 538.8 2+ 963.7 1+ y9 15 849.7 1
+ y8 15 
fmols peptide
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(A) SRM signal intensity as a function of peptide amount for one of the phosphopeptide substrates (pSP4)
used in this study, demonstrating linear dynamic range of the SRM-based kinase/phosphatase assay. Axes 
are log scale. (B) The indicated synthetic peptides were analyzed five independent times and the 
corresponding SRM signals plotted. The horizontal lines indicate the sample means. The percent deviation 
from the mean was then calculated for each trial. The average deviation was less than 4% for all peptides. 
Data from one transition are shown, but were nearly identical for the second transitions. (C-E) 
Dephosphorylation of the peptides pSP1 (C), pSP2 (D), and pSP4 (E) by Cdc14 as a function of time using a 
conventional spectrophotometric assay () compared to the SRM assay (). Data points are the mean of 
3 independent experiments. Error bars represent standard error of the mean. Lines are from linear 
regression analyses. The average difference in rates (from regression analysis) between the 2 assays was 
11 ± 5 %.   
Figure 2-1 Dynamic range and dephosphorylation rate analysis
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Figure 2-2  Validation of SRM for measurement of phosphatase and kinase steady-state kinetic parameters. 
(A) Dephosphorylation of peptide pSP4 by Cdc14 was plotted as a function of substrate concentration using either the 
spectrophotometric () or SRM () assays. (B) Relative phosphorylation (% of Vmax) of peptide SP1 by Cdk1 was 
plotted as a function of substrate concentration for the sake of comparison using either the spectrophotometric () 
or SRM () assays. In both panels, data represent the mean of 3 independent experiments and error bars represent 
standard error of the mean. The Michaelis-Menten equation was fit to the data using GraphPad Prism to generate the 
nonlinear regression lines and obtain the steady-state kinetic parameters KM (panels A and B) and kcat (panel A only) 
reported in Table 1. Note that we did not attempt to calculate kcat values for the kinase assays in panel B due to 






















Peptide KM (μM) kcat (sec
-1) 
SRM Colorimetric SRM Colorimetric 
pSP2 437 ± 28  348 ± 35 4.2 ± 0.2 4.1 ± 0.2 
pSP3 94 ± 8 98 ± 1 2.2 ± 0.1 2.0 ±0.1 
pSP4 202 ± 51 249 ± 5 1.3 ± 0.2 1.1 ± 0.01 
pSP5 350 ± 32 341 ± 44 3.8 ± 0.8 2.2 ± 0.2 
Steady-state kinetic parameters were determined from the experiment in Figure 2-2A, and similar 
experiments not shown with the other phosphopeptides, using the procedures described in 
Materials and Methods and previously [9]. Data are the average of three independent experiments 




















































Figure 2-3  Simultaneous measurement of multiple phosphatase substrates 
(A) A mixture of the phosphopeptide substrates pSP2 (), pSP3 (), pSP4 (), pSP6 (), pSP7 (), 
pSP8 (), and pSP9 (), each at 100 μM, was reacted with purified Cdc14 and aliquots removed at 
the indicated timepoints for analysis by SRM MS. The stoichiometry (% phosphorylation) at each 
timepoint was calculated as described in Materials and Methods. Data represent the average of 3 
independent assays. Error bars were omitted for clarity but were similar to those in the single peptide 
phosphatase assays shown in Figures 1 and 2. (B) Overlay of representative SRM traces (both 
transitions) from the experiment in A for all seven phosphopeptides. 
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Figure 2-4 Measuriing dephosphorylation of multiple sites on an intact protein substrate 
Recombinant GST-Fin1 phosphorylated in vitro with Cdk1 was treated with purified Cdc14 and aliquots 
removed over time. The protein was subjected to an in-gel digest with either Lys-C or trypsin and the 
resulting peptides analyzed by SRM MS as described in Materials and Methods either alone (A) or after 
addition to a large excess of trypsin-digested yeast whole cell extract (B). Data are the average of at least 
2 independent experiments. The percent of the original phosphorylation remaining relative to the zero 
time point is plotted. (C) SRM signals for each of the phosphopeptides plotted in panel B (both  
transitions) at the zero timepoint are overlaid to show the specificity in the background of a whole cell 
extract. (D) MS scans of the trypsin-digested yeast extract with (left plot) and without (right plot) 














2.3 Materials and methods 
2.3.1 Peptide synthesis and purification 
Peptides were synthesized using CLEAR-Amide resin (Peptides International) at 
50 µmol scale by solid-phase FMOC chemistry on a Prelude peptide synthesizer (Protein 
Technologies, Inc.) essentially as described previously [94]. The only modification was 
that coupling times for FMOC-phosphoserine and -phosphothreonine (Anaspec, Inc.) 
were increased to 3 hours. Unphosphorylated FMOC-protected amino acids were from 
Peptides International. Synthesis products were resuspended in 5% acetonitrile/0.1% 
TFA, fractionated by HPLC using a preparative C18 column (Agilent Technologies) and 
evaluated by MALDI-TOF mass spectrometry (Voyager 4800, Applied Biosystems). 
Fractions exhibiting the highest product purity were pooled, lyophilized, and 
resuspended in 50 mM Tris pH 8.0 at approximately 5 mM based on weight.  Precise 
concentrations of phosphopeptides were determined by measuring the inorganic 
phosphate released after ashing in a magnesium nitrate solution and reaction with an 
ammonium molybdate/malachite green mixture as described [95]. Unmodified peptide 
concentrations were determined by amino acid analysis at the Purdue Proteomics 
Facility. 
 
2.3.2 Protein purification 
The Saccharomyces cerevisiae FIN1 gene was cloned into pGEX-6P-1 (GE 
Healthcare) to create an in-frame fusion with the vector GST sequence. The N-terminal 
fusion protein GST-Fin1 was overexpressed in a 3 L E. coli culture by 0.5 mM IPTG 
induction at 37˚ C for roughly 4 hours. Unless otherwise stated, all purification steps 
were performed at 4 °C. Washed cells were suspended in 5 pellet volumes of 50 mM 
HEPES pH 8.0, 1% Triton X-100, 250 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM 
phenylmethlysulfonyl fluoride (PMSF), 100 μM leupeptin, and 1 μM pepstatin, treated 
with 1 mg/ml lysozyme on ice for 30 min and lysed by sonication on ice. The extract was 
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clarified by centrifugation at 35,000 x g for 30 min and then incubated with 500μL of 
GST-Bind Resin (EMD Biosciences) for 30 min. Unbound proteins were then removed by 
extensive washing with 50 mM HEPES pH 8.0, 0.1% Triton X-100, 250 mM NaCl, 1 mM 
EDTA, and 10% glycerol.   GST-Fin1 was then eluted with the same buffer supplemented 
with 10 mM reduced glutathione, collecting 500 μl fractions and the peak fraction was 
dialyzed against 10 mM HEPES pH 7.5, 10 mM MgCl2, 50 mM NaCl, 0.5 mM DTT and 10% 
glycerol overnight.  6His-Cdc14 was purified as previously described [96]. Following 
purification, pooled Cdc14 fractions were exchanged into 50 mM Tris-HCl pH 7.5, 300 
mM NaCl, 2 mM EDTA and 0.1% β-mercaptoethanol using a G-25 desalting column.  
Saccharomyces cerevisiae Cdk1 (Clb2-Cdc28) was purified from yeast strain 
BY4741 sic1∆ overexpressing a Clb2-protein A (Clb2-PrA) fusion protein from BG1805-
CLB2 (Open Biosystems). Clb2-PrA expression was induced for 4 hours at 30 °C by 
addition of 2% galactose to the YP-raffinose medium when cells had reached mid log 
phase. Washed cells were lysed in 5 pellet volumes of 50 mM Tris-HCl pH 8.0, 250 mM 
NaCl, 10% glycerol, 0.1% Triton X-100, 20 mM NaF, 1 mM PMSF, 100 μM leupeptin and 1 
μM pepstatin by disruption with glass beads in a Bead Beater (Biospec Products). 
Extracts were clarified by centrifugation at 35,000 x g for 30 min and incubated with 150 
μl IgG-agarose beads (Sigma) for 2 hours at 4oC. The IgG resin was collected by gentle 
centrifugation and washed 4x with 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 10% glycerol, 
0.1% Triton X-100, and 20 mM NaF. For peptide kinase assays the Clb2-PrA was eluted 
by cleavage with PreScission protease (GE Healthcare) overnight at 4 °C as 
recommended by the supplier and the GST-tagged protease subsequently removed by 
incubating the eluted material with 10 μl GST-Bind resin (EMD Biosciences) for 15 min 
followed by centrifugation to pellet the resin. The supernatant containing purified Cdk1 
was directly stored at -20 °C. For phosphorylation of recombinant GST-Fin1, the IgG 
agarose beads were washed with kinase buffer (see below), suspended in kinase buffer 




2.3.3 Extract preparation 
S. cerevisiae cells were grown to mid log phase in standard rich medium, 
harvested, washed, and lysed in the same buffer describe above for Cdk1 purification by 
glass bead disruption.  The clarified extract (50 μg) was subjected to SDS-PAGE and 
Coomassie blue staining. The entire lane was excised from the gel in small pieces and 
proteins digested with trypsin (see below). Extracted peptides were pooled to create 
the digested lysate sample for evaluation of GST-Fin1 dephosphorylation in a complex 
mixture. 
 
2.3.4 Kinase Assay 
Kinase assays (20 μl) contained 2 µL of affinity-purified Cdk1, varying 
concentration of synthetic peptide substrate, and 1 mM ATP in kinase buffer (10 mM 
HEPES pH7.5, 10 mM MgCl2, 50 mM NaCl, 10% glycerol, and 0.5 mM dithiothreitol). 
Duplicate reactions were performed, one of which contained [γ-32P]-ATP (MP 
Biomedicals). Reactions were initiated by addition of ATP and incubated at 30 °C for 20 
min. [γ-32P]-ATP reactions were terminated with 1% trifluoroacetic acid. Cold reactions 
were terminated by diluting the sample 5-fold with 3% acetonitrile in 0.1% formic acid. 
[γ-32P]-peptide products were purified from free ATP using OMIX-C18 micropipet tips 
(Varian, Inc.) according to the manufacturer’s protocol.  After washing, the portion of 
the tip containing the C18 resin was removed and the resin subjected to liquid 
scintillation counting. Product formation in the cold ATP reactions was monitored by 
SRM MS as described below. 
 Recombinant GST-Fin1 was phosphorylated in vitro by incubating 350 μl of stock 
protein with ~50 μl Cdk1 resin for 30 min at 30 °C. The reaction was stopped by pelleting 




2.3.5 Phosphatase assay 
Synthetic phosphopeptide dephosphorylation reactions contained 50 nM Cdc14, 
varying concentrations of phosphopeptide substrate, 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, and 1 mM EDTA. Reactions were incubated at 30 °C and stopped at the desired 
times by addition of an equal volume of 1.2 M HCl. Reaction products were divided in 
half. One half was diluted to 1 pmol/µL with 3% acetonitrile in 0.1% formic acid and 
analyzed by SRM MS as described below. The other half was analyzed 
spectrophotometrically by measuring A640 after mixing with a solution of ammonium 
molybdate and malachite green as described [97]. Total inorganic phosphate produced 
was determined from a Na2PO4 standard curve.  
 Phosphorylated recombinant GST-Fin1 was dephosphorylated by addition of 200 
nM Cdc14.  The reaction was incubated at 30°C and aliquots removed at 2, 5, 20, and 60 
min and stopped by boiling in SDS-PAGE loading dye. Reaction products were subjected 
to SDS-PAGE with Coomassie blue staining and the GST-Fin1 band excised, destained 
with 50% acetonitrile/50 mM ammonium bicarbonate, dried with pure acetonitrile, and 
digested in-gel with either 10 μg/ml Lys-C or 20 μg/ml trypsin in fresh 50 mM 
ammonium bicarbonate overnight at 37 °C. Peptides were extracted twice with 
acetonitrile, dried, and resuspended in 3% acetonitrile/0.1% formic acid immediately 
prior to MS analysis. 
 
2.3.6 Selected reaction monitoring (SRM) 
SRM experiments were conducted on an Agilent 6410 triple quadrupole mass 
spectrometer equipped with an HPLC-Chip cube interface and a 150 mm C18 ProtID-
Chip connected to an Agilent 1200 series nanoflow HPLC system.  SRM method 
parameters for all peptides monitored in this study, including parent ion charge state, 
collision energy, and fragment ion m/z values were manually determined and are listed 
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in Table 2-1. Collision energies (CE) were first estimated using the formulas CE = 0.044 x 
m/z + 5.5 (charge state = +2) and CE = 0.051 x m/z + 0.5 (charge state = +3) [12], and 
then further refined. At least two transitions were monitored for each peptide and were 
validated with product ion scans (not shown). Synthetic peptides were eluted from the 
C18 column and directly injected into the 6410 with a 6 minute gradient of increasing 
acetonitrile from 3 to 35% in 0.1% formic acid at a flow rate of 400 nL/min. Samples 
containing proteolytic peptides from recombinant GST-Fin1 were eluted from the C18 
column with a similar gradient extended to 20 minutes.  Resolution for quadrupoles 1 
and 3 was set to wide for synthetic peptide analyses and to unit and wide, respectively, 
for recombinant protein analyses.  The typical source voltage was 1900-2000 V and 
other instrument settings were ΔEMV = 300, gas temp = 300 °C, and gas flow = 4 L/min. 
 
2.3.7 Quantification of phosphorylation 
All raw SRM signals were integrated using Agilent’s MassHunter software. 
Standard peptides were included in all reactions to correct for run to run signal variation. 
For analyses of recombinant GST-Fin1, additional proteolytic peptides with strong signal 
intensity, no Cdk consensus phosphorylation sequences, and no detectable missed 
cleavages were used as internal standards. The average percent deviation of all standard 
peptide signals in each sample being compared was determined as described [9] and 
used to adjust the raw SRM signals. Moles of product formed in the synthetic peptide 
phosphatase assays were determined from phosphorylation stoichiometry calculations 
obtained by comparison of unmodified and phosphorylated peptide SRM signals [9] and 
the known starting substrate concentration. The kinetic parameters KM and kcat were 
determined by measuring product formation as a function of substrate concentration 




























enzymes, the specific biological functions of metazoan Cdc14 proteins remain unclear 
and few direct substrates have been identified outside of yeast model systems. The lack 
of knowledge of direct targets hampers our mechanistic understanding of Cdc14 
contributions to genome stability. 
In addition to the biological functions described above, several recent studies have 
provided evidence linking Cdc14 to the DNA damage response (DDR). Human Cdc14B is 
activated by nucleolar release in response to genotoxic stress to promote the G2 DNA 
damage checkpoint [48]. Similarly, in fission yeast, release of the Cdc14 ortholog Clp1 
from the nucleolus in response to replication stress contributes to full activation of DNA 
damage checkpoint signaling [51, 52]. Interestingly, deletion of the CDC14A  or CDC14B 
genes from chicken or human cultured cells was recently reported to cause defective 
repair of DNA damage without compromising checkpoint activation [49]. Likewise, 
Cdc14B-deficient mice exhibit premature aging, and embryo fibroblasts from these 
animals have defective DNA damage repair but an apparently normal checkpoint 
response [107]. Collectively, these studies clearly indicate that Cdc14 proteins in 
multiple organisms are activated by DNA damage and contribute in some way to the 
cellular DDR. Specific targets of Cdc14 involved in DNA repair or DNA damage 
checkpoints have not been identified.  
Cdc14 enzymes historically have been thought to possess general specificity for 
proline-directed Ser/Thr phosphorylation sites [3, 17, 18], matching the minimal 
consensus of Cdks and other proline-directed kinases. We recently reported the 
surprising finding that Cdc14 enzymes from diverse eukaryotes are actually highly 
specific for the subset of Cdk-type phosphorylation sites containing phosphoserine (pSer) 
and basic amino acids immediately downstream from pSer-Pro [2, 57]. The unexpected, 
strict enzymatic specificity of Cdc14 raises the possibility that novel substrates can be 
predicted bioinformatically.  
In this study, we further refined the consensus sequence requirements for optimal 
Cdc14 substrates, and using this information identified the Holliday junction (HJ) 
resolvase Yen1 as a novel early anaphase Cdc14 substrate. Yen1 was previously 
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identified as a preferential S phase cyclin-Cdk target in vitro [108] and its enzymatic 
activity was shown to be inhibited by phosphorylation until anaphase in vivo [109]. Here, 
we demonstrate that Cdk and Cdc14 are responsible for controlling the enzymatic 
activation and nucleocytoplasmic localization of Yen1, effectively restricting its DNA 
repair function during cell division to anaphase. We provide evidence that this 
regulation contributes to genome stability during the mitotic cell cycle, as proposed 
previously [109]. This work provides the first link between Cdc14 and the DNA damage 
response in budding yeast, identifies the first DNA damage repair substrate of Cdc14 in 
any organism, and reveals a mechanism by which DNA repair events are coordinated 
with the cell division machinery to ensure faithful segregation of chromosomes. 
3.2 Results 
3.2.1 Refinement of Cdc14 enzymatic specificity and prediction of Yen1 as a Cdc14 substrate 
Cdc14 enzymes display a strong preference for basic amino acids downstream 
from pSer-Pro [2]. Phosphopeptides lacking basic residues in the +2 to +6 region relative 
to pSer-Pro are poor substrates. However, we did not previously explore the preference 
for Lys and Arg in enough detail to define which specific positions are critical for Cdc14 
activity. We reasoned that identification of additional strong consensus site features 
might allow us to discover novel Cdc14 substrates using motif prediction algorithms. To 
define the basic amino acid requirement in more detail we generated a small 
phosphopeptide library based on the previously defined Cdc14 substrate site at residue 
71 in the securin ortholog Pds1 [110]. We first tested the contribution of an individual 
Lys or Arg at positions +2 through +6 to Cdc14 catalytic efficiency. The results are 
displayed as a heat map in Figure 3-1 (see Table 3-1 for rates). Consistent with our 
previous results, Cdc14 was unreactive towards the phosphopeptide lacking basic amino 
acids in the +2 to +6 region. Only a basic amino acid at position +3 provided activity 
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close in magnitude to the wild-type substrate. Moreover, Lys was clearly preferred over 
Arg at +3, generating approximately 4-fold higher activity.  
We also analyzed peptides with combinations of basic amino acids to determine 
which patterns provided the best catalytic efficiency. Of all the multi-basic peptides, 
only those containing a Lys at the +3 position produced significant activity (Fig. 3-1B and 
Table 3-1). For several of these peptides, the activity was substantially higher than that 
observed with a single Lys at +3. Enhanced activity in the multi-basic peptides correlated 
best with the presence of a basic residue at +4, although this effect was not universal. 
We conclude that a +3 basic amino acid represents an additional critical feature of the 
Cdc14 consensus substrate sequence, and that optimal activity is achieved with 
additional basic residues in the immediate vicinity of +3. 
A stretch of conserved acidic residues lines the peptide binding groove in the 
human Cdc14B (hCdc14B) crystal structure and was proposed to contribute to 
recognition of phosphosubstrates containing downstream basic sequences [3]. This 
extended acidic patch is insufficient though to explain the strong preference for Lys/Arg 
specifically at +3. To understand the strong +3 effect we performed docking and 
molecular dynamics (MD) simulations with the optimal substrate sequence 
A(pSer)PSKRR and either the hCdc14B structure or a homology model of the budding 
yeast Cdc14 (ScCdc14) catalytic domain. The ScCdc14 model revealed extensive amino 
acid conservation for the substrate binding channel (Fig. 3-10) and resulted in similar 
positions and contacts for the -1 Ala, pSer and +1 Pro compared to the empirical 
structure. Interestingly, the MD simulations with both ScCdc14 (Fig 3-2) and hCdc14B 
(Fig. 3-10) suggested that the +3 Lys does not directly contact the acidic portion of the 
substrate binding groove. Instead, the side chain of +3 Lys sits in a conserved pocket 
adjacent to the +1 Pro cage where it engages in cation-pi contacts, stabilized by a 
hydrogen bond network (Fig. 3-2A and 3-2B). The invariant Phe47 and Tyr44 (Phe85 and 
Tyr82 in hCdc14B) both contribute strongly to the cation-pi interaction in the ScCdc14 
MD simulation. Cation-pi interactions at solvent-exposed protein surfaces generally 
contribute much greater binding energy than ionic contacts [111], providing a plausible 
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explanation for the +3 Lys/Arg specificity. The preference of Lys over Arg at +3 was also 
explained by the MD results. Although Lys and Arg can both form cation-pi interactions, 
the longer aliphatic side chain of Lys allows for a favorable orientation of the epsilon 
amino group with the Tyr44/Phe47 aromatic cage. The shorter Arg side chain prevents a 
preferred guanidinium-pi stacking arrangement [112] and instead results in a less 
favorable edge-to-face contact with Phe47 (not shown). The +4 Arg makes a hydrogen 
bond contact with Glu174 (Glu212), and +5 Arg interacts with Glu171 (Glu209) and/or 
Asp177 (Asp215) of the acidic groove through most of the MD simulation. The models 
are consistent with our biochemical data defining the critical contribution of a +3 basic 
amino acid and the auxiliary contributions of surrounding basic residues to substrate 
selectivity. 
Using pSer, +1 Pro, and +3 Lys or Lys/Arg as fixed consensus features, and 
additional Lys/Arg residues in the +2 to +5 region as variable consensus features (Fig. 3-
1C), we scanned the yeast proteome for proteins enriched in candidate Cdc14 target 
sites (Tables 3-2 and 3-3). Collectively, these searches produced just over 60 hits, of 
which thirteen were previously reported Cdc14 substrates, including its essential targets 
Cdh1 and Swi5, along with Sli15, Ase1, Ipl1, Acm1, Ace2, and several replication factors. 
While not exhaustive, the majority of known Cdc14 substrates were identified, providing 
confidence that novel substrates might also be present in the list. As an additional filter, 
we looked for proteins with clusters of optimal Cdc14 sites since regulatory Cdk 
phosphorylation commonly occurs in clusters on disordered protein regions [88, 113]. 
Yen1 caught our eye because it contains more optimal Cdc14 sites than any other yeast 
protein (Table 3-3). The 5 optimal consensus sites are clustered within a 180 amino acid 
stretch near the C-terminus (Fig. 3-1D), and are well conserved across the order 
Saccharomycetales. Yen1 is likely a direct Cdk substrate [108] and contains a predicted 
Cdk-regulated NLS [11]. After initiating our study, the West lab reported that Yen1 
enzymatic activity is strictly regulated by phosphorylation during the cell cycle [109], 
although the kinase(s) and phosphatase(s) responsible were not revealed. We therefore 
proceeded to test if Yen1 is a regulatory target of the opposing Cdk and Cdc14 activities. 
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3.2.2 Yen1 is phosphorylated in vivo by Cdk 
We first tested if Yen1 is an in vivo substrate of the cell cycle Cdk, Cdc28. 
Phosphorylated Yen1 species can be effectively separated from unphosphorylated Yen1 
using Phos-tag™ SDS-PAGE and immunoblotting [109]. We compared the migration of 
Yen1-TAP (expressed from the YEN1 promoter) present in extracts of cells arrested in G1 
and S phase. Yen1-TAP migration was strongly retarded when cells were arrested in S 
phase, a time when Cdc28 activity is high, compared to G1, when Cdc28 is inactive (Fig. 
3-3A). Mutation of the 9 Ser-Pro sequences in Yen1 to Ala-Pro (Yen19A) completely 
abolished the slow mobility species in S phase cells (Fig. 3-3A), demonstrating that Yen1 
phosphorylation is dependent on Cdk consensus sites. To test if phosphorylation is 
dependent on Cdc28 activity, we used a cdc28-as1 strain in which a Cdc28 active site 
mutation renders the kinase uniquely sensitive to inhibition by the ATP analog 1-NM-
PP1 [114]. Cdc28 inhibition resulted in rapid loss of slow mobility phosphorylated Yen1-
TAP but did not affect migration of Yen19A-TAP (Fig. 3-3B). To directly detect 
phosphorylation we purified Yen1-3FLAG from large cdc14-1 cultures arrested in late 
mitosis with high Cdk activity and analyzed it by mass spectrometry (MS). Detection of 
proteolytic peptides containing many of the Cdk sequences in Yen1 by MS is 
problematic due to inconvenient protease cleavage sites and the low expression level of 
Yen1. Nonetheless, 3 peptides containing Ser-Pro sequences, one from each cluster 
depicted in Figure 1F, were convincingly identified. All 3 were detected predominantly in 
Ser-phosphorylated form (Fig. 3-3C and 3-11). Collectively, we conclude that Yen1 is 
heavily phosphorylated in vivo by Cdc28 at multiple Ser-Pro sites throughout the 
primary sequence. 
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3.2.3 Yen1 is a novel early anaphase Cdc14 substrate 
To determine if Yen1 is a Cdc14 substrate we first synthesized five 
phosphopeptides containing putative optimal Cdc14 target sequences near the Yen1 C-
terminus and measured the rate of Cdc14-catalyzed dephosphorylation under steady-
state conditions. Catalytic efficiencies (kcat/Km) for pSer-Pro sites can vary by over 3 
orders of magnitude [2]. For comparison, we analyzed phosphopeptides representing 
known in vivo Cdc14 substrate sites that exhibit high activity and phosphopeptides from 
an N-terminal Cdk site cluster on Cdc16 that are all poor substrates. The five Yen1 
phosphopeptides were efficiently dephosphorylated by Cdc14, most with catalytic rates 
comparable to our “gold standards” (Fig. 3-4A).  
To determine if Cdc14 can recognize Yen1 as a substrate in vivo we performed 
co-immunoprecipitation (co-IP) experiments with a Cdc14 substrate trap variant, Cdc14-
C283S, which is catalytically inactive but retains high affinity substrate binding [96]. 
Wild-type Yen1 co-purified with 3HA-Cdc14-C283S (Fig. 3-4B). In contrast, the Yen19A 
mutant and another mutant, Yen19T, containing Thr substitutions at all nine Ser-Pro sites 
were not detected in 3HA-Cdc14-C283S  immunoprecipitates despite being expressed at 
similar levels. Thus, Cdc14 physically associates with Yen1 in vivo, dependent on Yen1 
Cdk phosphorylation sites. 
We next ectopically overexpressed Cdc14 in S phase cells and monitored the 
phosphorylation status of Yen1-TAP by immunoblotting of whole cell extracts. After 
Cdc14 expression, Yen1-TAP mobility increased substantially, demonstrating that Cdc14 
promotes the dephosphorylation of Yen1 (Fig. 3-4C). We monitored the stability of the 
mitotic cyclin Clb2 to ensure that under these experimental conditions the 
overexpressed Cdc14 had not induced mitotic exit conditions that terminate Cdk activity 
via cyclin proteolysis. 
To test if Yen1 dephosphorylation in mitosis is dependent on Cdc14 function we 
synchronized W303, cdc14-1, or cdc15-2 strains expressing YEN1-TAP in G1 with α-factor 
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at 23 °C and released them from arrest at 37 °C. The phosphorylation status of Yen1-TAP 
was monitored by immunoblotting (Fig. 3-4D). In W303, Yen1-TAP became 
phosphorylated roughly 45 minutes after release and was dephosphorylated as cells 
entered anaphase and segregated their chromosomes, consistent with previous results 
[109]. cdc14-1 and cdc15-2 strains both arrest in late anaphase at 37°C with segregated 
DNA, the only difference being that cdc15-2 cells transiently release active Cdc14 from 
nucleolar sequestration in early anaphase via the FEAR network [115] whereas cdc14-1 
cells completely lack Cdc14 function. Yen1-TAP was phosphorylated with similar kinetics 
in both cdc14-1 and cdc15-2 cells. In contrast, dephosphorylation was completely absent 
in the cdc14-1 strain but occurred similar to W303 in the cdc15-2 strain. Thus, Cdc14 
function is essential for Yen1 dephosphorylation during mitosis. The lack of dependence 
on Cdc15 and the mitotic exit network argues strongly that Yen1 is a target of FEAR-
activated Cdc14 at anaphase onset, consistent with the reported timing of Yen1 
dephosphorylation and activation [109]. 
3.2.4 Cdk sites regulate Yen1 biological function 
Yen1 functions in the repair of replication born double-strand DNA breaks (DSBs) 
by homologous recombination (HR), and strong sensitivity to chemicals that impair 
replication and lead to DSBs can be observed in mus81Δ yen1Δ strains [6, 116, 117]. 
Mus81 is a component of the Mus81-Mms4 endonuclease that performs an overlapping 
function with Yen1 in HR-based DNA repair. mus81Δ yen1Δ strains also exhibit a slow 
growth phenotype [6, 116, 117]. To determine if regulation of Yen1 at Cdk 
phosphorylation sites is important for its HR repair function, we performed 
complementation experiments with Yen1 phosphosite mutants. We split the Yen1 Cdk 
sites into 3 clusters as depicted in Figure 3-1D. For example, Yen1c1A refers to mutation 
of the three Ser-Pro sites in the N-terminal nuclease domain (cluster 1) to Ala-Pro to 
prevent Cdk phosphorylation, whereas Yen1c1D contains Asp-Pro substitutions at the 
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same sites to mimic constitutive Cdk phosphorylation. Clusters c2 and c3 were of the 
most interest because they contained all of the optimal Cdc14 substrate sites. All YEN1 
variants were integrated as TAP fusions into mus81Δ yen1Δ strains under control of the 
YEN1 promoter.  
Consistent with previous results, yen1Δ growth was indistinguishable from the 
parental W303 strain, whereas mus81Δ exhibited a slight growth delay and mus81Δ 
yen1Δ took nearly twice as long to double (Fig. 3-5A). Wild-type Yen1 (Yen1WT), Yen1c2A, 
and Yen1c3A all complemented the yen1Δ growth defect in the mus81Δ background. 
Yen1c2D almost completely failed to complement, whereas Yen1c3D appeared fully 
functional. The cluster 1 mutants also affected growth complementation. Yen1c1D 
completely failed to complement whereas Yen1c1A partially complemented.  
Next, we examined the ability of the same YEN1 alleles to complement the acute 
sensitivity of mus81Δ yen1Δ to the DNA damaging agents methyl methanesulfonate 
(MMS) and hydroxyurea (HU). Similar to the growth experiments, Yen1WT, Yen1c2A, 
Yen1c3A, and Yen1c3D all provided full Yen1 function and eliminated the chemical 
sensitivity of mus81Δ yen1Δ cells (Fig. 3-5B). Yen1c1D and Yen1c2D appeared non-
functional as they failed to complement the yen1Δ-dependent sensitivity, and Yen1c1A 
was only partially functional. Together, the growth and DNA damage sensitivity results 
are consistent with Cdk phosphorylation within clusters 1 and 2 inhibiting the biological 
function of Yen1 in repair of DNA damage via HR and Cdc14-mediated 
dephosphorylation of these clusters being required to activate Yen1 function. However, 
mutations in cluster 1 may be affecting Yen1 function independent of phosphorylation 
as well since the Ala variant was not fully functional. 
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3.2.5 Cdc14 is essential for Yen1 nuclear accumulation 
The apparently normal function of Yen1c3D was somewhat surprising given the 
prior evidence that Cdk phosphorylation of S679 prevented Yen1 nuclear localization 
[11]. To directly test if Cdc14 is required for nuclear accumulation of Yen1, we examined 
cdc14-1 cells expressing a Yen1-GFP fusion from the constitutive GPD promoter by 
fluorescence microscopy (we could not detect Yen1-GFP expressed from its natural 
promoter). As expected, Yen1-GFP was evenly distributed throughout the cytoplasm of 
pre-mitotic cells in an asynchronous culture grown at permissive temperature, but 
exhibited strong nuclear signal in large-budded late mitotic cells that had segregated 
their DNA (Fig. 3-6A). In some cases, we observed Yen1-GFP accumulation in the nucleus 
of cells that appeared to be undergoing anaphase and had not fully separated their two 
chromosome sets (Fig. 3-6B). At 37 °C, cdc14-1 cells arrest in late mitosis with 
segregated DNA, however Yen1-GFP failed to accumulate in the nucleus under these 
conditions (Fig. 3-6A). The requirement for Cdc14 function to accumulate Yen1 in the 
nucleus was completely bypassed by expressing Yen1c3A-GFP. Neither Yen1c1A nor 
Yen1c2A bypassed this Cdc14 requirement, and cell cycle-dependent nuclear localization 
was not altered by the c1D and c2D mutations (Fig. 3-6C and 3-12). Thus, the cluster 3 
Cdk sites near the putative NLS uniquely control the nucleocytoplasmic distribution of 
Yen1. Oddly, Yen1c3D-GFP behaved similar to Yen1c3A-GFP (Fig. 3-12).  Instead of being 
constitutively cytoplasmic, as would be expected if the Ser to Asp mutations mimicked 
the effect of phosphorylation, Yen1c3D-GFP signal was detected in the nucleus at all cell 
cycle stages. The Asp mutations clearly do not effectively mimic the inhibitory effect of 
Cdk phosphorylation on nuclear localization, likely explaining why Yen1c3D appeared fully 
functional in the complementation assays. Nonetheless, our results clearly show that 
Cdc14-mediated dephosphorylation of one or both cluster 3 Cdk sites are essential for 




3.2.6 Cdc14 and Cdk1 directly regulate Yen1 enzymatic activity 
Since Yen1 resolvase activity is influenced by phosphorylation [109], we used an 
in vitro HJ resolution assay to explore the effects of purified Cdc14 and Cdk1. We 
isolated Yen1-3FLAG from cdc14-1 cells arrested at 37 °C to obtain phosphorylated, 
inactive protein. We first confirmed that treatment of isolated Yen1 with recombinant 
Cdc14 caused dephosphorylation and that subsequent treatment with purified Cdk1 
(Clb2-Cdc28) restored phosphorylation, based on gel mobility (Fig. 3-13C). Pre-
treatment of Yen1-3FLAG with Cdc14 strongly enhanced cleavage of the fluorescent HJ 
substrate into nicked duplex products (Fig. 3-7A). This effect was suppressed by sodium 
tungstate, a potent inhibitor of Cdc14. We next isolated Yen1-3FLAG from cycling cells 
without using phosphatase inhibitors and found that it was highly active (Fig. 3-7B). Pre-
treatment with Cdk1 completely inhibited HJ resolution and additional treatment of the 
Cdk-inhibited Yen1 with Cdc14 restored activity. These results demonstrate that Cdc14 
and Cdk directly activate and inhibit the Yen1 resolvase activity, respectively. 
Yen1c3A-3FLAG (Fig. 3-7C) and Yen1c3D-3FLAG (Fig. 3-7D) isolated from cdc14-1 
cells at restrictive temperature behaved similar to wild-type Yen1-3FLAG, exhibiting low 
basal activity and strong stimulation after treatment with recombinant Cdc14. Thus, the 
cluster 3 Cdk sites do not appear to affect Yen1 enzymatic activity. In contrast, Yen1c2A-
3FLAG exhibited relatively high activity prior to Cdc14 treatment, suggesting that it was 
isolated in active form (Fig. 3-7C). Moreover, Yen1c2D-3FLAG was devoid of basal activity 
and was stimulated only slightly by treatment with recombinant Cdc14 (Fig. 3-7D). 
These results suggest that phosphorylation of the cluster 2 Cdk sites directly controls 
Yen1 enzymatic activity, despite being distant from the catalytic domain in the Yen1 
primary sequence. The Yen1c1A-3FLAG activity profile was similar to wild-type Yen1. 
Surprisingly, Yen1c1D-3FLAG exhibited elevated activity without Cdc14 treatment. 
Treatment of Yen1c1D-3FLAG with Cdc14 further enhanced activity close to the maximal 
level observed with wild-type Yen1 (presumably due to dephosphorylation of the cluster 
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2 sites). Thus, the cluster 1 Cdk sites appear to influence activity in an unexpected way. 
Notably, the Asp substitutions in Yen1c1D appear to compromise the ability of the cluster 
2 Cdk sites to inhibit Yen1 activity, although this mutant is not functional in vivo (see 
Discussion). 
 
3.2.7 Activation of Yen1 by Cdc14 influences chromosome segregation during mitosis 
Matos et al. proposed that specific activation of Yen1 during mitosis might be 
important to resolve persistent recombination intermediates that had escaped non-
crossover (NCO) HR repair pathways and thereby ensure all sister chromatids can be 
segregated during anaphase [109]. In support of this idea, Ho et al. reported that 
mus81Δ yen1Δ cells exhibit a significantly elevated rate of sister chromatid non-
disjunction that is largely dependent on HR [6]. We used this same assay to determine if 
expression of the non-functional Yen1c2D mutant that mimics constitutive cluster 2 Cdk 
phosphorylation would also cause elevated sister chromatid non-disjunction. The assay 
is based on spontaneous deletion of the URA3 marker by recombination between 
flanking ade2 repeats to restore ADE2 in one of the sister chromatids, and segregation 
of both markers to the same daughter cell if the sister chromatids co-segregate at 
mitosis (Fig. 3-8A). The rate of sister chromatid non-disjunction in yen1c2D-TAP cells was 
indistinguishable from yen1Δ and significantly higher than in YEN1-TAP and yen1c2A-TAP 
cells (Fig. 3-8B). This result reveals that activation of Yen1 by Cdc14 contributes to 
genome stability by ensuring complete segregation of sister chromatids during mitosis. 
 mus81Δ yen1Δ cells exhibit a defect in bulk DNA segregation and an associated 
G2/M cell cycle delay when grown in low concentrations of MMS {Blanco, 2010 #407}. If 
Cdc14 is critical for Yen1 activation, then a similar effect should be observed in mus81Δ 
cdc14-1 cells at the restrictive temperature. To test this, we released G1-arrested cells 
at 37 °C in the presence of 0.0012% MMS and monitored DNA segregation cytologically 
by DAPI staining (Fig. 3-8C & 3-8D). We used the cdc15-2 background for comparison 
 
52 
due to its similar late mitotic arrest at 37 °C. All strains released and reached G2/M as 
large-budded cells with similar kinetics, although substantially slower than at lower 
temperatures (data not shown). At both 4 and 5 hours post-release, the cdc14-1, cdc15-
2, and cdc15-2 mus81Δ strains exhibited statistically indistinguishable fractions of cells 
with clearly segregated DNA masses. In contrast, a much smaller fraction of cdc14-1 
mus81Δ cells had fully segregated DNA masses (Fig. 3-8D). This difference was highly 
significant. We interpret this result as failure to properly resolve MMS-induced damage 
repair intermediates leading to a persistent DNA damage checkpoint, a physical barrier 
to segregation, or a combination of both. This provides additional evidence that Cdc14 
function is required for Yen1 activation and proper chromosome segregation, 
independent of mutations in Yen1 phosphorylation sites 
 
3.2.8 Constitutively active Yen1 increases the crossover (CO) frequency during mitotic 
DSB repair 
 Yen1c2A has constitutive enzymatic activity and Yen1c3A is constitutively nuclear. 
We therefore predicted that the combined Yen1c2A_c3A mutant containing Ala 
substitutions at all 6 C-terminal Ser-Pro sequences might result in constitutive Yen1 
function that could influence the CO outcome of DSB repair by HR. To address the roles 
of the Yen1 Cdk site mutants in DSB-induced recombination we used a well-
characterized system to monitor CO formation between dispersed chromosomal 
repeats [1, 117]. A haploid strain expressing a galactose-inducible HO endonuclease was 
used to monitor repair by recombination between a DSB generated at the HO 
endonuclease cut site (HOcs) inserted within the URA3 locus on chromosome (Ch) V and 
a 5.6Kb URA3 donor sequence inserted at the LYS2 locus on Ch II (Figure 3-9A). After 
galactose induction, a DSB is continuously generated at the Ch V locus until repair by 
gene conversion transfers the HOcs-inc sequence from the donor to the recipient locus. 
Repair of the DSB by either an NCO gene conversion event or a reciprocal CO is required 
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for cell viability. The plating efficiency on galactose versus glucose media is used to 
address the overall repair efficiency. CO products can be monitored and quantified 
physically by using asymmetrically located restriction sites flanking both the URA3 
regions on Ch V and Ch II (Figure 3-9A). The percent CO 24 h after HO induction is 
normalized to the plating efficiency to take into account differences in the overall repair 
frequency. 
 As described previously, the Yen1 effect on CO formation can only be seen in a 
mus81∆ background [1]. We therefore evaluated CO levels in a mus81∆ yen1∆ strain 
complemented by YEN1-TAP or mutant derivatives (Fig. 3-9B & 3-9C). Expression of 
yen1c2D only partially complemented the decreased CO level while yen1c2D_c3D 
completely failed to complement the mus81∆ yen1∆ CO defect (6.8% and 4.3% CO with 
a plating efficiency of 63% and 51% respectively). These results were mostly consistent 
with the lack of function of the Asp mutants in the DNA damage sensitivity assays. In 
contrast, expression of both the constitutively active yen1c2A allele and the yen1c2A_c3A 
combination mutant not only fully complemented the CO defect but resulted in a 
modest, but significant elevation in CO levels compared to the strain complemented 
with YEN1 (10.3 and 10.7% CO with 80% and 75% plating efficiencies, respectively, 
compared to 7.7% CO and 76% plating efficiency; p=0.044 and p=0.028, respectively).  
 
3.3 Discussion 
3.3.1 A novel function for Cdc14 in the DDR identified by sequence scanning for 
optimal substrates 
A daunting challenge in the functional characterization of kinases and 
phosphatases is the identification of bona fide physiological substrates. For 
phosphatases, this problem is exacerbated by the structural complexity of many 
phosphatase families and lack of strong active site specificity. The Cdc14 family has 
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several advantages that, in principle, facilitate substrate identification. First, Cdc14 
enzymes appear to function alone, without accessory or regulatory subunits. Second, as 
protein tyrosine phosphatase family members, Cdc14 enzymes can be modified at 
catalytic residues to generate substrate trap variants capable of stable interaction with 
substrates. Cdc14 substrate trap variants have been used in proteomic screens to 
identify candidate substrates [30, 31]. Third, as shown here and previously [2, 3], the 
Cdc14 active site region imposes strict substrate selection requirements on the enzyme. 
This includes 1) steric occlusion Thr from the phosphate binding pocket, rendering 
Cdc14 enzymes highly selective for pSer [2], 2) a hydrophobic pocket for exclusive 
accommodation of the trans isomer of a +1 Pro [3], and 3) a strong preference for a +3 
basic amino acid that appears to arise from an unexpected cation-pi interaction 
involving invariant Phe and Tyr residues. Absence of any single one of these features 
renders a substrate nearly unreactive in vitro using phosphopeptides [2]. Ionic 
interactions with conserved acidic residues in the substrate binding channel appear to 
further enhance substrate recognition. We used this strict enzymatic specificity to 
predict optimal Cdc14 substrates in silico and identified a novel role for Cdc14 in 
activating the DNA repair enzyme Yen1 that contributes to genome stability. Such an 
approach may be a useful companion tool to substrate trap methodologies to facilitate 
direct substrate identification, or even as a stand-alone approach to identification of 
novel substrates in metazoan systems where very little is known about Cdc14 functions.  
Cdc14 has been implicated in both DNA damage checkpoint signaling and repair 
in several model systems [48, 49, 51, 107]. Consistent with this, several Cdc14 orthologs 
are apparently activated by nucleolar release upon genotoxic stress [48, 49, 51, 52]. 
However, little evidence exists directly linking Cdc14 to specific DNA repair functions. 
Aside from a report that Cdc14 activates the anaphase-promoting complex to facilitate 
DNA damage checkpoint arrest in human cells [48], the direct targets of Cdc14 in the 
DDR are not known. To our knowledge, Yen1 is the first reported DNA repair substrate 
of Cdc14 and the first connection between Cdc14 function and DNA repair in budding 
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yeast. The evidence for Cdc14 involvement in the DDR in budding yeast, fission yeast, 
and metazoans suggests that it may be a conserved function for this phosphatase family.  
 
3.3.2 Cdc14 enzymatic specificity and the DDR 
Cdk phosphorylation is required for an effective DDR but also must be 
suppressed to prevent cell cycle progression until damage is repaired [103]. Cdk directly 
promotes checkpoint signaling and repair, for example by stimulating DSB end resection 
[118]. It can also suppress HR-based repair, for example by phosphorylating the C-
terminus of BRCA2 to inhibit interaction with Rad51 [119]. Cdk is a positive regulator of 
CO pathways of HR in budding yeast [120], yet our work suggests it suppresses the CO-
promoting activity of Yen1. How the pro- and anti-HR effects of Cdk (and likely other 
kinases) are coordinated to yield an appropriate DDR is unclear. Phosphatase specificity 
may be one contributing factor. The strict specificity of Cdc14 for a distinct class of Cdk 
substrates could act to selectively reverse phosphorylation on optimal substrates at 
times when overall Cdk activity is high. This would be an effective strategy to selectively 
activate repair proteins that are otherwise kept dormant in the absence of DNA damage. 
It also may underlie Cdc14 substrate selection in late mitosis as cells execute the 
ordered dephosphorylation of Cdk substrates to coordinate chromosome segregation, 
mitotic exit, and cytokinesis [40]. 
We previously reported that mutation of Ser Cdk sites to Thr Cdk sites prevented 
in vivo recognition of the substrate Acm1 by Cdc14 [2], demonstrating physiological 
relevance of Cdc14 specificity. Similarly, mutation of Yen1 Cdk sites from Ser to Thr 
prevented in vivo recognition by Cdc14 (Fig. 3-4B) but did not alter the overall level of 
Yen1 phosphorylation in S phase (data not shown). Interestingly, stable phosphorylation 
of Yen19T was not maintained through mitosis, and the protein became 
dephosphorylated prior to metaphase, independent of Cdc14 function (data not shown). 
This precluded a useful characterization of phenotypes associated with Yen19T. We do 
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not currently understand this observation or whether it represents a defect in stable 
phosphorylation of Yen19T by Cdk, activity of a distinct phosphatase that prefers Thr 
substrates, or some other perturbation of Yen1 structure or localization that renders it 
more sensitive to general phosphatase activity. 
 
3.3.3 Yen1 is a new regulatory target of the FEAR network 
Yen1 appears to be a target of the transient nuclear pool of Cdc14 activated by 
the FEAR network in anaphase, as it was independent of the other major Cdc14 
activation pathway, the mitotic exit network (Fig. 3-4A). The apparent timing of Yen1 
activation is consistent with it being a FEAR target. FEAR signaling originates at the 
metaphase-anaphase transition when separase is activated via proteolysis of its 
inhibitor, securin, and works with several other proteins to promote nucleolar release of 
Cdc14 from its own inhibitor, Net1 [38, 115, 121]. FEAR-released Cdc14 selectively 
dephosphorylates a handful of Cdk substrates to ensure proper spindle function and 
chromosome segregation during anaphase [53]. Since cells expressing the Yen1c2D 
phosphomimetic mutant exhibited a sister chromatid segregation defect similar to 
yen1Δ strains (Fig. 3-8B), dephosphorylation of Yen1 by Cdc14 represents another 
mechanism by which the FEAR pathway promotes faithful chromosome segregation and 
safeguards genome integrity. 
 
3.3.4 Strict regulation of Yen1 function contributes to genome stability 
Yen1 was identified as a HJ resolvase several years ago, along with its human 
ortholog GEN1, based on detection of its enzymatic activity [122]. Since then, several 
studies have shown that the symmetrical HJ cleavage activity of Yen1 functions in HR-
based repair of DSBs during mitosis [6, 116, 117, 123]. Cells lacking YEN1 seem to be 
mostly proficient for DNA repair, and strong phenotypes are typically only observed in 
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combination with deletion of other structure-specific endonucleases. However, yen1Δ 
cells do exhibit a modest defect in the repair of replication-derived DSBs by sister 
chromatid recombination [124]. Collectively, these studies suggest that Yen1 function in 
resolving HR intermediates overlaps heavily with other structure-specific nucleases and 
implies a highly robust network of repair pathways that ensure genome integrity during 
cell division.  
A previous study also revealed that Yen1 activity is strictly regulated by 
phosphorylation during both meiotic and mitotic division cycles [109]. Yen1 is heavily 
phosphorylated and inactive during S phase and becomes dephosphorylated and 
enzymatically active during mitosis. Yen1 was proposed to serve as a last line of defense 
against sister chromatid non-disjunction caused by unresolved recombination 
intermediates that arise during the repair of DSBs [109]. The inhibition of Yen1 from S 
phase through early mitosis would encourage non-CO pathways of DSB repair, which are 
preferred during mitotic divisions to limit loss of heterozygosity [109]. In support of the 
model of Matos et al. our results show that Cdc14-mediated dephosphorylation of Yen1 
promotes faithful chromosome segregation, likely by removing residual branched 
structures that would otherwise prevent sister chromatid disjunction. Furthermore, lack 
of Cdk phosphorylation on Yen1 results in constitutive activity and elevates the fraction 
of HR repair events resulting in CO formation (Fig. 3-9), potentially leading to an 
increase in loss of heterozygosity. This phenotype is modest, (although statistically 
significant), likely because mechanisms exist to limit COs associated with homology-
directed repair of DSBs. Helicase-catalyzed displacement of the extended invading 3’ 
end is the primary mechanism. Recombination intermediates that mature to a double HJ 
structure are preferentially removed by Sgs1-Top3-Rmi dissolution to form non-COs 





3.3.5 Multiple mechanisms of Yen1 inhibition by Cdk 
The opposing activities of Cdk and Cdc14 enforce specific activation of Yen1 at 
anaphase by two independent mechanisms. Cdk phosphorylation of the cluster 2 Cdk 
sites (and to some extent the cluster 1 sites in the catalytic domain) directly inhibits 
Yen1 enzymatic activity, whereas phosphorylation of the cluster 3 sites near the C-
terminal NLS restricts Yen1 to the cytoplasm. FEAR network-released Cdc14 
dephosphorylates Yen1 to allow its accumulation in the nucleus in a fully active state. 
The existence of two independent regulatory mechanisms may be necessary to 
completely silence Yen1 function until anaphase onset. Phosphorylated Yen1 may retain 
minimal catalytic activity or be competent to bind its DNA repair substrates, thereby 
interfering with other DSB repair pathways and justifying an additional mechanism to 
sequester it in the cytoplasm. On the other hand, cytoplasmic Yen1 may actively shuttle 
between the cytoplasm and nucleus with phosphorylation status shifting the equilibrium 
between export and import. In this context, the small amount of Yen1 present at any 
given time in the nucleus prior to anaphase could potentially function in repair without 
inhibition of its enzymatic activity. Our observation that Yen1c2A leads to increased COs 
(Fig. 3-9), despite a normal localization pattern, is consistent with this idea. 
The mechanism by which the cluster 2 Cdk sites contribute to Yen1 inhibition 
remains an open question. These sites are distant from the catalytic domain in the 
primary sequence, but may interact with it in the folded, native protein. Our results with 
the cluster 1 mutations within the catalytic domain suggest that they also modulate 
Yen1 activity, although based on sequence we would not predict that they are highly 
efficient Cdc14 substrates. The cluster 1 results are more difficult to interpret. First, 
mutation to both Ala and Asp compromises Yen1 function, to different degrees, in 
biological assays (Fig. 3-5), suggesting that mutations in these sites, in general, may 
compromise Yen1 function. Second, Yen1c1D actually has increased activity in the 
absence of Cdc14 treatment (Fig. 3-7). One interpretation is that serine residues at 
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these positions are necessary to allow normal enzymatic inhibition of Yen1 by 
phosphorylation at cluster 2 sites. We assume (but do not have direct evidence to 
support) that mutations in the cluster 1 sites do not affect the ability of Cdk to 
phosphorylate cluster 2. Thus, some type of interaction or communication may exist 
between the Cdk sites in clusters 1 and 2. One model would be that a physical 
interaction between the C-terminus of Yen1 and its catalytic domain controls enzymatic 
activation, and that the interaction itself is regulated by Cdk phosphorylation. Additional 
work will be required to define the mechanism of phosphorylation-mediated Yen1 






   




























































































Figure 3-1 Refinement of Cdc14 enzymatic specificity 
A-B) The indicated peptide sequence from Pds1 was synthesized with a central phosphoserine (pS), and 
variants contained different combinations of basic amino acids in the +2 to +6 region (boxed) relative to 
pS. WT, wild-type sequence. Heat map cells show positions (+2 to +6) and identity of basic residues, Lys 
(K) or Arg (R), in each peptide. Shading indicates the relative level of activity (white = low, black = high) in 
Cdc14 enzymatic assays conducted under steady-state conditions that approximate kcat/Km. Kinetic data 
used to make pannels A & B was obtained by Brendan L. Powers. C) Summary of Cdc14 optimal substrate 
features. Essential requirements are in large red font. Positions that can enhance activity are in smaller 
gray font. The pS and P requirements are from previous studies [2, 3]. See additional information in 
Tables S1-S3. D) Diagram of relevant Yen1 protein features. All nine Ser-Pro Cdk site positions with 
downstream basic residues are shown and divided into the 3 clusters used for the purpose of 
mutagenesis throughout the paper. N, I, and H3 (helix-hairpin-helix) are conserved domains of the XPG 























Figure 3-2  Molecular docking simulations
A) Representative frame from MD simulation of the ScCdc14 homology model
(molecular surface representation) with bound optimal peptide substrate Ac-A(pSer)PSKRR-NHMe (ball 
and stick). The acidic groove and other residues that contact the substrate KRR are colored (red, acidic; 
green, hydrophobic; cyan, polar neutral) and labeled in white. Key residues of the substrate peptide are 
labeled in black. The inset highlights the local arrangement of the substrate +3 Lys engaged in cation-pi 
contacts with Tyr44 and Phe47, stabilized by a hydrogen bonding network (dashed lines). See also Fig. S1. 
B) 2-dimensional representation of stable (≥ 40% of simulation time) contacts (direct or water-bridged)
between peptide substrate (black) and ScCdc14 residues obtained from an MD experiment. Percentages 
represent the fraction of time that the contact was maintained. Purple arrows are hydrogen bonds, red 
lines are cation-pi interactions, residue colors are as in panel C with basic residues in blue.  Molecular 















































Figure 3-3 Yen1 is an in vivo Cdk target 
A) Anti-protein A immunoblots from Phos-tag™ SDS-PAGE gels. Yeast extracts from cells arrested in
G1 or S and expressing integrated YEN1-TAP or yen19A-TAP from PYEN1 were compared. B) Same as 
A) except asynchronous cdc28-as1 cells were treated with 20 μM 1-NM-PP1 or an equal volume of
DMSO for 30 min. C) Extracted ion chromatograms for the most prominent charge state of the 
indicated Yen1 tryptic peptides in both unmodified (-HPO3, black line) and phosphorylated (+HPO3, 
gray line) forms detected by LC-MS analysis. Identity of the peak in each case was verified by 
product ion spectra (Fig. 3-10). A third peptide, YTTFLPNIPISSQ(pS)PLKR, containing 
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Figure 3-4 Yen1 is a physiological Cdc14 substrate 
A) Relative activity of Cdc14 towards the indicated phosphopeptide substrates was measured under
steady state conditions. All reactions contained 200 nM peptide and 250 nM purified GST-Cdc14. Data are 
the average of three trials and error bars are standard deviations. Peptide sequences shown in Table S4. 
B) Co-IP of the substrate trap 3HA-Cdc14-C283S expressed from PGAL1 and Yen1-TAP, Yen1
9A-TAP, or
Yen19T-TAP expressed from PYEN1 in S phase cells. 3HA-Cdc14-C283S was isolated on anti-HA affinity resin 
and co-purification of Yen1 variants monitored by anti-protein A immunoblotting. G6PD is a loading 
control. C) 3HA-Cdc14 was ectopically overexpressed from PGAL1 for either 1.5 or 3 hours in S phase cells 
expressing Yen1-TAP or Yen19A-TAP from PYEN1. Phosphorylation status of Yen1 was monitored by anti-
protein A immunoblot of Phos-tag™ gels. Clb2 level is an indicator of artificially-induced mitotic exit and 
G6PD is a loading control. D) W303, cdc14-1, and cdc15-2 strains, each expressing Yen1-TAP from PYEN1 
were arrested at 23 °C in G1, then released into fresh medium at 37 °C. Cells were harvested at the 
indicated times for analysis by Phos-tag™ immunoblotting and nuclear staining. The graph shows the 
percentage of large-budded anaphase cells with segregated chromosomes, based on detection of two 
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Figure 3-5 Phosphomimetic Cdk site mutants block Yen1 function 
A) Strains of the indicated genotypes were grown in YPD in 96-well culture plates and absorbance at 600
nm measured over time and used to calculate doubling times. B) Ten-fold serial dilutions of the indicated 
strains were spotted on YPD agar plates or YPD plates containing either 40 mM HU or 0.0025% MMS and 
grown at 30 °C. Similar results were obtained with 25 mM HU and 0.005 % MMS (not shown). C) Anti-























Figure 3—6 Cdc14 is required for nuclear accumulation of Yen1 in anaphase 
A) The cdc14-1 strain containing a CEN plasmid expressing Yen1-GFP or Yen1c3A-GFP from PGPD was grown in selective 
medium at 23 °C. Where indicated, growth temperature was shifted to 37 °C for 4 hours. Cells were briefly fixed and 
stained with DAPI prior to microscopic imaging. At 37 °C less than 5% of cells expressing Yen1-GFP exhibited 
detectable nuclear fluorescence above the cytoplasmic signal. Greater than 90% of cells expressing Yen1c3A-GFP 
exhibited strong accumulation of nuclear fluorescence (n>100). B) Select images from cultures used in A) showing 
cells in early anaphase with nuclear accumulation of Yen1-GFP signal. C) Similar to A), cdc14-1 cells expressing 
Yen1c1A-GFP or Yen1c2A-GFP were arrested at 37 °C and imaged. Less than 2% and 10% of cells exhibited detectable 
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Figure 3-7 Cdc14 and Cdk directly control Yen1 endonuclease activity 
In all panels, Yen1-3FLAG resin was added to reactions containing the fluorescent synthetic HJ substrate 
(see Fig. 3-12). Products were resolved by native PAGE and quantified by fluorescence imaging. A) Yen1-
3FLAG was immunoaffinity isolated from soluble extracts of cdc14-1 cells arrested at 37 °C. Equal fractions 
of Yen1-bound resin were either untreated or treated with recombinant Cdc14 (+ or - sodium tungstate) 
prior to HJ resolution assays. B) Yen1-3FLAG isolated under permissive conditions without phosphatase 
inhibitors was treated with purified Cdk1. Half of the Cdk1-treated resin was washed and additionally 
treated with recombinant Cdc14. C) Yen1-3FLAG and Ala variants were isolated and used in HJ resolution 
assays as in A). Prior to reactions, Yen1-bound resins were divided, and one half treated with recombinant 
Cdc14. The anti-FLAG immunoblot of isolated Yen1 protein used in each reaction was used to normalize 
the product levels (shown as adjusted resolution percentage in the bottom graph). D) Same as C), 
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* p = 0.01
Figure 3-8 Activation of Yen1 by Cdc14 helps prevent chromosome segregation defects 
A) Schematic of sister chromatid co-segregation assay [6]. Spontaneous recombination between the
direct repeats of ade2 alleles in the ade2-5'::URA3::ade2-3' construct on one sister generates a chromatid 
pair with URA3 and ADE2 markers that are monitored for co-segregration on medium lacking uracil and 
adenine. Illustration provided by Gerard Mazon.  B) Co-segregation of sister chromatids in strain LSY2307-
2C harboring integrated YEN1-TAP, yen1c2A-TAP, and yen1c2D alleles driven by PYEN1 was monitored using 
the assay from A). The method of the median was used to calculate co-segregation rates and data 
represent the average of 3 independent experiments. Error bars are standard deviations. Asterisk and p 
value indicate a statistically significant difference compared to the YEN1-TAP complementing strain 
determined using Student’s t-test. C) Representative fields of view of the indicated strains collected by 
either DIC or fluorescence microscopy at 4 hours after release from G1 arrest at 37 °C in the presence of 
0.0012% MMS. White arrows indicate examples of fully segregated DNA. D) Quantification of images from 
experiments represented in panel C at 4 and 5 hours after release. A minimum of 120 cells were counted 
for each strain at each time point. Asterisks indicate a significant difference compared to cdc14-1 in a chi-
square test (p < 0.0001 for both timepoints). cdc15-2 and cdc15-2 mus81Δ were not significantly different 
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0 20 40 60 80
CO 24h (%) PE (%) CO/PE (%)
10.7 ± 1.2 74.7 ± 4.1 8.0 ± 0.9
4.3 ± 0.6 50.6 ± 0.5 2.2 ±  0.3
10.3 ± 1.0 79.6 ± 7.8 8.2 ± 0.8
6.8 ± 1.7 63.0 ± 9.2 4.3 ± 1.0
7.7 ± 0.8 75.6 ± 5.7 5.9 ± 0.6
4.3 ± 0.9 57.3 ± 8.0 2.5 ± 0.7
7.1 ± 1.3 75.4 ± 7.6 5.3 ± 1.0
8.3 ± 0.5 81.9 ± 11.5 6.8 ± 0.4
*
*
Figure 3-9 Mis-regulation of Cdk sites on Yen1 influences CO formation 
A) Schematic of the ectopic recombination assay used to monitor CO formation between ura3 repeats [1].
P and A mark the PvuII and AvaLI restriction sites used to monitor CO formation by Southern blot and B 
indicates the HO cut site. B) CO products are detected as ApaLI (A)/PvuII (P) restriction fragments of 10.7 
and 8.6 kb in Southern blot analysis of DNA extracted from cells after HO-endonuclease induction. C) The 
estimation of CO product % at 24 h after HO induction by Southern blotting was normalized to the plating 
efficiency (PE, number of colonies formed on galactose medium/number of colonies formed on glucose 
medium). Values for the raw estimate of % COs, PE, and the relative CO fraction are shown in the table 
and are averages of 3 independent trials. Error bars and values are standard deviations. Asterisks indicate 
p-values < 0.05 from a Students t-test comparing CO/PE to that from the YEN1-TAP strain.  Figure 
provided by Gerard Mazon. 
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3.4 Experimental procedures 
3.4.1 Homology modeling and ligand docking 
A homology model for ScCdc14 was generated by the Prime homology modeling 
workflow (version 3.3, Schrödinger, LLC) using the liganded structure of the C314S 
hCdc14B mutant (1OHE) as the template. Briefly, the sequences were initially aligned by 
BLAST homology search (Altschul et al., 1990), and the resulting alignment was further 
optimized using the Prime STA program that relies on secondary structure propensities 
of the query sequence. The model was then built by Prime’s energy-based algorithm to 
construct and refine residues not present in the template. A three-step docking 
sequence provided a starting point for molecular dynamics-based optimization of the 
model complex between ScCdc14 and a P7 peptide (Ac-ApSPSKRR-NHMe). Initially, the 
peptide was docked flexibly using the SP-Peptide algorithm (Tubert-Brohman et al., 
2013) within Glide (version 6.0, Schrödinger, LLC) into the receptor grid defined by a 
30x30x30 Å enclosing box centered by the active site and the acidic groove residues. 
Van der Waal radii of nonpolar ligand atoms (partial charges ≤ 0.15) were scaled to 80% 
to permit less optimal conformational and binding solutions to account for model’s 
imperfections and static nature in the docking experiments. The top-scoring poses were 
optimized using local ligand refinement procedure at the maximum level of precision 
(XP) of Glide. Finally, the peptide ligand and the receptor residues within 5Å were 
minimized using OPLS2005 force field (Banks et al., 2005) and VSGB solvation model (Li 
et al., 2011) implemented within Prime.  
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3.4.2 Molecular dynamics simulations 
The resulting substrate–receptor complex was subjected to an unconstrained 1.2 
ns simulated annealing procedure within Desmond (version 3.5, D. E. Shaw Research & 
Schrödinger, LLC) to ascertain conformational preferences for the 22-residue poorly 
conserved loop (A189–P210) that partially occluded the distal region of the acidic 
groove in the homology model. Six stages were used (10K@30ps, 100K@100ps, 
300K@200ps, 400K@300ps, 400K@500ps, and 300K@1000ps) with a neutralized 
system in explicit SPC solvent model at 150 mM NaCl. The loop conformation at the end 
of the simulation was spliced onto the force field-optimized model, and the junctions 
were re-minimized using Prime. The grafted models of the complexes with the P7 
peptide and the +3 Arg variant (produced by docking and minimization) were subjected 
to two consecutive 1.2 ns-long isothermal (300K) simulations by Desmond to establish 
ligand-receptor contacts and their stability. The detailed summary of ligand–receptor 
interactions from the final simulation are presented in the supporting Simulation 
Interaction Diagram Report. 
3.4.3 Strains, plasmids and yeast growth 
Yeast strains expressing the indicated Yen1 constructs were generated by 
integration of the appropriate linearized plasmid using standard lithium acetate 
transformation. Complete gene deletions were generated by PCR-based recombination. 
All pHIP integrating plasmids were derived from the Advanced Gateway Destination 
Vector suite [57], obtained from Addgene (www.addgene.org).  To generate pHIP 
plasmids expressing YEN1 alleles from the YEN1 promoter, the GAL1 promoter was 
removed from pAG306GAL-ccdB-TAP and pAG304GAL-ccdB-TAP by digestion with SacI 
and XbaI, or SacI and SpeI, respectively.  The digested vectors were treated with Klenow 
to generate blunt ends and re-ligated.  For C-terminal 3FLAG tagging in these vectors, 
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the promoter-less plasmids were digested with ClaI and XhoI to remove the TAP tag 
sequence.  Oligonucleotides encoding three tandem FLAG epitope sequences were 
annealed and cloned into the ClaI and XhoI sites.  Mutagenesis was performed using the 
QuikChange Multi kit (Agilent Technologies). All plasmids and mutations were confirmed 
by sequencing.   
Yeast were grown either in standard YPD or synthetic dropout media for plasmid 
selection. Cultures were chemically arrested in G1 phase by treatment with 5 μg/ml α-
factor peptide (Genscript), or S phase with 10 mg/ml hydroxyurea (HU), typically for 2.5 
hours. Cultures of cdc14-1 were arrested in late anaphase by shifting log phase cultures 
from permissive (23 °C) to restrictive (37 °C) temperature. All arrests were verified by 
flow cytometry analysis of DNA content and/or microscopic inspection of cell 
morphology. For synchronous release from G1, arrested cells were captured on a 
membrane and washed with fresh medium lacking α-factor using a vacuum filtration 
device and then suspended in YPD pre-warmed to 37 °C. For drug sensitivity assays, HU 
and methyl methanesulfonate (MMS) were added at the desired final concentrations to 
warm agar medium and mixed thoroughly immediately prior to pouring into plates. For 
ectopic expression of Cdc14 and for co-IPs, cells were grown to mid-log phase at 30 °C in 
YP medium supplemented with 2% raffinose and arrested with HU. Cdc14 expression 
was induced by addition of 2% galactose. Cells were harvested at 1.5 and 3 hours for the 
ectopic expression and at 2 hours for co-IPs. 
3.4.4 Phosphopeptides and enzymatic assays 
Peptides were suspended in water and concentrations determined as described 
[95]. We manually verified the identity and apparent purity of all peptides by MALDI-
TOF mass spectrometry (MS). To conduct phosphatase assays, I diluted the stock Cdc14 
to 20 µM in reaction buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1 mM EDTA, 3 mM β-ME) 
and the stock peptides to 1 mM.  The reactions were set up by transferring 2 µL of each 
substrate to a microfuge tube.  The reactions were initiated by adding 8 µL of the 
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diluted Cdc14 to each reaction tube.  Under these conditions, the final reaction volume 
is 10 µL and the final peptide and Cdc14 concentrations were 200 nM and 250 nM, 
respectively.  The reactions were then incubated at 30°C for 20 minutes except for the 
Yen1pS507 reaction which was allowed to proceed for 60 minutes.  The reactions were 
then terminated by the addition of 40 µL of BIOMOL Green™ reagent (Enzo Life 
Sciences).  After 30 minutes, 45 µL of each reaction was transferred to a micro plate and 
the A650 was measured using a BioTek Synergy 2 micro plate reader. 
3.4.5 Purification of Yen1-3FLAG 
Yen1-3FLAG and variants were isolated from cdc14-1 yen1∆ cells expressing the 
integrated tagged allele from the natural YEN1 promoter. Cells were grown to mid-log 
phase at 23 °C followed by a four hour arrest at 37 °C. For enzymatic assays 1 liter 
cultures were used. For MS analysis 6 liters were used.  Cells were lysed with glass beads 
in ice cold 40 mM Tris-HCl, pH 7.5, 10% glycerol, 0.1% NP-40, 50 mM β-
glycerophosphate, 20 mM NaF, protease inhibitors, and either 150 mM (for enzymatic 
assays) or 300 mM (for MS analysis) NaCl. The lysate was clarified by centrifugation at 
16,000 x g for 40 min at 4 °C and the soluble portion incubated with anti-FLAG M2 resin 
(Sigma-Aldrich, 20 μl for enzymatic assays, 200 μl for MS) for one hour at 4°C with 
gentle agitation. The resin was extensively washed with cold 40 mM Tris-HCl pH 7.5, 150 
or 300 mM NaCl, 10% glycerol, and 0.1% NP-40. For enzymatic assays, Yen1-3FLAG was 
used directly on the agarose beads. For MS analysis, Yen1-3FLAG was eluted by 
competition with 150 µg/mL 3FLAG peptide (Sigma-Aldrich). The eluate was TCA-
precipitated and subjected to SDS-PAGE.  A more detailed protocol for purification of 
Yen1 can be found in chapter 5. 
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3.4.6 MS analysis 
In-gel digestion of the Yen1-3FLAG band with trypsin or Lys-C and preparation of 
peptides for MS analysis was performed as described [96]. Extracted peptides were 
desalted and purified on C18 StageTips (Thermo Scientific) prior to LC-MS/MS analysis 
on an AB Sciex 5600 TripleTOF mass spectrometer using a data-dependent acquisition 
mode. Spectra were searched against a database of budding yeast proteins using 
Mascot (Matrix Science) and phosphopeptides confirmed by manual inspection of the 
product ion spectra. Extracted ion chromatograms for modified and unmodified 
peptides containing Cdk consensus sites were generated using PeakView (AB Sciex). 
3.4.7 SDS-PAGE, immunoblotting and co-IP 
Whole cell extracts were prepared for SDS-PAGE and immunoblotting by glass 
bead lysis in 10% trichloroacetic acid, centrifugation, washing with EtOH, and 
resuspension in SDS loading dye.  Standard tris-glycine-SDS running buffer and tris-
glycine transfer buffers were used. Phos-tag™ gels were run at 20 mA for 90 min, soaked 
in transfer buffer containing 2 mM EDTA for 10 min, and washed in transfer buffer 
without EDTA for 10 min before transfer to PVDF at 27 V for 180 min. For 
immunoblotting, the following antibodies were used: 1:10,000 monoclonal anti-HA 
(12CA5, Roche); 1:10,000 rabbit anti-Protein A (P3775, Sigma-Aldrich), 1:10,000 
monoclonal anti-FLAG (2368, Cell Signaling Technologies); 1:1000 rabbit anti-Clb2  (SC-
9071, Santa Cruz Biotechnology) and 1:50,000 rabbit anti-G6PD (Sigma-Aldrich).  
Horseradish peroxidase conjugated anti-mouse (GE Healthcare) and anti-rabbit (Jackson 
ImmunoResearch) secondary antibodies were used at 1:10,000 dilutions. ECL 2 (Thermo 
Scientific) or Luminata Crescendo (Millipore) chemiluminescent reagents were used for 
detection. 
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3.4.8 HJ resolution assays 
To make the X0 synthetic HJ substrate described previously [122], one of the 
oligonucleotides contained a 5’ TYE 563 fluorescent label for visualization with a 
fluorescence imager. The four oligonucleotides (Integrated DNA Technologies) were 
mixed and annealed in TE buffer supplemented with 50 mM NaCl by heating and slowly 
cooling in a beaker of hot water. The four-way junction was separated from undesired 
species by native12% PAGE at 180 V for 2 hours (Figure 3-12), excised, and eluted by 
diffusion into a buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM MgCl2 and 50 mM NaCl. 
The concentration of the purified HJ substrate was determined by absorbance at 260 
nm.  A more detailed protocol for assembling a HJ can be found in chapter 5.  Reactions 
contained 20 nM purified HJ substrate, 250 ng poly(dI-dC), 2.5 mM MgCl2, 50 mM Tris-
HCl pH 7.5, and the immobilized Yen1-3FLAG agarose beads from a single purification 
and were incubated at 30°C for 1 hour. The beads were pelleted and the supernatant 
containing substrate and products was processed by native PAGE (10%) at 150 V for 45 
minutes. Reaction products were visualized using a Typhoon FLA variable mode imager 
(GE Healthcare). Yen1-3FLAG from each reaction was eluted from the resin by 
competition with 3FLAG peptide and analyzed by western blotting.  Percent substrate 
resolved in each reaction was quantified using ImageQuant TL software.  Background 
was subtracted using the rolling ball method.  The relative amount of Yen1-3FLAG 
variants isolated in comparative experiments was quantified by immunoblotting using 
standard SDS-PAGE conditions. Signals were detected and quantified using a Bio-Rad 
ChemiDoc XRS+ digital imager and Image Lab software. When appropriate, bead-bound 
Yen1-3FLAG was first dephosphorylated by the addition of 1 µM recombinant Cdc14 and 
incubation at 30°C for 30 minutes, followed by washing with reaction buffer. Cdk1 (Clb2-
Cdc28) was purified by IgG affinity chromatography from 2 L of mid-log phase cells 
expressing Clb2 as a Protein A fusion from the GAL1 promoter as described [57] and 
eluted by cleavage with PreScission protease (GE Healthcare). For Cdk1 treatment, 
Yen1-bound resin was washed with and resuspended in kinase buffer (10 mM Hepes [pH 
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7.5], 10 mM MgCl2, 50 mM NaCl, 10% glycerol, 0.5 mM DTT and 1 mM ATP). 
Approximately 10% of the purified Cdk1 preparation was added and mixture incubated 
at 30° C for 30 min. Cdk1 was then removed by extensive washing with Yen1 wash 
buffer (above) prior to HJ assays. 
3.4.9 Fluorescence microscopy 
For Yen1-GFP localization experiments, cultures were grown in SD-Ura medium 
supplemented with 50 µg/mL adenine and maintained below 5x106 cells/mL to minimize 
autofluorescence. Immediately prior to observation, cells were washed with 0.1 M
potassium phosphate  pH 7.5 (KPO4) and fixed with 4% paraformaldehyde in 4% sucrose 
for 5 minutes at room temperature.  Cells were washed and resuspended in 0.1 M KPO4 
supplemented with 2 µg/mL 4',6-diamidino-2-phenylindole (DAPI).  After 2 minutes, 
cells were extensively washed with 0.1 M KPO4. For DNA segregation experiments, cells 
harvested at different times after release were fixed with 70% EtOH, stained for 3 min 
with 1 μg/ml DAPI in PBS, and washed with PBS. 
3.4.10 Functional assays 
Strain growth rates were measured by diluting mid-log phase YPD cultures to an 
identical starting density in sterile 96-well microplates and recording OD600 over time in 
a BioTek Synergy 2 microplate reader with shaking at 30°C.  The doubling time was 
calculated by plotting the log of the OD600 values verses time and dividing the slope of 
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Table 3-2 Predicted high efficiency Cdc14 substrates from PatMatch search and Cdc14 
consensus sequences. 
aProtein bSP(K/R)2+ cSPxK dBiological Process Annotation
Ace2 2 Cell cycle-dependent transcription 
Acm1 2 4 Cell cycle, mitosis 
Ase1 3 3 Spindle function, cytokinesis 
Ash1 4 3 Transcriptional regulation 
Atg20 2 Vacuolar, endosomal transport 
Bck2 2 Pkc signaling 
Bem3 5 Polarized growth 
Bir1 2 Chromosome segregation, cytokinesis 
Boi1 3 Polarized growth, cytokinesis 
Bud3 2 Bud site selection 
Bud4 4 Bud site selection 
Caf120 3 Transcriptional regulation 
Cdh1 2 3 Cell cycle, mitotic exit 
Chs2 3 Cytokinesis 
Csr2 2 Cell wall organization 
Dss1 2 Mitochondrial mRNA processing 
Epo1 3 4 Unknown 
Exo84 3 3 Exocytosis, secretory pathway 
Far1 2 Pheromone response 
Fun30 3 Chromatin silencing 
Fus2 2 Mating, karyogamy 
Gac1 3 Protein phosphorylation 
Hos4 3 Transcriptional regulation 
Inp52 2 3 Endocytosis 
Ipl1 3 Chromosome segregation, cytokinesis 
Iqg1 2 Cytokinesis 
Irc8 4 Unknown 
Kkq8 3 Putative kinase, unknown function 
Lte1 4 Mitotic exit, cytokinesis 
Mcm3 2 DNA replication 
Mds3 2 TOR signaling 
Mlp1 3 Nuclear transport 
Nur1 2 rDNA repeat stability 
Orc2 3 DNA replication 
Orc6 3 DNA replication 
Pkc1 5 Polarized growth 
Plm2 3 Unknown 
Prk1 3 Actin cytoskeleton, endocytosis 
Rad9 2 5 DNA damage response 
Rga2 2 3 Polarized growth 
Rog3 2 Ubiquitin-dependent endocytosis 
Rom2 2 Rho GTPase signaling 
Sak1 4 Protein phosphorylation 
Sfi1 3 Spindle pole body duplication 
Sir4 2 Chromatin silencing 
Sld2 2 4 DNA replication 
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Sli15 2 5 Chromosome segregation, cytokinesis  
Srs2 4  DNA repair  
Ssn2  3 Transcriptional regulation  
Stb1  3 Transcriptional regulation  
Swi5 4 6 Cell cycle-dependent transcription  
Tfg1  3 Transcription  
Vps64 2  Vacuolar protein targeting  
Yen1 5 4 DNA recombination/repair  
YDR131C 2  Ubiquitin-dependent proteolysis  
YKL105C 2  Unknown  
YML119W 2  Unknown  
YNL058C 2  Unknown  
YOR022C 2   Unknown  
Yta7 2  Chromatin organization, transcription  
Yox1 2  Cell cycle-dependent transcription  
Zip1  3 Meiotic recombination  
Zrg8 2  Unknown  
  
Table 3-2 cont. 
Identification of proteins containing Cdc14 consensus sites was performed using the PatMatch algorithm [122]. 
a) Previously reported Cdc14 substrates are highlighted in green. Yen1 is highlighted in purple. 
b) number of SPx(K/R) sequences with at least one additional K/R at +2, +4 or +5 relative to S. Minimum two 
required. 
c) number of SPxK sequences in the indicated protein (x = any amino acid). Minimum 3 required. 




Table 3-3 Ranking of candidate Cdc14 substrates by number of potential target sites 
 
 
Protein Number  Protein Number  Protein Number 
Swi5 8  Swi5 6  Yen1 5 
Yen1 8  Pkc1 5  Swi5 4 
Sli15 6  Sli15 5  Srs2 4 
Rad9 6  Rad9 5  Ash1 4 
Ash1 6  Bem3 5  Chs2 3 
Lte1 5  Lte1 4  Exo84 3 
Cdc15 5  Yen1 4  Zip1 3 
Boi1 5  Sak1 4  Prk1 3 
Pkc1 5  Irc8 4  Sfi1 3 
Rga2 5  Srs2 4  Epo1 3 
Zrg8 5  Bud4 4  Ase1 3 
Sak1 5  Sld2 4  Ipl1 3 
Cdh1 5  Epo1 4  Fun19 2 
Srs2 5  Acm1 4  Sli15 2 
Bud4 5  Fun30 3  Hpc2 2 
Ase1 5  Boi1 3  Bud3 2 
Bem3 5  Orc2 3  Nur1 2 
Chs2 4  Exo84 3  Atg20 2 
Bud3 4  Zip1 3  YDR131C 2 
Fin1 4  Rga2 3  Vps64 2 
Mcm3 4  Ssn2 3  Rad9 2 
Bck2 4  Plm2 3  Sir4 2 
Irc8 4  Mcm3 3  Rga2 2 
Sld2 4  Cdh1 3  Mcm3 2 
Msa2 4  Tfg1 3  Zrg8 2 
Sfi1 4  Orc6 3  Bck2 2 
Smc4 4  Hos4 3  Rog3 2 
Epo1 4  Ash1 3  Cdh1 2 
Bop3 4  Mlp1 3  Mds3 2 
Acc1 4  Inp52 3  Tfg1 2 
Mse1 4  Caf120 3  Yta7 2 
Acm1 4  Stb1 3  Far1 2 
Fun30 3  Ase1 3  Bir1 2 
Frt2 3  Gac1 3  YKL105C 2 
Gip4 3     Sld2 2 
Previously reported Cdc14 substrates are highlighted in green, Yen1 in purple. Minimum 3 
occurrences of SPx(K/R) or SPxK, or 2 occurrences of SP(KR)2+  required for listing. SP(KR)2+. 
SPx(K/R) SPxK SPx(K/R)2+ 
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Orc2 3 Kkq8 2 
Exo84 3 Ace2 2 
Hpc2 3 Ifh1 2 
Rif1 3 Rom2 2 
Lre1 3 Yox1 2 
Hcm1 3 YML119W 2 
Zip1 3 Fus2 2 
Ssn2 3 Dss1 2 
Plm2 3 YNL058C 2 
Fir1 3 Inp52 2 
Boi2 3 YOR022C 2 
Mds3 3 Iqg1 2 
Tfg1 3 Acm1 2 


































Table 3-4 Phosphopeptide sequences used for comparison of Cdc14 activity towards 











Peptide Name Peptide Sequencea 
Acm1pS31 VKGNELR [pS] PSKRRSQI 
Swi6pS160 DAHRELG [pS] PLKKLKID 
Pds1pS71 IQGGKEV [pS] PTKRLHT 
Yen1pS500 NIPISSQ [pS] PLKRSNSP 
Yen1pS507 SPLKRSN [pS] PSRSKSPT 
Yen1pS583 EFLRKHT [pS] PIKSIGKV 
Yen1pS655 SQSVLDS [pS] PGKRIRDL 
Yen1pS679 WKDVIEI [pS] PIKKSRTT 
Cdc16pS59 HNSTLAA [pS] PFVSNVSA 
Cdc16pS95 NRTNTAT [pS] PYQSLANS 
Cdc16pS103 PYQSLAN [pS] PLIQKLQA 
Cdc16pT115 KLQANIM [pT] PHQPSANS 
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Table 3-5 Yeast strains created for this study (all strains are derivatives of W303) 
Strain Relevant Genotype Source 
a W303 MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 
HCY114 MATa cdc14-1 [96] 
HCY104 MATa cdc15-2 H. Charbonneau, 
Purdue U. 
YKA613 MATa cdc14-1 ura3::YEN1-TAP:URA3 This study 
YKA612 MATa cdc15-2 ura3::YEN1-TAP:URA3 This study 
YKA656 MATa cdc14-1 ura3::yen19A-TAP:URA3 This study 
RJD2632 MATa cdc28-as1 Raymond Deshaies, 
Cal. Inst. Tech. 
YKA689 MATa cdc28-as1 ura3::YEN1-TAP:URA3 This study 
YKA691 MATa cdc28-as1 ura3::yen19A-TAP:URA3 This study 
YKA686 MATa ura3::YEN1-TAP:URA3 This study 
HCY116 MATa leu2::PGAL1-HA-CDC14C283S:LEU2 This study 
YKA619 MATa leu2::PGAL1-HA-CDC14C283S:LEU2 ura3::YEN1-
TAP:URA3 
This study 
YKA661 MATa leu2::PGAL1-HA-CDC14C283S:LEU2 ura3::YEN19T-
TAP:URA3 
This study 
YKA662 MATa leu2::PGAL1-HA-CDC14C283S:LEU2 ura3::YEN19A-
TAP:URA3 
This study 
LSY2244-90B MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4   [6] 
LSY2244-2C MATa ADE2 mus81::KanMX6 his3::HphMX4       [6] 
LSY2244-16B MATa ADE2 yen1::HIS3 his3::HphMX4    [6] 
YKA652 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::YEN1-TAP:URA3   
This study 
YKA682 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c1A-TAP:URA3   
This study 
YKA692 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c3A-TAP:URA3   
This study 
YKA693 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c3D-TAP:URA3   
This study 
YKA811 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c1D-TAP:URA3   
This study 
YKA812 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c2A-TAP:URA3   
This study 
YKA813 MATα ADE2 mus81::KanMX6 yen1::HIS3 his3::HphMX4 
ura3::yen1c2D-TAP:URA3   
This study 
YKA686 MATa ura3::YEN1-TAP:URA3 This study 
LSY2307-2C MATa yen1::HIS3 mus81::KanMX6 ade2-3’∆::URA3::ade2-
5’∆ ura3::HphMX4  
[6] 
LSY2307-1D MATa mus81::KanMX6  ade2-3’∆::URA3::ade2-5’∆ 
ura3::HphMX4  
[6] 
YKA835 MATa mus81::KanMX6  ade2-3’∆::URA3::ade2-5’∆ 
ura3::HphMX4 trp1::YEN1-TAP:TRP1 
This study 




YKA841 MATa mus81::KanMX6  ade2-3’∆::URA3::ade2-5’∆ 
ura3::HphMX4 trp1::yen1c2A-TAP:TRP1 
This study 
YKA833 MATa cdc14-1 yen1::KanMX6 This study 
YKA873 MATa cdc14-1 yen1::KanMX6 ura3::yen1c1A-3FLAG:URA3 This study 
YKA874 MATa cdc14-1 yen1::KanMX6 ura3::yen1c1D-3FLAG:URA3 This study 
YKA875 MATa cdc14-1 yen1::KanMX6 ura3::yen1c2A-3FLAG:URA3 This study 
YKA876 MATa cdc14-1 yen1::KanMX6 ura3::yen1c2D-3FLAG:URA3 This study
YKA877 MATa cdc14-1 yen1::KanMX6 ura3::yen1c3A-3FLAG:URA3 This study 
YKA878 MATa cdc14-1 yen1::KanMX6 ura3::yen1c3D-3FLAG:URA3 This study 
YKA879 MATa cdc14-1 yen1::KanMX6 ura3::YEN1-3FLAG:URA3 This study 
YKA882 MATa cdc14-1 mus81::KanMX This study 
YKA883 MATa cdc15-2 mus81::KanMX This study 
LSY2520 MATa-inc ura3::HOcs lys2::ura3-HOcs inc (5.6 kb) 
ade3::GAL-HO 
[117] 
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MATa-inc ura3::HOcs lys2::ura3-HOcs inc (5.6 kb) 
ade3::GAL-HO 
mus81::KanMX yen1::HIS3 trp1:: yen1c2A_c3A -TAP:TRP1 
This study 
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Table 3-6 Plasmids used in this study 
Plasmid Name Origin Marker Promoter Expressed protein 
Restriction 
enzyme 
pHIP046 integrating URA3 YEN1 Yen1-TAP Stu I 
pHIP056 integrating URA3 YEN1 Yen19T-TAP Stu I 
pHIP057 integrating URA3 YEN1 Yen19A-TAP Stu I 
pHIP071 integrating URA3 YEN1 Yen1c1A-TAP Stu I 
pHIP076 integrating URA3 YEN1 Yen1c3A-TAP Stu I 
pHIP077 integrating URA3 YEN1 Yen1c3D-TAP Stu I 
pHIP093 integrating URA3 YEN1 Yen1c1D-TAP Stu I 
pHIP094 integrating URA3 YEN1 Yen1c2A-TAP Stu I 
pHIP095 integrating URA3 YEN1 Yen1c2D-TAP Stu I 
pHIP125 integrating TRP1 YEN1 Yen1-TAP BstApI 
pHIP126 integrating TRP1 YEN1 Yen1c2D-TAP BstApI 
pHIP131 integrating TRP1 YEN1 Yen1c2D_c3D-TAP BstApI 
pHIP133 integrating TRP1 YEN1 Yen1c2A-TAP BstApI 
pHIP136 integrating TRP1 YEN1 Yen1c2A_c3A-TAP BstApI 
pHIP128 integrating URA3 YEN1 Yen1-3FLAG Stu I 
pHIP157 integrating URA3 YEN1 Yen1c1A-3FLAG Stu I 
pHIP158 integrating URA3 YEN1 Yen1c1D-3FLAG Stu I 
pHIP159 integrating URA3 YEN1 Yen1c2A-3FLAG Stu I 
pHIP160 integrating URA3 YEN1 Yen1c2D-3FLAG Stu I 
pHIP161 integrating URA3 YEN1 Yen1c3A-3FLAG Stu I 
pHIP162 integrating URA3 YEN1 Yen1c3D-3FLAG Stu I 
pHLP493 CEN/ARS URA3 GPD GFP-Yen1c2D
pHLP494 CEN/ARS URA3 GPD GFP-Yen1c2A
pHLP495 CEN/ARS URA3 GPD GFP-Yen1c1D
pHLP496 CEN/ARS URA3 GPD GFP-Yen1c1A
pHLP440 CEN/ARS URA3 GPD GFP-Yen1 
pHLP441 CEN/ARS URA3 GPD GFP-Yen1c3A
pHLP442 CEN/ARS URA3 GPD GFP-Yen1c3D
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Figure 3-10 Homology model of ScCdc14 and simulation 
of phsphopeptide substrate binding 
A) Comparison of molecular dynamics simulations
of the phosphopeptide substrate (Ac-
A(pSer)PSKRR-NHMe) binding to hCdc14B and 
ScCdc14, colored as described in Fig. 1C. B) The 
ScCdc14 model with initial docked 
phosphopeptide substrate colored to indicate 
amino acid similarity compared to hCdc14B and 
hCdc14A. Molecular docking studies and 





Major a, b, and y series product ions and any ions arising from neutral loss of phosphoric acid are 
labeled in the spectra. The y and b ions are also marked in the peptide sequences. The 
phosphorylated amino acid is written in lowercase, red, underlined text within each peptide 
sequence and the charge state of the detected parent ion is noted in superscript following the 
sequence. A) The peptide containing phosphoserine 245. B) Peptide containing phosphoserine 500. 
C) Peptide containing phosphoserine 679.




















Figure 3-12 Cell cycle localization of Yen1 phosphomimetic mutants 
Cells were considered pre-anaphase if they had a single DAPI-stained DNA mass.  Cells were considered 
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Figure 3-13 Assembly of a fluorescent HJ substrate for in vitro resolution assays and validation of 
activity of purified Cdc14 and Cdk on immunoaffinity purified Yen1 
A) The 5’ TYE 563 labeled fluorescent oligonucleotide X0-1 was annealed with either 1, 2, or all 3 of the
other X0 oligos as indicated and the products separated on a native PAGE gel, demonstrating successful 
and complete assembly into the 4 oligo HJ structure indicated in B). The product of the 4 oligo annealing 
reaction in lane 3 was purified from the gel and used as substrate in all Yen1 resolution assays. C) 
Immunoaffinity purified Yen1-3FLAG treated with recombinant Cdc14 exhibited enhanced electrophoretic 
mobility consistent with dephosphorylation (left). Inclusion of the Cdc14 inhibitor sodium tungstate 
prevented dephosphorylation. Purified Cdk1 (Clb2-Cdc28) restored the slow mobility form of 
immunoaffinity purified Yen1-3FLAG that had been dephosphorylated by recombinant Cdc14 (right). 
Standard SDS-PAGE conditions were used and Yen1-3FLAG was detected by immunoblotting with an anti-
FLAG monoclonal antibody. 
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CHAPTER 4. UNPUBLISHED DATA, CONCLUSIONS AND FUTURE DIRECTIONS 
Throughout this document I have presented experimental data demonstrating 
that the Cdc14 protein phosphatases have a unique intrinsic specificity for phospho 
serine residues within Cdk consensus sequences. Furthermore, I have presented 
experimental data in which we rigorously characterized the enzymatic specificity of 
ScCdc14 to generate an optimal consensus sequence for Cdc14.  Importantly, I have 
demonstrated that this experimentally defined consensus sequence for Cdc14 can be 
used to predict novel Cdc14 substrates such as the Holliday junction resolvase Yen1. The 
work presented in this document has led to a substantial change in our understanding of 
how Cdc14 regulates cellular events.  One important conclusion from the work 
presented in this document is that in budding yeast, the protein phosphatase Cdc14 
likely only dephosphorylates a subset of Cdk-dependent phosphorylation events 
suggesting that other protein phosphatases play a previously unappreciated role in 
catalyzing the reversal of Cdk-dependent phosphorylation events.   
In this chapter I will highlight and discuss the ramifications of some of the 
important findings of the work presented in chapters 2 and 3.  I will also present some 
unpublished data and discuss the implications of the presented findings. Furthermore I 
will also discuss some intriguing hypotheses that have arisen from the work presented 
and suggest some experimental approaches for testing them.   
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4.1  Development of an in vivo phosphatase assay 
In chapter 2 of this document, I presented a mass spectrometry based assay 
which I developed to study multisite protein phosphorylation using label free SRM MS.  I 
have demonstrated that this approach can be used to accurately measure steady-state 
enzyme kinetic parameters.  However, the true power of the method that I have 
developed lies in the ability to measure kinetic parameters for the dephosphorylation of 
multiple phsphopeptides simultaneously. Using conventional techniques to study 
protein phosphorylation/dephosphorylation, one is often forced to examine the 
enzymatic activity of an enzyme towards its substrates in independent reactions due to 
the inability to specifically detect individual substrates.  In contrast, the SRM assay that I 
developed allows for multiple substrates of a kinase/phosphatase to be mixed together 
and assayed in a single reaction; however, the products formed are detected 
simultaneously as individual entities in the mass spectrometer.  This approach is 
particularly well suited to those who are interested in identifying kinase/phosphatase 
substrates from a large pool of substrates, studying enzyme selectivity and, for 
investigating the influence that one substrate may have on another.  In addition to 
demonstrating that this assay is useful for studying the dephosphorylation of multiple 
synthetic phosphatase substrates simultaneously, I also demonstrated that this 
approach is well suited for the simultaneous analysis of several phosphorylation sites on 
an intact protein substrate.  The data I obtained using this approach was instrumental in 
classifying Cdc14 as a serine-selective phosphatase. This work has brought attention to 
the fact that when possible, phosphorylation sites must be examined individually, as 
global phosphorylation data may not be a true representation of enzyme specificity and 
activity.   
My goal for the SRM based assay was that it would facilitate the development of 
an in vivo phosphatase assay.  I had hoped to employ this assay to measure the 
dephosphorylation of many phosphatase substrates simultaneously upon activation of 
the enzyme in the cell.  It was hoped that this assay would provide insight into which 
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proteins and which sites are in fact Cdc14 substrates.  I also wanted to employ this assay 
to investigate the ordering of Cdc14 substrate dephosphorylation during mitotic exit. To 
this end, I found that this approach was sensitive and specific enough to detect 
individual peptides generated from digesting recombinant Fin1 and spiking the resulting 
peptides into a digested whole cell lysate.  However, I found that when I arrested cells 
harboring wild-type Fin1 and cells in which Fin1 had been deleted in metaphase (a point 
in the cell cycle when Cdk activity should be high) and generated protein extracts that I 
digested and prepared for SRM MS analysis, I was unable to specifically identify any 
peptides harboring Fin1 phosphorylation sites of interest (Figure 4-1).  The inability to 
study in vivo phosphorylation using my experimental approach is largely attributable to 
limitations in the instrumentation available at the time. 
Although the assay that I worked to develop did not result in the development of 
an in vivo phosphatase assay, the development of such an assay would still be of benefit 
to the scientific community, particularly to those who are interested in understanding 
how protein dephosphorylation directs late mitotic events.  For this reason, we have 
recently acquired a new mass spectrometer which is more sensitive than the previously 
used Agilent 6410.  Therefore, continued efforts in the lab are still aimed at developing 
an in vivo phosphatase assay in addition to a whole cell extract based in vitro 
phosphatase assay.  Importantly, the in vitro whole cell extract based phosphatase assay 
could prove to be a useful tool in identifying Cdc14 substrates in higher eukaryotes 
where there is very little knowledge of Cdc14 substrates.  Although our lab is not set up 
to culture metazoan cells, it may be easy to obtain appropriately arrested metazoan 
cells from a lab that is pre-equipped to produce such cells. Recombinant Cdc14A and B 
could then be generated in our lab and used to treat extracts derived from the 
metazoan cells.  If such an approach is successful, it would be the first large scale study 
conducted to identify Cdc14 substrates in higher eukaryotes.  At present it is unclear if 
the two Cdc14 homologs dephosphorylate a distinct set of substrates and to what 
extent their substrates overlap.  Therefore, an in vitro, whole cell extract phosphatase 
assay could provide some initial insight into the substrate specificity of the Cdc14A and 
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B homologs. The results however should be interpreted with caution. Cdc14A and B are 
known to exhibit different localization patterns [11].  Thus, an extract based approach 
could provide access of one homolog or the other to a substrate that it would not 
normally encounter.   Nonetheless, such an experiment would provide an important first 
glimpse and the substrates and functions of Cdc14 in higher eukaryotes. 
As discussed in chapter 1 of this document, knowledge of phosphatase 
substrates is significantly lacking compared to the large, but by no means complete, 
knowledge of kinase substrates.  One advancement that moved the kinase field forward 
was the application of mass spectrometry to conduct large scale proteomic studies to 
identify kinase substrates.  While mass spectrometry has been sparsely employed to 
investigate interaction partners of several phosphatases, to date, large scale studies 
have yet to be conducted to identify substrates for many of the serine/threonine or dual 
specificity phosphatases.  As discussed previously, an ongoing project in the lab is to 
develop a mass spectrometry based in vitro phosphatase assay.  In addition to using this 
approach to identify phosphorylation sites that are targeted by Cdc14, I propose that 
this method be applied more broadly to investigate additional protein phosphatases. 
Phosphatases of the PPP family often function via the formation of large multimeric 
protein complexes thus making their purification technically challenging.  However, 
active PP2ACdc55 and PP2ARts1 have been successfully purified from yeast via 
incorporation of an affinity tag into the regulatory subunit [125].  Furthermore, the PP1 
catalytic subunit in budding yeast, Glc7, has been successfully isolated with its targeting 
subunit Sds22 [126]. In light of our recent findings that Cdc14 contributes to DNA 
damage repair in budding yeast, it would also be interesting to identify substrates for 
the protein phosphatases Ptc2 and Ptc3 which are both known to play a role in 
inactivation of the DNA damage checkpoint [127].  Although isolation of some protein 
phosphatase complexes will be more challenging than others, it would be of great 
benefit to characterize protein dephosphorylation in identical cell lysates treated with 
different phosphatases.  Such an experiment has the potential to provide useful 
information about potential phosphatase interplay.  Nonetheless, any large scale 
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proteomics experiments designed to identify phosphatase substrates holds the 
potential to drive the phosphatase field forward. 
4.2 Investigations of the specificity of Cdc14 
Chapter 3 of this document describes an experiment in which we used a 
synthetic phosphopeptide library derived from a known, physiologically relevant Cdc14 
substrate and we found that Cdc14 possesses a strict specificity for peptides that 
contain a +3 basic amino acid (relative to the phosphorylated serine).  Importantly, 
these results were consistent results obtained using a small collection of synthetic 
peptides that I generated to examine the significance of basic amino acids in the +3, +4 
and +5 positions of a Cdc14 substrate. Data obtained from these experiments supported 
the hypothesis that a poor Cdc14 substrate could be generated from a good Cdc14 
substrate simply by the removal of basic residues while a good Cdc14 substrate could be 
generated from a poor Cdc14 substrate by replacing non basic residues with basic 
residues [2].  In chapter 3 of this document, I demonstrate that using our experimentally 
defined consensus sequence for Cdc14, which is centered on the requirement for a +3 
basic amino acid, I was able to predict and characterize a novel Cdc14 substrate.  These 
findings lend support to the idea that Cdc14 exhibits the same substrate specificity in 
vitro and in vivo.  However, the dependence of Cdc14 substrate selection on a +3 basic 
amino in vivo has yet to be rigorously tested. Building on the experiments that I have 
currently done with Yen1 may provide a simple means of testing the specificity of Cdc14 
in vivo.   
In Figure 3-5 of this document I have shown that mutation of the cluster 2 
phosphorylation sites in Yen1 to aspartic acid renders cells sensitive to the DNA 
damaging agents HU and MMS.  This phenotype is constant with the loss of function of 
Yen1.  Conversely, mutation of the cluster 2 phosphorylation sites on Yen1 to alanine is 
able to compliment the loss of function observed with the Asp mutant.  With that said, I 
hypothesize that if the +3 basic residue of the four phosphorylation sites in cluster 2 of 
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Yen1 were mutated to alanine, if the basic residue is necessary for Cdc14 dependent 
dephosphorylation, cells would be sensitive to growth in the presence of HU and MMS 
due to the inability of Cdc14 to dephosphorylate these sites.  As shown in Figure 3-5, 
upon loss of function of Yen1, there is essentially no growth in the presence of DNA 
damaging agents.  If the proposed experiment were conducted, the results may not be 
as black and white as the loss of function studies, but rather the mutant may produce an 
intermediate phenotype.  Furthermore, as discussed previously, work in the lab to 
develop an in vivo phosphatase assay is ongoing and this work is expected to yield 
information about the specificity of Cdc14 in vivo. 
4.3 Does Cdc14 specificity influence late mitotic events? 
Throughout this document I have presented work conducted with synthetic 
peptides that has provided insight into the molecular mechanisms that direct the 
specificity of Cdc14.  One important finding from this work was the experimental 
definition of a Cdc14 consensus sequence. In chapter 3 of this document, I demonstrate 
that while a +3 basic residue is essential for Cdc14 catalysis, additional basic residues in 
the +2 to +5 positions act to further enhance the catalytic activity of Cdc14.   It is 
understood that in order for a cell to successfully complete the mitotic program, there 
are a number of events that must occur in an orderly fashion.  Regulated and ordered 
protein dephosphorylation is one mechanism that cells have employed to ensure that 
events such as chromosome segregation, spindle disassembly and cytokinesis all occur 
in the correct order.  In budding yeast, dephosphorylation of key proteins required to 
drive these events is largely the responsibility of Cdc14.  However, the mechanisms that 
direct Cdc14 to dephosphorylate substrates required for chromosome segregation prior 
to substrates that lead to execution of cytokinesis are not understood.   
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In a recent study published by Bouchoux and colleagues, they suggest that when 
the Cdk to Cdc14 activity reaches a defined threshold, Cdc14 is targeted to specific 
substrates leading to the precise ordering of late mitotic events [40].  In light of our 
recent findings, I propose that the selectivity of Cdc14 is an important factor that 
contributes to the ordering of late mitotic events.  Under these conditions, 
phosphorylation sites matching the high efficiency Cdc14 consensus sequence (see 
chapter 2) would likely be targeted by Cdc14 first, even in the presence of high Cdk 
activity.  As the activity of Cdk decreases, Cdc14 would then target substrates containing 
the lower efficiency consensus sequences.  
Using well-constructed biochemical assays, one could begin to examine the 
contribution that Cdc14 substrate specificity has on the ordering of late mitotic events.  
As a first approach, one could generate a series of recombinant proteins in which all the 
phosphorylation sites on the protein have been mutagenized to represent what we 
predict are high efficiency Cdc14 substrate sites, medium efficiency sites and least 
efficient sites.  Once purified, each of the recombinant protein species would then be 
phosphorylated and mixed together and their dephosphorylation could be followed and 
quantified by mass spectrometry.  To better reconstitute the intracellular environment, 
dephosphorylation of the protein mixture could also be examined in the presence of 
persistent Cdk activity.  By using the same recombinant protein (rather than different 
Cdc14 substrates) to generate each of the consensus site mutants, one is able to 
alleviate any potential intrinsic differences between proteins that may also contribute to 
specificity.  If the results suggest that the specificity of Cdc14 does contribute to the 
order of substrate dephosphorylation, one could then design experiments aimed at 
changing the order of substrate dephosphorylation by changing the Cdc14 consensus 
sequences within substrates. It is important to point out that the in vivo environment 
that Cdc14 faces is inherently much more complex than this experimental set up.  
However, such an experiment would provide an important first glimpse at the role that 
substrate selectivity may play in ordering substrate dephosphorylation.   
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4.4  Inappropriate dephosphorylation of Yen19T occurs in the absence of Cdc14 
activity 
While characterizing the specificity of Cdc14, one finding that I have been 
particularly interested in is the specificity of Cdc14 for phosphoserine sites.  In vitro 
studies conducted using both synthetic peptides and recombinant proteins have 
demonstrated that phosphothreonine sites are resistant to Cdc14 activity [2, 57].  
Furthermore, I and others in the lab have demonstrated that if the serine sites on a 
Cdc14 substrate are mutated to threonine, a substrate trapping mutant of Cdc14 fails to 
associate with the mutagenized substrate (Figure 3-4B and [2]).  Consistent with our in 
vitro studies, these findings suggest that in vivo, Cdc14 does not dephosphorylate Cdk-
dependent phosphothreonine residues.  
As discussed in chapter 3, the protein Yen1 contains nine serine amino acids that 
fit into the consensus sequence for Cdk. During initial studies aimed at characterizing 
the biological significance of threonine vs. serine phosphorylation, I mutated the nine 
serine sites on Yen1 to threonine and examined the phosphorylation status of these 
sites in various experiments.  In order to further test the hypothesis that threonine 
phosphorylation is resistant to Cdc14 activity, I conducted a block and release 
experiment to compare the phosphorylation status of Yen1WT to Yen19T in cdc15-2 cells.  
Cells harboring the cdc15-2 allele progress through the cell cycle like WT cells when 
cultured at the permissive temperature of 25°C.  However, when cultured at 37°C, the 
cells arrest in late anaphase after transiently releasing active Cdc14 in early anaphase. 
Based on the co-immunoprecipitation and synthetic peptide experiments, I 
hypothesized that when cdc15-2 cells harboring either Yen1WT-TAP or Yen19T-TAP were 
blocked in G1 by the addition of α-factor at 23˚C and released into fresh media at 37˚C, 
Yen1-TAP would be transiently dephosphorylated whereas Yen19T-TAP would be 
resistant to the release of active Cdc14 in early anaphase and remain phosphorylated 
throughout the duration of the experiment. What I found however, was an unexpected 
pattern of Yen19T-TAP phosphorylation (Figure 4-2A).  Yen19T-TAP appeared to be 
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phosphorylated less efficiently and dephosphorylated prematurely.  Additionally, I 
found that when Cdc14 was ectopically expressed in cells arrested in S-phase, Yen1WT-
TAP and Yen19ST-TAP again produced different patterns of phosphorylation and 
dephosphorylation (Figure 4-2B).  In considering the data in figures 4-2A and 4-2B, it was 
unclear as to whether or not Cdc14 is dephosphorylating Yen19T-TAP.  I therefore 
examined the phosphorylation status of Yen19T-TAP in cdc14-1 cells arrested with HU, 
nocodazole and by inactivation of Cdc14 at 37˚C (Figure 4-2C).  The results of this 
experiment were perplexing as at the restrictive temperature of 37˚C when Cdc14 is 
inactive, Yen19T-TAP was dephosphorylated. It also appeared to be mostly 
dephosphorylated in nocodazole-treated cells, which are not thought to have active 
Cdc14. In chapter 3, I demonstrated that the HJ resolvase activity of Yen1 is inhibited 
when Yen1 is phosphorylated.  However, treatment of Yen1 with recombinant Cdc14 
stimulates the resolvase activity of Yen1 when purified from cdc14-1 arrested cells. 
Interestingly, I found that when I examined the resolvase activity of Yen19T isolated from 
cdc14-1 cells arrested at the restrictive temperature, Yen19T was already active 
suggesting that it was either not phosphorylated or that phosphothreonine does not 
have the same inhibitory effect (Figure 4-2D).  Furthermore, treatment of the isolated 
Yen19T with recombinant Cdc14 failed to further stimulate the catalytic activity of Yen19T.  
This suggests that either Yen19T was maximally dephosphorylated when it was isolated 
or, recombinant Cdc14 is unable to dephosphorylate the isolated Yen19T in vitro. Taken 
together, the data presented in Figure 4.2 suggests that in contrast to Yen1WT, Yen19T is 
dephosphorylated in a Cdc14 independent manner.  This suggests that in the absence of 
Cdc14 activity, another phosphatase is capable of specifically recognizing the threonine 
form of Yen1.  From the results presented in Figure 4, it is also possible that Cdk does 
not phosphorylate Yen19T as efficiently as Yen1WT.  Nonetheless, the significance of the 
inappropriate dephosphorylation of Yen19T and the implication that a phosphatase 
other than Cdc14 is responsible for this has yet to be investigated. 
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4.5 Yen1c3T localizes to the nucleus in the absence of Cdc14 activity 
Nuclear localization of Yen1 in anaphase is dependent upon dephosphorylation of 
serine 655 and serine 679 (also referred to as the c3 phosphorylation sites) by Cdc14 
(Figure 3-6).  As discussed throughout this document, phosphothreonine residues are 
resistant to Cdc14 activity at both the peptide and recombinant protein level. 
Furthermore, phosphothreonine substrates fail to associate with the substrate trapping 
Cdc14 mutant in vivo.  I therefore hypothesized that due to the selectivity of Cdc14 for 
phosphoserine, mutation of the c3 phosphorylation sites on Yen1 to threonine would 
inhibit nuclear accumulation of Yen1 resulting in constitutively cytoplasmic retention.   
To test this hypothesis, I expressed Yen1c3T-GFP in cdc14-1 cells and examined the 
localization of Yen1 in the presence (asynchronous cells cultured at room temperature) 
and absence of Cdc14 (Figure 4-3).  In doing so, I found that in the presence of Cdc14 
activity, Yen1c3T-GFP resides in the cytoplasm in pre-mitotic cells and in the nucleus in 
late anaphase cells (Figure 4-3A).  Dephosphorylation of Yen1 is necessary to promote 
nuclear accumulation of Yen1 (Figure 3-5A).  Thus, the results in figure 4-3A indicate 
that Yen1c3T-GFP is dephosphorylated in late anaphase.  Interestingly, I found that in the 
absence of Cdc14 activity, in 70% of the cells imaged, Yen1c3T-GFP accumulated in the 
nucleus (Figure 4-3B).  These results suggest that dephosphorylation of Yen1c3T-GFP is 
independent of Cdc14 activity, consistent with the results presented in figure 4-2. 
From the results presented in figure 4-3, it is clear that Yen1c3T accumulates in the 
nucleus in the absence of Cdc14 activity.  However, how the accumulation correlates 
with cell cycle progression is unknown. Figure 4-3 suggests that the accumulation of 
Yen1c3T is independent of Cdc14 activity as it is occurring in the presence and absence of 
fully functional Cdc14.   The data in figure 4-2 suggests that Yen19T is dephosphorylated 
earlier than Yen1WT and that this dephosphorylation is occurring in the absence of Cdc14 
activity.  To date, the full phosphorylation profile of Yen19T has only been examined in 
cdc15-2 cells.  In the future it would be interesting to examine the phosphorylation of 
Yen19T in WT cells.  If Yen19T is dephosphorylated prematurely compared to Yen1WT in 
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WT cells, it would then be interesting to examine the localization pattern of Yen1c3T and 
Yen1WT in relation to cell cycle progression.  One would predict that premature 
dephosphorylation of the Yen1 threonine mutant would also lead to premature nuclear 
accumulation.  As discussed in the next section, there are interesting phenotypic 
consequences associated with expression of Yen19T and, it is possible that premature 
nuclear accumulation could in part be contributing to the observed phenotypes. 
4.6 Inappropriate phosphoregulation of Yen19T is toxic 
In budding yeast, there are no phenotypic consequences associated with deletion 
of Yen1 [6, 116].  However, deletion of Yen1 in combination with another structure 
selective endonuclease, Mus81, results in a slow growth phenotype and reduced growth 
in the presence of DNA damaging agents [6, 116].  Interestingly, while investigating the 
biological significance of threonine vs. serine phosphorylation, I found that mus81∆ cells 
expressing Yen19T exhibited reduced fitness and growth sensitivity in the presence of 
DNA damaging agents (Figure 4-4 A&B), indicative of a loss of function mutation.  
Perplexingly, I also found that when Yen19T is expressed in WT cells, it also results in a 
reduced growth rate (Figure 4-4C), suggesting that the Yen19T allele functions as a 
dominant negative in vivo. 
The observed loss of function phenotype associated with expression of 
Yen19T mus81∆ cells was initially thought to be the result of persistent phosphorylation 
of the threonine mutant.  However, as illustrated in figure 4-2A, Yen19T is not 
constitutively phosphorylated rather, it is prematurely dephosphorylated compared to 
Yen1WT.  Furthermore, purified Yen19T is capable of resolving a Holliday junction in vitro 
(Figure 4-2D) suggesting that Yen19T mutant is still catalytically competent.  Recently, 
Steve West shared unpublished data with us demonstrating that constitutive activation 
of Yen1 leads to growth sensitivity in the presence of DNA damaging agents.  Taken 
together, I hypothesize that the observed phenotypic effects of expressing the Yen19T 
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allele in mus81∆ cells is the due to a failure to fully inactivate Yen1 by phosphorylation 
rather than a failure to activate the enzyme by dephosphorylation.   
Although the observed phenotypic effects of the Yen19T mutant in mus81∆ cells 
and WT cells are interesting, the biological causes of these effects are not understood.   
Holliday junction formation is a central component of homologous recombination. HJs 
can either be dissolved via a dissolution pathway involving proteins such as Sgs1-Top3-
Rmi1 or they can be resolved via proteins such as Yen1 and Mus81.  In mitotically 
dividing cells, dissolution of HJs is preferred over resolution. Resolution of HJs by 
proteins such as Yen1 is known to be associated with CO formation and LOH [109].  Thus, 
if the Yen19T allele is prematurely activated, the observed phenotypes may be the result 
of increased CO formation.  Alternatively, if the Yen19T allele is prematurely activated, 
the observed phenotype could be due to inappropriate resolution of 5’-flap/fork 
structures that arise during S/G2 as Yen1 has been shown to resolve such structures in 
vitro (personal communication, Steve West).  Inappropriate resolution of 5’-flap/fork 
structures by Yen1 would require that Yen1 be localized to the nucleus prematurely.  In 
figure 4-3, I have demonstrated that the Yen1c3T mutant accumulates in the nucleus in 
the absence of Cdc14 activity suggesting that under these conditions Yen1 is 
dephosphorylated.  Given the premature dephosphorylation of Yen19T observed in 
figure 4-2A, it seems likely that nuclear accumulation of Yen1c3T could be occurring 
prematurely thereby resulting in inappropriate resolution of 5’-flap/fork structures that 
could be present at late firing origins.   
The observed dominant negative phenotype associated with expression of Yen19T 
in WT cells is rather interesting.  The human homolog of Yen1, Gen1, is thought to 
function as a dimer and, although the dimerization state of Yen1 has not been rigorously 
characterized, it too is thought to function as a dimer [128].  It therefore seems 
plausible that when expressed in the presence of Yen1WT, Yen19T may be interfering 
with the appropriate formation of the Yen1 dimer.  At present it is unknown how or if 
phosphorylation of Yen1 could be important to control the dimerization state of Yen1.  
It is possible that one mechanism by which phosphorylation restricts the enzymatic 
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activity of Yen1 is by inhibiting inappropriate dimerization.  As discussed previously, the 
Yen19T allele may be a prematurely active Yen1 variant.  Interestingly, expression of 
Yen19A in WT cells does not lead to a dominant negative phenotype.  This suggests that 
constitutive activity of Yen1 in WT cells is not toxic and that there are additional, 
currently undefined, reasons that the Yen19T allele is toxic.   
Taken together, the biological reasons behind the observed Yen19T phenotypes are 
a mystery waiting to be solved.  Why expression of the Yen19T allele is toxic in the 
presence of Yen1WT but expression of Yen19A is not is a conundrum that is not 
understood.  Nonetheless, these observations suggest that there may be intrinsic 
differences between serine and threonine phosphorylation.  Investigations into the 
possibility of such differences will be important for further understanding how 
phosphorylation affects signaling pathways and biological processes. 
An overarching conclusion that can be drawn from the work presented in this 
document is that the substrate specificity of the protein phosphatase Cdc14 restricts the 
capacity of Cdc14 to reverse Cdk-mediated protein phosphorylation.  In contrast to what 
was previously thought, Cdc14 likely only reverses a subset of Cdk-dependent 
phosphorylation events.  Amongst the Cdk-dependent phosphorylation events reversed 
independent of Cdc14 is threonine phosphorylation.  Although the observation that 
phosphorylation of Yen19T is reversed independent of Cdc14 activity may be an artifact 
of expressing a protein that has the potential to be phosphorylated at threonine sites 
rather than serine sites, the observed results are consistent with other findings that 
have led to the hypothesis that Cdk-dependent threonine phosphorylation is targeted 
by a protein phosphatase other than Cdc14.  With that said, Yen19T could be used as a 
substrate to begin to identify and characterize the protein phosphatases that reverse 
Cdk-dependent threonine phosphorylation.   
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4.7 Identifying the phosphatase(s) that dephosphorylate Yen19T in the absence of 
Cdc14 
The protein phosphatase PP2A is a good candidate for reversing Cdk-threonine 
dependent phosphorylation as PP2A is known to oppose Cdk activity in higher 
eukaryotes.  I have already demonstrated that Yen19T is dephosphorylated in the 
absence of Cdc14 activity in a cdc14-1 strain.  This strain can therefore be used as a 
starting point to examine the phosphorylation status of Yen19T in response to mutations 
in other phosphatase components that would render the phosphatase inactive, thereby 
restoring Yen19T to its phosphorylated status.   One approach to doing this is to 
systematically delete the regulatory subunits of PP2A, Cdc55 and Rts1. Another 
approach that could be taken is to generate conditional alleles of PP2ACdc55 or PP2ARts1 
by fusing a heat-inducible degron [129, 130] to either Cdc55 or Rts1.  Under these 
conditions, if cells were arrested with alpha-factor and released into fresh media at 37°C, 
both the activity of Cdc14 and the regulatory subunit of PP2A would be simultaneously 
inactivated allowing for examination of the phosphorylation status of Yen19T.  The 
introduction of a heat-inducible degron to generate a cdc14-td allele has been shown to 
be an effective means of regulating the stability of Cdc14 [131] and it is a particularly 
attractive approach for this experiment as it limits the disruption of other events 
regulated by PP2ACdc55 or PP2ARts1 to a defined window of time. 
In addition to genetic screens for the phosphatase responsible for reversing 
Yen19T phosphorylation, biochemical approaches combined with mass spectrometry 
could also be utilized.  Purified Cdk complexes have been shown to be able to utilize the 
ATP derivative ATPγS in vitro [132, 133].  Upon transfer of the gamma thiophosphate 
group to a kinase substrate, a phosphatase recognizes it as a phosphorylated substrate 
and will associate with it.  Although phosphatases are able to bind tightly with the 
thiophosphorylated substrate, the thiophosphorylated substrate is resistant to de-
thiophosphorylation by the phosphatase allowing for isolation of the substrate-
phosphatase complex [14, 134].  Upon isolation of the substrate-phosphatase complex, 
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the bound phosphatase can be separated from the substrate with a salt gradient and 
identified.  This approach has led to the successful identification of both PTP and PPP 
family members [134-137]. In order to identify phosphatases that recognize Yen19T as a 
substrate, immobilized Yen19T could be thiophosphorylated in vitro by Cdk.  Following 
thiophosphorylation the immobilized Yen19T could then be incubated with a whole cell 
extract and the isolated interacting partners could be eluted with a salt gradient and 
identified by mass spectrometry. 
4.8 Is there more to Cdc14 specificity? 
Although we have demonstrated that the protein surface of Cdc14 surrounding 
the active site contributes substantially to substrate recognition, it is still unknown if 
additional contacts between Cdc14 and its substrates distal from the active site 
contribute to substrate selection and catalysis.  One possible approach to examine the 
influence of potential Cdc14-substrate contacts on Cdc14 substrate recognition and 
catalysis is to compare kinetic parameters of Cdc14 for a peptide and full length 
substrate. In order to do this, one could generate a recombinant protein substrate that 
can only be phosphorylated at a single site.  Once the recombinant protein has been 
phosphorylated in vitro, the substrate could then be treated with Cdc14 and a 
spectrophotometric assay can be used to measure the kinetic parameters KM, Kcat and 
Km/Kcat.   Then, the same kinetic parameters could be calculated for the 
dephosphorylation of a synthetic phosphopeptide derived from the same site that was 
phosphorylated on the recombinant protein.  If the activity of Cdc14 for the synthetic 
peptide and the recombinant protein are comparable, this would indicate that the 
active site of Cdc14 is solely responsible for Cdc14 substrate selectivity.  A lower activity 
of Cdc14 for the singly phosphorylated recombinant protein would indicate that 
additional Cdc14-substrate contacts are occurring that contribute to substrate 
recognition.  Conversely, if the activity of Cdc14 is greater for the synthetic peptide, this 
could be an indication that additional contacts between Cdc14 and its substrates are 
104 
inhibitory.  Such a finding would suggest that Cdc14 substrate specificity is primarily 
driven by interactions surrounding the active site however, additional contacts could 
serve as a fine tuning mechanism to either enhance or decrease the overall affinity of 
Cdc14 for its substrates. 
While the work that I and my colleagues have conducted has significantly 
enhanced our understanding of how Cdc14 is capable of selecting specific substrates, do 
we know all that there is to know about Cdc14 substrate selectivity?  No.  One area that 
remains to be investigated is whether or not dephosphorylation of one site by Cdc14 
can influence the rate at which another phosphorylation site on the same protein is 
dephosphorylated by Cdc14.  At present, it is unknown if dephosphorylation of a multi-
substrate protein by Cdc14 occurs via multiple independent binding events or if 
dephosphorylation occurs in a processive manner such that the substrate is not released 
from Cdc14 until all sites have been dephosphorylated.  The answer to this question 
could impact how we think of Cdc14 substrate recognition.  If dephosphorylation of a 
multi-substrate protein occurs via independent binding events, this would suggest that 
Cdc14 would first target all phosphorylation sites that contain the optimal consensus 
sequence.  Under these conditions, if a protein has a mixture of optimal Cdc14 sites and 
mediocre Cdc14 consensus sites (as most proteins do), the mediocre sites would remain 
phosphorylated on a protein until all optimal sites on all substrates have been 
dephosphorylated.  In contrast, if substrate dephosphorylation proceeds in a processive 
manner, the ratio of optimal consensus sites to mediocre consensus sites could 
contribute to recruitment of Cdc14 to that substrate.  Once recruited to a substrate, 
Cdc14 would then dephosphorylate all consensus sites before moving on to another 
substrate. 
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4.9 Summary of experimental findings 
The work that I have presented in this document has contributed to the finding 
that the protein phosphatases Cdc14 are specific for phosphoserine sites within Cdk 
consensus sequences.  These findings demonstrate that Cdc14 selectively reverses only 
a subset of Cdk-dependent phosphorylation events.  In addition to being selective for 
phosphoserine Cdk-substrates, we have also demonstrated that Cdc14 substrate 
selection is dependent on the presence of a +3 basic amino acid.  In chapter 3, I 
presented work that has led to the first experimentally developed Cdc14 consensus 
sequence.  I have demonstrated that using this consensus sequence to search the yeast 
proteome, one can identify novel Cdc14 substrates.  Furthermore, with the 
identification that the protein Yen1 is a Cdc14 substrate, I have uncovered a previously 
unknown role for Cdc14 in regulating DNA damage in budding yeast.  Although Cdc14 
has been implicated to play a role in the DNA damage response in higher eukaryotes, 
Yen1 is the first DNA damage repair substrate of Cdc14 to be identified in any organism.  
Although the work presented here has led to significant advances in understanding how 
Cdc14 recognizes its substrates and the biological significance of substrate selection, our 





Figure 4-1 Nonspecific detection of endogenous Fin1 phosphopeptides 
A) W303 cells and B) W303 fin1::KanMX cells were arrested in metaphase by the
addition of nocodazol. Protein extracts were generated and digested with 
endoproteinase LysC.  The digested peptides were analyzed on an Agilent 6410 
operated in SRM mode set to detect transitions derived from LysC digested 
recombinant Fin1. A peptide is considered to be positively detected when the SRM 
signal for two transitions with identical retention times are detected in the 
experimental sample (panel A) but not in the negative control sample (panel B). 
Counts vs. Acquisition time (mins.) 
Counts vs. Acquisition time (mins.) 
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α-Factor + - - - - 
HU - + - - - 
Nocodazole 37˚C - - + - - 
Nocodazole 25˚C - - - + - 












A) W303, cdc14-1, and cdc15-2 strains, each expressing Yen1-TAP or Yen19T-TAP from PYEN1 were
arrested at 23 °C in G1, then released into fresh medium at 37 °C. Cells were harvested at the 
indicated times for analysis by Phos-tag™ immunoblotting.  B) 3HA-Cdc14 was ectopically 
overexpressed from PGAL1 for 1.5 hours in S phase cells expressing Yen1-TAP, Yen1
9T-TAP or Yen19A-
TAP from PYEN1. Phosphorylation status of Yen1 was monitored by anti-protein A immunoblot of 
Phos-tag™ gels.  C)  Asynchronously growing cdc14-1 cells expressing Yen19T-TAP from PYEN1 were 
arrested by the addition of the indicated reagent or by incubation at 37°C.  Upon arrest, cells were 
harvested and analyzed by Phos-tag immunoblotting.  D) Yen1-3FLAG  and Yen19T-3FLAG were 
immunoaffinity isolated from soluble extracts of cdc14-1 cells arrested at 37 °C. Equal fractions of 
Yen1-bound resin were either untreated or treated with recombinant Cdc14 prior to HJ resolution 
assays.  The isolated Yen1 variants were added to reactions containing the fluorescent HJ 
substrate.  Reaction products were separated by native-PAGE.   
Figure 4-2 The phosphorylation status of Yen19T is different from that of Yen1WT 
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Figure 4-3 Inappropriate phosphorylation of Yen19T is toxic 
A) The indicated strains were grown in YPD at 30°C and the absorbance at 600 nm was
measured.  B) Tenfold serial dilutions of the indicated strains were spotted onto either YPD 
plates or YPD plates containing 0.005% MMS or 25 mM HU.  Plates were incubated at 30°C for 
48 hours (MMS plate) or 72 hours (YPD and HU plates).  C) As in A except that all strains 



















Figure 4-3 Yen1c3T-GFP localizes to the nucleus in the absence of Cdc14 activity. 
A) Asynchronous cdc14-1 cells expressing Yen1c3T-GFP from a CEN plasmid under control of PGPD were
cultured at the permissive temperature and the intracellular localization of Yen1c3T-GFP was examined by 
fluorescence microscopy.  Prior to visualization, cells were fixed and stained with DAPI.  B)  As in A except 
that cells were arrested in late anaphase to inactivate Cdc14-1 by shifting the temperature to 37°C.  























3. After degassing, add appropriate volume (10µM = 20µL, 15 µM = 30µL, and
20µM = 40µL) of the 5mM Phos-tag stock solution and an equivalent volume of
10mM MnCl2. After gently mixing, add 50µL of 20% APS and 10 µL TEMED.  Draw
solution into a 10mL glass pipette and distribute about 4.5 mLs between two gels.
Alternatively, cast only 1 gel and discard the left overs. Once the solution has
been poured into the glass plates, overlay the gel with 95% EtOH (do not use the
t-butonol that we normally use for overlaying the gels).
4. Once the gel has solidified, remove 95% EtOH and carefully rinse the top of the
gel with H2O.
5. Prepare and cast stacking gel as normal
Important considerations for casting the phos-tag gel: 
• Acrylamide and the 1.5 M Tris-HCl should be no more than 30 days old.  The 20%
APS stock solution should be made fresh just prior to casting the gel.
• To prepare a 25 mL stock solution of 26.7% 37:1 Acryl:bis-acryl add mix together
16.23 mLs of 40% acrylamide (Amresco ACRYL-40 (M121-500ML)) and 8.76 mLs
of 2% bis-acrylamide (Amresco, Bis-2 (0832-500ML)).
• For the most reproducible gel shift, use the gel immediately after casting.  I have
stored them at 4˚C wrapped in paper towels and plastic wrap in a plastic bag for
a day or so without any problems; however, there is more run to run variability
with the gels when they are stored for several days.
• I have learned that for best consistency, the solutions should be pipetted with a
standard pippetter rather than using the glass pipets.  Another words, the phos-
tag gel is very sensitive to changes in gel composition due to inaccuracy in
pipetting with the glass pipettes.
Running and transferring the phos-tag gel: 
1. Load 7 µL of the loading dye to the appropriate lane (on a normal gel only 5µL of
the loading dye is needed; however, for the phos-tag gels the marker bands
become diffuse so I load slightly more).
2. Between the marker lane and the first sample lane, load the same volume of 1x
loading dye as the volume of samples that you intend to run.
3. Load 5-10µL of samples to the appropriate lanes.  Fill the remaining lanes with 1x
loading dye
4. Run the gel at a constant 20 mA.  The running time will vary depending on the
concentration of phos-tag.  For a 10µM gel, I run the gel for 60 mins.  For a 15 or
20µM gel, I run the gel for 100 mins.
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5. After the gel is done running, a good indication for Yen1 experiments that the gel
was run correctly is that the 2nd marker band will ‘smile’ (this is more noticeable
with higher concentrations of the phos-tag reagent).
6. To prepare the gel for transfer, remove the gel from the glass plates (Be very
careful, the gel is very fragile and incredibly slippery) and incubate for 10 mins.
with rocking in transfer buffer containing 2 mM EDTA (I make the EDTA solution
by diluting my 0.5 M stock of EDTA into the transfer buffer).  After 10 mins,
remove the solution (I recommend pouring the solution into another small
container rather than directly into the sink as the gel is very slippery and I have
lost a handful of them to the drain) and incubate the gel in transfer buffer for 10
mins with rocking.  During this 20 min. incubation period, fill a transfer tank half
full with transfer buffer and chill it in the -20 (you should still use an ice pack
during the transfer).  After incubating the gel with transfer buffer, prepare the
western ‘sandwich’ as normal.
7. Transfer the proteins from the gel to the PVDF membrane at a constant 27 mV
for 180 mins.  I have also done the transfers at 35 mV for 120 mins without any
negative consequences; however, my standard approach is the 180 mins.
8. Conduct westernblott as normal.  For ProA tagged Yen1, use α-ProA at 1:10,000
at room temp for 45-60 mins.
Additional notes about running the phos-tag gels: 
• When I was examining time course experiments using phos-tag gels I noticed
that the phosphorylation dependent shift of Yen1 was very poor at high
concentrations (20µM) of the phos-tag reagent.  For time course analysis, I used
10 µM phos-tag and ran the gel for 60 mins. In contrast, when analyzing the
phosphorylation status of Yen1 in response to ectopic expression of Cdc14 and
1-NM-PP1 inhibition of Cdk, I found that using only 10 µM of phos-tag resulted in
a very large shift of Yen1 (probably about a 1.5 inch shift) therefore, in order to
tame the shift under these conditions I had to increase the concentration of
phos-tag to 15 µM and I ran the gel for 100 mins.  It is unclear to me what the
basis for this variation could be due to.  However, between the gel shift
experiments and the ectopic expression of Cdc14 and 1-NM-PP1 inhibition of
Cdk experiments we ordered new phos-tag reagent.  It is therefore possible that
the observed variation between the experiments could be due to ‘freshness’ of
reagent or manufacturer variability.
• All wells of the gel should be filled when analyzing your samples.  If all wells of
the gel are not filled, the samples have a tendency to bow which in some cases
could skew the interpretation of the gel shift.  Also, the sample volume and
overall sample composition needs to be the same in all wells (except the marker
lane).  If sample volumes or composition is different, you will notice that one
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sample is “pulled” toward the other.  This is most noticeable if you load your 
experimental sample next to the marker.   
• In regards to how much sample to load, less is best.  Even though I typically load
15 µL of my Yen1 extracts on a normal gel, when analyzing the same sample on a
phos-tag gel I would start by loading only 5 µL.  I have found that the appropriate
volume of sample to load is highly variable from experiment to experiment.
Another words, if you do an experiment once and you found that 5 µL was a
good amount to load to a phos-tag gel, don’t be surprised if when you do the
same experiment a second time, 5 µL of sample may be too much or too little.
Validation of Phos-tag reagent with α-casein: 
1. Prepare a 10% gel (using standard lab recipe) containing 100µM phos-tag
reagent and 200µM MnCl2.
2. Make a 6 mg/mL stock solution of α-casein in H20.
3. Make a 50µl sample containing:
Volume (µL) Reagent 
8.3 6 mg/ml α-casein 
5 20 mM MnCl2 
5 Λ phosphatase 
buffer 
30.7 H2O 
4. Divide sample in half
5. To one sample add 0.5 µL of λ phosphatase, to the other sample add 0.5 µL H2O.
6. Incubate both samples at 30˚C for 40 mins.
7. Add 4x loading dye to the samples
8. Load to gel and run gel at 30 mA for 70 mins.
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5.2 Determination of cell doubling time 
Experimental setup: 
1. Grow 5 mL cultures of the desired strains in the appropriate media overnight.
2. In the morning, back dilute cultures to an OD600 of 0.1.  Allow the cells to grow
through several generations (6-7 hours).
3. Determine the OD600 of each culture.  In a microfuge, tube, make a 1 mL aliquot
of each strain so that the OD600 of each culture is 0.5.
4. Transfer 100 µL of each culture to a 96 well round bottom plate.  In addition to
the cultures of interest, fill a row of wells with the appropriate media and use
this as your blank.
5. Set the plate reader the appropriate temperature, set the shaking to fast and to
read the OD600 every hour for the desired length of time (I typically set it for 15
hours).
6. Once the experiment is complete, transfer the OD600 readings to excel and
process the data.
Data processing: 
1. Subtract the average reading of all blanks from each OD600 value.
2. Take the natural log of each corrected OD600 value and plot that verses time.
3. Identify the window of time during which the growth of all strains is linear.  Use
this region to determine the slope of the line for each strain.
4. To determine the doubling time of each strain, divide the slope by Ln2.
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5.3 Growth sensitivity spotting assay in the presence of DNA damaging agents 
Preparation of plates: 
MMS is known to break down and become ineffective over time.  For this reason, when 
doing the spotting assay using MMS as a DNA damaging agent, the MMS plates should 
be made no more than 24 hours before one plans to use them.  I generally autoclave 
enough media to make twice as many plates as I need.  Once the media has cooled after 
autoclaving, I add the desired concentration of MMS to the media and immediately 
pour the plates.  Although it is not necessary to pour fresh plates for other chemicals 
(such as HU) or the control plate, I typically pour them fresh as well so that all media 
that is being used is consistent. 
Spotting the samples onto the plates: 
1. Grow desired strains overnight to saturation.
2. Determine the OD600 of each saturated culture (it is a good idea to make
dilutions to do this to ensure that the values are within the linear range of the
spectrophotometer).
3. In a 1.5 mL tube, dilute the strains so that they are at an OD600 of about 1.0 in a
final volume of 1 mL.
4. Briefly centrifuge the cells and wash with water.  Resuspend the cells in 1 mL of
water.
5. Make 6 serial dilutions of each strain by diluting the cells 1:8 in water.
6. Spot 4µL of each dilution onto plate.  When spotting the samples onto the fresh
MMS plates (or any fresh plate for that matter), use caution as the spots do not
absorb quickly into fresh plates and they have a tendency to bead up and run
away if spotted to quickly.
7. Incubate the plates at 30°C for 48 hours.  After 48 hours, photograph all plates
and return all plates to the incubator for another 24 hours, photograph again.
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5.4 Sister chromatid co-segregation assay 
One important thing to keep in mind when doing this assay is that this strain is unstable 
and will sporadically loose the URA3 marker.  For this reason, the strain stocks should be 
maintained in/on SD-URA media and if a new construct needs to be integrated into these 
strains, selection for the integrated gene should be carried out using the integrant 
selective marker and SD-URA (for example SD-URA-TRP). 
1. Streak cells from the frozen stock onto SD-URA plates.  Incubate at 30°C until
single colonies form.  Typically 2-3 days.
2. Pick a single colony and streak it onto a YPAD plate (YPAD is made by adding 30
mg/L of adenine to our standard YPD recipe).  Incubate plates at 30°C for about 2
days.
3. Inoculate nine 5 mL cultures of YPAD by picking nine single colonies from the
YPAD plates.  Incubate the cultures at 30°C overnight.
4. The following day, harvest all 5 mLs of each 5 mL culture.  Resuspend cell pellets
in 1 mL of water and transfer to a microfuge tube.  Centrifuge cells, remove
supernate and resuspend in 500 µL of water.
5. Make a series of 10 fold dilutions for each culture into water such that the final
dilution is 1x10-7.
6. Plate 50 and 100 µL of the 10-6 dilution for each culture onto SCcomp plates.  Plate
50 µL of the 10-3 dilution for each culture onto SC-ADE plates and 100 µL of the 100
dilution of each culture onto SC-ADE-URA plates.  Incubate all plates at 30°C.
7. After 72 hours, count the number of colonies that have formed on the SCcomp
and SC-ADE.  After 120 hours, count the number of colonies that have formed on
the SC-ADE-URA plates.
Note: the ideal number of colonies to have on each plate is between 50 and 100 thus, one may need 
to adjust either the volume or dilution of cells plated for each strain tested, particularly on the SDComp.  
In general, if a strain is not expected to have segregation defects, 50 µL of the 10-6 dilution should be 
plated on the SDComp plates.   
8. Once the number of colonies has been counted on all plates, the data should be
analyzed using the method of the meadian as described by Lea and Coulson
[138].  The rate of sister chromatid co-segregation is determined by dividing the
SD-ADE-URA rate by the SD-ADE rate.
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5.5 Purification of Yen1-FLAG 
If the isolated Yen1-FLAG will be used for HJ resolution assays, Yen1 should be isolated 
from at least 1L of cells.  If the isolated Yen1 is to be used for mass spec studies, it 
should be isolated from at least 10L of cells. 
1. Resuspend frozen cell pellets in lysis buffer supplemented with 50 mM β-
glycerolphosphate, 20 nM NaF, 2 mM Benzamadine and protease inhibitors.
Aliquot resuspended cells into microfuge tubes containing approximately 500 µL
of glass beads.
2. Disrupt cells in bead beater for 10 mins followed by 10 minuet incubation on ice.
Repeat two more times.
3. Transfer lysate to new microfuge tube and sonicate each tube for 20 seconds to
shear genomic DNA.
4. Centrifuge samples at max speed for 40 minutes at 4°C.  After centrifugation,
there will likely be a lipid layer on the top of the supernatant, to remove this
syringe filter the supernatant.
5. Transfer the clarified supernatant to a new tube containing the appropriate
volume of FLAG-M2 resin that has been equilibrated in lysis buffer.  For HJ assays,
use 30 µL of the 50/50 FLAG slurry.  For Mass spec analysis, use 200 µL of the
50/50 FLAG slurry.
6. Incubate the lysate with the FLAG resin for 60 minutes at 4°C with gentle rocking.
7. Pellet resin and wash 3x with lysis buffer with phosphatase inhibitors.  If the
isolated Yen1 will be treated with Cdc14, wash 2 more times with buffer lacking
the phosphatase inhibitors.
8. If the isolated Yen1 is to be used for mass spec analysis, elute the isolated Yen1-
3FLAG by the addition of 3xFLAG peptide.  Following elution, TCA precipitate the
protein and isolate the purified Yen1 by SDS-PAGE.  If the isolated Yen1 is to be
used in an HJ assay, continue on to the Holliday Junction resolution protocol.
Yen1 Lysis Buffer 
40 mM Tris-HCl pH 7.5 




5.6 Formation of Holliday junction X0 
Ordering oligos: 
1. Order 100 nmole of each oligo from IDT with HPLC purification
2. To oligo X0-1 add the 5’-5TYE563 modification.
Note: When this oligo is received it should be wrapped in foil to prevent
unwanted photo bleaching.
Name Sequence (5’ to 3’)
X0-1 ACG CTG CCG AAT TCT ACC AGT GCC TTG CTA GGA CAT CTT TGC CCA 
CCT GCA GGT TCA CCC 
X0-2 GGG TGA ACC TGC AGG TGG GCA AAG ATG TCC ATC TGT TGT AAT 
CGT CAA GCT  TTA TGC CGT 
X0-3 ACG GCA TAA AGC TTG ACG ATT ACA ACA GAT CAT GGA GCT GTC 
TAG AGG ATC CGA CTA TCG 
X0-4 CGA TAG TCG GAT CCT CTA GAC AGC TCC ATG TAG CAA GGC ACT 
GGT AGA ATT CGG CAG CGT 
3. Re-suspend oligos at 100 µM using TE (make sure pH is 7.5).  Once re-
suspended the oligos should be stored in the -20. 
Annealing the 4-way junction: 
1. Boil 1L of H2O on a hot plate.




42.5 Sterile TE 





3. Add the tube containing the HJ mix to the beaker of boiling water.  Remove
beaker from hot plate and allow to cool on bench top overnight.
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Purification of the 4-way junction: 
1. Prepare a 12% neutral PAGE gel.  Once the gel has solidified, rinse the wells and
pre-run the gel at 200 V for 180 minutes at 4˚C.
Note: The running buffer is 1xTBE and pre-running the gel is very important to
remove any excess APS and TEMED from the gel!!  The presence of these
molecules could interfere with visualizing the Cy5 dye.  Also, the bands will ‘smile’
if you do not pre-run the gel.  Neutral PAGE gels heat up and therefore must be
run in the cold box.
2. Add 6x loading dye to the annealing reaction.
3. Load 25µL of the annealing reaction into two lanes of the 12% gel and run the gel
at 200 V for 120 mins. at 4˚C.  Cover the gel tank with a box to prevent photo
bleaching of the synthetic junction.
4. To visualize where the synthetic junction is, if you are not color blind, when you
look at the gel there will be a red region on the gel.  This is the junction.  If you
are color blind, you can visualize the junction on the typhoon imager.  To
visualize on the imager, do not remove the junction from the glass plates.  Also,
since you will need to cut the junction out of the gel once you know where it is, it
is a good idea to take a ruler and mark 1 cm segments (from top to bottom) on
the gel with a sharpie.  Once you have visualized where the junction is, the marks
will help you know where to cut.
5. Once you know where your junction is on the gel, excise it from the gel using a
clean razorblade.  Chop the gel slice into smaller sections and transfer them to a
light resistant microfuge tube.
6. To the microfuge tube, add 200 µL TMgN buffer.  Incubate the microfuge tube
over night at 4˚C with end over end rotation.
7. After eluting the junction into the TMgN buffer by diffusion, transfer the
supernatant to a new light resistant microfuge tube.
Quantification of the 4-way Holliday junction: 
1. Determine the OD260 nm using 1 OD260 = 33 µg/mL
2. The molecular weight of the 4-way junction is 74392.5
Buffers and reagents: 
6x loading dye- 40%sucrose (w/v) in H2O, filter sterilize 
TMgN buffer – 10 mM Tris-HCl, pH8.0, 1 mM MgCl2, 50 mM Nacl, filter sterilize 
10x TBE – 108 g Tris Base, 55 g Boric Acid, 7.44 g Na2-EDTA-H2O 
• Also make sterile 5x TBE to use for casting the gel
12% neutral PAGE – 6.75 mL acrylamide, 5.04 mL H2O, 3.0 mL sterile 5xTBE, 200 µL 10% 
APS, 10 µL TEMED 
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5.7 Holliday Junction resolution assay 
If the dependence of the catalytic activity of Yen1 on its phosphorylation status is being 
examined, the resin should be aliquoted appropriately and treated with either Cdk or 
Cdc14 for 30 minutes at 30°C.  After treatment, the resin containing the bound Yen1 
should be washed 2x with lysis buffer that has been warmed to room temperature.  I 
have found that when I change the temperature of the resin from 30° C to 4°C and back 
to 30° C for the resolvase assay, Yen1 activity is abolished.  Therefore, once I incubate 
the sample at 30°C, all subsequent wash steps are done at RT. 
1. Immediately prior to starting the resolvase assay, centrifuge the resin
containing the isolated Yen1 and remove the supernatant.  Consider the
remaining resin to be 10 µL.
2. Prepare a master mix containing the fluorescently labeled HJ and Poly dI-dC
in 50 mM Tris pH7.5, 2.5 mM MgCl2.  The final concentration of the
fluorescently labeled HJ should be 20 nM and a total of 250 ng of Poly di-dc
should be used in the reaction.  I typically prepare my master mix so that I
can add 10 µL of it to the assumed 10 µL of resin and have a final reaction
volume of 20 µL.
3. Incubate the reaction in the dark for 60 minutes at 30°C.
4. After the reaction is complete, centrifuge the sample and transfer as much of
the supernatant as possible to a new microfuge tube.  It is important that no
resin is transferred with the supernatant as it will be detected in the gel.
Also, if multiple samples are being analyzed make sure to transfer the same
volume for each reaction.
5. To the supernatant that was transferred to a new tube, add the appropriate
volume of 6x native PAGE loading dye (40% sterile sucrose) and load each
sample to a pre-ran 10% neutral PAGE gel.  Run gel in the dark at 150 V for
45 minutes at 4°C.  Once the gel is done running, the reaction products can
be visualized on the Typhoon imager.  To do so, leave the gel intact (do not
separate the gel from the glass plates) but be sure to clean the glass plates
with ethanol prior to visualization.
To make a 10% native gel, mix together 5.6 mLs of 26.7% acrylamide, 3.0 mLs of 
sterile 5xTBE, 6.4 mLs of water, 200 µL 20% APS and 10 µL TEMED.  Pre-run the 
gel at 150 V for 180 minutes at 4°C. 
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6. To analyze the isolated Yen1, elute it from the resin by addition of 3xFLAG
peptide.  Analyze 20% of the eluted protein by western blotting after
separation on an 8% SDS-PAGE gel.  The gel should be run at 185 V for 65
minutes.
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5.8 Bulk DNA segregation 
1. Grow 50 mL cultures of cells in YPD media to an OD600 between 0.8 and 1.0.
2. Back dilute cells to an OD600 of 0.2 and add alpha factor, incubate cells at room
temperature for 1.5 hours.  After 1.5 hours, add a second aliquot of alpha factor
and continue incubating for another 1.5 hours.
3. After the second incubation, visually asses the quality of the alpha factor arrest.
If the cells appear to be greater than 95% arrested continue onto step 4.  If they
are not fully arrested, continue incubating until greater than 95% of the cells are
arrested.
4. To release the cells from the alpha factor block, harvest 25 mLs of the cells by
vacuum filtration.  Wash the cells with 300 mLs of YPD that has been warmed to
37°C.
5. Add 0.001% MMS to a 50 mL culture of YPD that has been pre-warmed to 37°C.
It is best to dilute the MMS into YPD and then add the appropriate volume of the
diluted MMS to the 50 mL culture so that you are adding no less than 10 µL.
Also, to prevent possible breakdown of the MMS, I do not add it prior to this
step.
6. Once the MMS has been added to the 50 mL cultures, transfer the filter paper
containing the harvested cells to the 50 mL culture and incubate the cells at 37°C.
7. Remove 1 mL aliquots for analysis at 0, 60, 120, 180, 240, 300 and 360 minutes
post alpha factor release.  Each time point should be fixed in 70% ethanol
immediately after harvesting.
8. To visualize DNA segregation, wash the fixed cells with PBS two times.
Resuspend the cells in PBS and add DAPI to a final concentration of 1 µg/mL.
Incubate for 3 minutes, centrifuge and wash two more times with PBS.  After the
second wash, resuspend cells in PBS and incubate on a rocker for 1 hour at room
temperature (lay the samples on their side and cover them to protect them from
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a b s t r a c t
The majority of eukaryotic proteins are phosphorylated in vivo, and phosphorylation may be the most
common regulatory posttranslational modification. Many proteins are phosphorylated at numerous sites,
often by multiple kinases, which may have different functional consequences. Understanding biological
functions of phosphorylation events requires methods to detect and quantify individual sites within a
substrate. Here we outline a general strategy that addresses this need and relies on the high sensitivity
and specificity of selected reaction monitoring (SRM) mass spectrometry, making it potentially useful for
studying in vivo phosphorylation without the need to isolate target proteins. Our approach uses label-
free quantification for simplicity and general applicability, although it is equally compatible with stable
isotope quantification methods. We demonstrate that label-free SRM-based quantification is comparable
to conventional assays for measuring the kinetics of phosphatase and kinase reactions in vitro. We also
demonstrate the capability of this method to simultaneously measure relative rates of phosphorylation
and dephosphorylation of substrate mixtures, including individual sites on intact protein substrates in
the context of a whole cell extract. This strategy should be particularly useful for characterizing the phys-
iological substrate specificity of kinases and phosphatases and can be applied to studies of other protein
modifications as well.
 2011 Elsevier Inc. All rights reserved.
The function of most proteins is regulated in some way by enzy-
matic posttranslational modifications (PTMs)1. A large number of
covalent PTMs exist in nature and can affect many aspects of protein
function, including enzymatic activity, binding partners, stability,
structure, and cellular localization. Most PTMs are reversible and,
therefore, allow dynamic control of protein function. Reversible
phosphorylation of serine, threonine, and tyrosine, controlled by
the opposing activities of kinases and phosphatases, is the most
abundant and heavily studied regulatory PTM in eukaryotic cells.
At least 75% of human proteins are phosphorylated in vivo [1], and
many proteins are phosphorylated on multiple sites that can be sub-
ject to differential regulation [2], often by more than one kinase and/
or phosphatase. As an example, more than 100 in vivo phosphoryla-
tion sites have been mapped on the human anaphase-promoting
complex (APC), a large E3 ubiquitin ligase complex that regulates
progression through mitosis [1,3,4]. Evidence suggests that the APC
is regulated, both positively and negatively, by at least four different
kinases [5–12]. This complexity makes functional studies of protein
phosphorylation challenging. There is a need for improved methods
for detection and quantification of individual PTM sites on multiply
modified proteins.
Very few analytical methods employed to study phosphoryla-
tion, or PTMs in general, are effective at quantitatively detecting
multiple sites independently on the same protein. Mass spectrom-
etry (MS) is one exception. Reduction of proteins to peptides is an
effective way to separate the PTMs on a single protein into distinct
molecules for mass spectral analysis. Tandem MS can provide the
sequence of individual peptides and the exact location of any PTMs.
Although the complexity of biological systems poses a constant
challenge to the detection and quantification of target molecules,
the development of affinity enrichment strategies, multidimen-
sional chromatographic separations, improved instrument designs,
and various other methodological advances are steadily allowing
0003-2697/$ - see front matter  2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.ab.2011.07.015
⇑ Corresponding author at: Department of Biochemistry, Purdue University, West
Lafayette, IN 47907, USA. Fax: +1 765 494 7897.
E-mail address: mchall@purdue.edu (M.C. Hall).
1 Abbreviations used: PTM, posttranslational modification; APC, anaphase-promot-
ing complex; MS, mass spectrometry; SRM, selected reaction monitoring; HPLC, high-
performance liquid chromatography; EDTA, ethylenediaminetetraacetic acid; PMSF,
phenylmethlysulfonyl fluoride; DTT, dithiothreitol; Clb2-PrA, Clb2-protein A; IgG,
immunoglobulin G; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis; CE, collision energy; EMV, electron multiplier voltage.
Analytical Biochemistry 418 (2011) 267–275
Contents lists available at ScienceDirect
Analytical Biochemistry
journal homepage: www.elsevier .com/locate /yabio
137 
more comprehensive study of the proteome. Selected reaction
monitoring (SRM) MS, which relies on the filtering capabilities of
a triple quadrupole mass spectrometer, has become a popular
method for direct detection of specific target proteins within com-
plex biological samples. Because of its sensitivity and specificity,
SRM is also a useful approach for the quantitative study of PTM reg-
ulation in living systems.
To fully understand the regulation and function of PTMs, it is
necessary to measure their dynamic changes under different con-
ditions and in response to physiological and environmental signals.
A variety of methods exist for the absolute and relative quantifica-
tion of proteins and PTMs from peptide-based mass spectral data
[13,14]. Most quantitative MS approaches employ some form of
stable isotope dilution, which has the advantage of allowing simul-
taneous analysis and comparison of multiple samples or a single
sample with an internal standard [15–17]. However, the use of sta-
ble isotopes is not essential for quantification, and a number of ‘‘la-
bel-free’’ approaches have also been developed [14]. Label-free
quantification requires comparison of separate MS experiments,
and this necessitates exquisite care in sample preparation and
the appropriate controls or standards to account for run-to-run sig-
nal variations. Although stable isotope-based methods are gener-
ally thought to be more accurate than label-free approaches [13],
there are important advantages to label-free methods such as sim-
plicity and general applicability. With label-free quantification,
there are no specialized reagents required and no extra chemical
reaction and sample processing steps, and the methods are suitable
for any experimental system. For these reasons, label-free quanti-
tative MS methods have important advantages for the study of
PTMs and are becoming more common.
A variety of strategies have been developed for quantitative MS-
based analysis of phosphorylation and other PTMs (see, e.g., Refs.
[18–24]). The majority of these methods rely on stable isotope
labeling or the addition of specific standards for quantification.
Some are limited to studies of synthetic peptide substrates or
highly purified protein preparations or require phosphopeptide
enrichment steps. We set out to establish a strategy that will be
generally useful for the quantitative measurement of changes in
phosphorylation on intact proteins. Our approach uses label-free
quantification of phosphorylation stoichiometry [21,25,26] for
simplicity, compatibility with all experimental systems, and prac-
ticality for studies of large numbers of phosphorylation sites. We
used SRM MS of peptides generated by enzymatic digest because
the sensitivity, specificity, and dynamic range of SRM [27] make
it suitable for analysis of highly complex biological samples, and
it is also capable of simultaneous monitoring of up to hundreds
of target molecules in a single sample run. Related SRM MS meth-
ods have been developed and used recently. In one case, changes in
phosphorylation of the Pho4 transcription factor in budding yeast
were measured [28], but without a rigorous quantification strat-
egy. In another case, autophosphorylation sites on the Lyn tyrosine
kinase in mouse xenograft tumors were monitored [26]. Our strat-
egy is equally useful for studying phosphatases and kinases, and it
can be applied in vitro as an enzymatic assay or in vivo to quantify
changes in many phosphorylation sites in response to experimen-
tal variables. Among other potential applications, we predict that it
will be very useful for the exploration of kinase and phosphatase
specificity. The general method is also suitable for studying other
PTMs.
In this article, we describe proof-of-principle experiments that
validate this strategy. We demonstrate that SRM MS combined
with label-free quantification is comparable to conventional assays
for measuring reaction rates and steady-state kinetic parameters of
phosphatases and kinases. We also demonstrate the utility of the
method for simultaneously monitoring multiple phosphorylation
sites on intact protein substrates, including in a whole cell extract,
and the potential to reveal different responses of individual sites to
experimental variables. Possible experimental designs and practi-
cal aspects of applying this method to large-scale studies in com-
plex biological mixtures and in vivo are discussed.
Materials and methods
Peptide synthesis and purification
Peptides were synthesized using CLEAR-Amide resin (Peptides
International) at a 50-lmol scale by solid-phase Fmoc chemistry
on a Prelude peptide synthesizer (Protein Technologies) essentially
as described previously [29]. The only modification was that cou-
pling times for Fmoc-phosphoserine and Fmoc-phosphothreonine
(Anaspec) were increased to 3 h. Unphosphorylated Fmoc-pro-
tected amino acids were obtained from Peptides International.
Synthesis products were resuspended in 5% acetonitrile/0.1% triflu-
oroacetic acid (TFA), fractionated by high-performance liquid chro-
matography (HPLC) using a preparative C18 column (Agilent
Technologies), and evaluated by matrix-assisted laser desorption/
ionization time-of-flight (MALDI–TOF) MS (Voyager 4800, Applied
Biosystems). Fractions exhibiting the highest product purity were
pooled, lyophilized, and resuspended in 50 mM Tris–HCl (pH 8.0)
at approximately 5 mM based on weight. Precise concentrations
of phosphopeptides were determined by measuring the inorganic
phosphate released after ashing in a magnesium nitrate solution
and reaction with an ammonium molybdate/malachite green mix-
ture as described previously [30]. Unmodified peptide concentra-
tions were determined by amino acid analysis at the Purdue
Proteomics Facility.
Protein purification
The Saccharomyces cerevisiae FIN1 gene was cloned into pGEX-
6P-1 (GE Healthcare) to create an in-frame fusion with the vector
GST sequence. The N-terminal fusion protein GST-Fin1 was overex-
pressed in 3 L of Escherichia coli culture by 0.5 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) induction at 37 C for roughly 4 h.
Unless otherwise stated, all purification steps were performed at
4 C. Washed cells were suspended in 5 pellet volumes of 50 mM
Hepes (pH 8.0), 1% Triton X-100, 250 mM NaCl, 1 mM ethylenedi-
aminetetraacetic acid (EDTA), 10% glycerol, 1 mM phen-
ylmethlysulfonyl fluoride (PMSF), 100 lM leupeptin, and 1 lM
pepstatin, treated with 1 mg/ml lysozyme on ice for 30 min, and
lysed by sonication on ice. The extract was clarified by centrifuga-
tion at 35,000g for 30 min and then incubated with 500 ll of GST-
Bind resin (EMD Biosciences) for 30 min. Unbound proteins were
then removed by extensive washing with 50 mM Hepes (pH 8.0),
0.1% Triton X-100, 250 mM NaCl, 1 mM EDTA, and 10% glycerol.
GST-Fin1 was then eluted with the same buffer supplemented with
10 mM reduced glutathione and dialyzed against 10 mM Hepes
(pH 7.5), 10 mM MgCl2, 50 mM NaCl, 0.5 mM dithiothreitol
(DTT), and 10% glycerol overnight. His6-Cdc14 was purified as de-
scribed previously [31]. Following purification, pooled Cdc14 frac-
tions were exchanged into 50 mM Tris–HCl (pH 7.5), 300 mM NaCl,
2 mM EDTA, and 0.1% b-mercaptoethanol using a G-25 desalting
column.
Saccharomyces cerevisiae Cdk1 (Clb2-Cdc28) was purified from
yeast strain BY4741 sic1D overexpressing a Clb2-protein A (Clb2-
PrA) fusion protein from BG1805-CLB2 (Open Biosystems). Clb2-
PrA expression was induced for 4 h at 30 C by the addition of 2%
galactose to the YP-raffinose medium when cells had reached mid-
log phase. Washed cells were lysed in 5 pellet volumes of 50 mM
Tris–HCl (pH 8.0), 250 mM NaCl, 10% glycerol, 0.1% Triton X-100,
20 mM NaF, 1 mM PMSF, 100 lM leupeptin, and 1 lM pepstatin
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by disruption with glass beads in a Bead Beater (Biospec Products).
Extracts were clarified by centrifugation at 35,000g for 30 min and
incubated with 150 ll of immunoglobulin G (IgG)-agarose beads
(Sigma) for 2 h at 4 C. The IgG resin was collected by gentle cen-
trifugation and washed four times with 50 mM Tris–HCl (pH 8.0),
250 mM NaCl, 10% glycerol, 0.1% Triton X-100, and 20 mM NaF.
For peptide kinase assays, the Clb2-PrA was eluted by cleavage
with PreScission protease (GE Healthcare) overnight at 4 C, as rec-
ommended by the supplier, and the GST-tagged protease was sub-
sequently removed by incubating the eluted material with 10 ll of
GST-Bind resin (EMD Biosciences) for 15 min followed by centrifu-
gation to pellet the resin. The supernatant containing purified Cdk1
was stored directly at 20 C. For phosphorylation of recombinant
GST-Fin1, the IgG agarose beads were washed with kinase buffer
(see below), suspended in kinase buffer supplemented with 30%
glycerol, and stored directly at 20 C without elution.
Extract preparation
Saccharomyces cerevisiae cells were grown to midlog phase in
standard rich medium, harvested, washed, and lysed in the same
buffer described above for Cdk1 purification by glass bead disrup-
tion. The clarified extract (50 lg) was subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and
Coomassie blue staining. The entire lane was excised from the gel
in small pieces, and proteinswere digestedwith trypsin (see below).
Extracted peptideswere pooled to create the digested lysate sample
for evaluation of GST-Fin1 dephosphorylation in a complexmixture.
Kinase assay
Kinase assays (20 ll) contained 2 ll of affinity-purified Cdk1,
varying concentrations of synthetic peptide substrate, and 1 mM
ATP in kinase buffer (10 mM Hepes [pH 7.5], 10 mM MgCl2,
50 mM NaCl, 10% glycerol, and 0.5 mM DTT). Duplicate reactions
were performed, one of which contained [c-32P]ATP (MP Biomed-
icals). Reactions were initiated by the addition of ATP and incu-
bated at 30 C for 20 min. [c-32P]ATP reactions were terminated
with 1% TFA. Cold reactions were terminated by diluting the sam-
ple 5-fold with 3% acetonitrile in 0.1% formic acid. c-32P-labeled
peptide products were purified from free ATP using OMIX-C18
micropipet tips (loading capacity 8 lg) according to the manufac-
turer’s protocol (Varian). After washing, the portion of the tip con-
taining the C18 resin was removed and the resin was subjected to
liquid scintillation counting. Product formation in the cold ATP
reactions was monitored by SRM MS as described below.
Recombinant GST-Fin1 was phosphorylated in vitro by incubat-
ing 350 ll of stock protein with approximately 50 ll of Cdk1 resin
and 1 mM ATP for 30 min at 30 C. The reaction was stopped by
pelleting the resin, removing the supernatant, and storing in ali-
quots at 80 C.
Phosphatase assay
Synthetic phosphopeptide dephosphorylation reactions con-
tained 50 nM Cdc14, varying concentrations of phosphopeptide
substrate, 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, and 1 mM
EDTA. Reactions were incubated at 30 C and stopped at the de-
sired times by the addition of an equal volume of 1.2 M HCl. Reac-
tion products were divided in half. One half was diluted to 1 pmol/
ll with 3% acetonitrile in 0.1% formic acid and analyzed by SRMMS
as described below. The other half was analyzed spectrophotomet-
rically by measuring A640 after mixing with a solution of ammo-
nium molybdate and malachite green as described previously
[32]. Total inorganic phosphate produced was determined from
an Na2PO4 standard curve.
Phosphorylated recombinant GST-Fin1 was dephosphorylated
by the addition of 200 nM Cdc14. The reaction was incubated at
30 C, and aliquots were removed at 2, 5, 20, and 60 min and
stopped by boiling in SDS–PAGE loading dye. Reaction products
were subjected to SDS–PAGE with Coomassie blue staining, and
the GST-Fin1 band was excised, destained with 50% acetonitrile/
50 mM ammonium bicarbonate, dried with pure acetonitrile, and
digested in-gel with either 10 lg/ml Lys-C or 20 lg/ml trypsin in
fresh 50 mM ammonium bicarbonate overnight at 37 C. Peptides
were extracted twice with acetonitrile, dried, and resuspended in
3% acetonitrile/0.1% formic acid immediately prior to MS analysis.
Selected reaction monitoring
SRM experiments were conducted on an Agilent 6410 triple
quadrupole mass spectrometer equipped with an HPLC-Chip cube
interface and a 150-mm C18 ProtID-Chip connected to an Agilent
1200 series nanoflow HPLC system. SRM method parameters for
all peptides monitored in this study, including parent ion charge
state, collision energy, and fragment ion m/z values, were deter-
mined manually and are listed in Table 1. Collision energies (CEs)
were first estimated using the formulas CE = 0.044 m/z + 5.5
(charge state = +2) and CE = 0.051 m/z + 0.5 (charge state = +3)
and then further refined. At least two transitions were monitored
for each peptide and were validated with product ion scans (not
shown). Synthetic peptides were eluted from the C18 column
and injected directly into the 6410 instrument with a 6-min gradi-
ent of increasing acetonitrile from 3 to 35% in 0.1% formic acid at a
flow rate of 400 nl/min. Samples containing proteolytic peptides
from recombinant GST-Fin1 were eluted from the C18 columnwith
a similar gradient extended to 20 min. Resolution for quadrupoles
1 and 3 was set to wide for synthetic peptide analyses and to unit
and wide, respectively, for recombinant protein analyses. The
typical source voltage was 1900–2000 V, and other instrument
settings were DEMV (electron multiplier voltage) = 300, gas tem-
perature = 300 C, and gas flow = 4 L/min.
Quantification of phosphorylation
All raw SRM signals were integrated using Agilent’s MassHunter
software. Standard peptides were included in all reactions to cor-
rect for run-to-run signal variations. For analyses of recombinant
GST-Fin1, additional proteolytic peptides with strong signal inten-
sity, no Cdk consensus phosphorylation sequences, and no detect-
able missed cleavages were used as internal standards. The average
percentage deviation of all standard peptide signals in each sample
being compared was determined as described previously [25] and
used to adjust the raw SRM signals. Moles of product formed in the
synthetic peptide phosphatase assays were determined from phos-
phorylation stoichiometry calculations obtained by comparison of
unmodified and phosphorylated peptide SRM signals [25] and the
known starting substrate concentration. The kinetic parameters KM
and kcat were determined by measuring product formation as a
function of substrate concentration and fitting the Michaelis–
Menten equation to the data using GraphPad Prism software.
Results and discussion
Our goal was to establish an approach to measure the activities
of kinases and phosphatases on their natural physiological sub-
strates in a site-specific manner that could be applied to in vitro
and in vivo studies with any experimental system. To facilitate
the use of the approach in complex mixtures such as cell extracts
or to monitor activities in vivo, we used SRM MS on a triple
quadrupole mass spectrometer. We also chose a simple label-free
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method for determining PTM stoichiometry for quantification
[21,25,26]. Although SRM has been used previously to measure
enzymatic activities, its use in measuring kinase and phosphatase
activities, or changes in phosphorylation stoichiometry under dif-
ferent experimental conditions, has been very limited. To our
knowledge, measurement of phosphatase and kinase activities by
SRM MS, particularly with label-free quantification, has not been
validated by comparison with conventional assays. Therefore, we
set out initially to do so using a defined system with synthetic pep-
tide substrates and purified enzyme preparations.
Comparison of SRM MS to conventional assays for measuring kinetics
of phosphatase and kinase activities
Consistent with other SRM studies using triple quadrupole
instruments, product detection in our phosphatase reactions was
linear over a 10,000-fold concentration range with sub-femtomole
sensitivity (Fig. 1A). The dynamic range was limited only by the
capacity of the HPLC column used and, therefore, may be even
greater. The sensitivity was typical for our synthetic peptide sub-
strates but varies substantially with sequence. The precision of
SRM measurements was tested by repeat analysis of single sam-
ples. Run-to-run variation was consistently less than 4% (Fig. 1B).
Satisfied with these basic properties of the SRM analysis, we next
compared initial dephosphorylation rates of several phosphopep-
tide substrates of the yeast Cdc14 phosphatase measured using a
malachite green dye-based colorimetric assay and our SRM
method to determine whether SRM MS is capable of accurate ki-
netic measurements. Individual completed reactions were split
and products were analyzed by the two methods (using a spectro-
photometer and a mass spectrometer) in parallel.
Fig. 1C–E show overlay plots of dephosphorylation versus time
for three phosphopeptide substrates measured using the two inde-
pendent methods. The plots and calculated rates of peptide
dephosphorylation were very similar. In our experiments, we used
our previously described method to determine the percentage of
peptide dephosphorylated at each time point from the substrate
and product SRM signals [25] and converted this to moles of prod-
uct formed using the known initial substrate concentration. Other
approaches are also possible when absolute quantification of prod-
uct is required, including use of stable isotope-labeled product as
an internal standard.
We also compared the ability of the conventional and SRM-
based phosphatase assays to measure reaction velocity as a func-
tion of substrate concentration for determination of the steady-
state kinetic parameters KM and kcat (Fig. 2A). Consistent with the
rate measurements, overlays of velocity versus substrate concen-
tration plots generated from the independent methods were in
close agreement and calculated KM and kcat values obtained by
nonlinear regression analyses were very similar (Table 2). To dem-
onstrate that the approach is equally useful for measuring kinase
activity, we measured KM values for budding yeast Cdk1-catalyzed
phosphorylation of an unmodified peptide containing a consensus
Cdk phosphorylation sequence using conventional 32P incorpora-
tion compared with SRM MS (Fig. 2B). Again, the plots and calcu-
lated KM values were very similar. These results demonstrate that
SRMMS can be used for the accurate measurement of phosphatase
and kinase activities in vitro.
Table 1
SRM method parameters.
Peptide name Peptide sequence Precursor ion Transition 1 Transition 2
m/z Charge m/z Charge Ion CE m/z Charge Ion CE
SP1 VKGNELRSPSKRRSQI 464.4 4+ 543.1 3+ y14 15 585.8 3+ y15 15
pSP1 VKGNELR(S)PSKRRSQI 484.5 4+ 569.8 3+ y14 23 612.5 3+ y15 23
SP2 TDYALRRSPIKTIQIS 621.2 3+ 822.4 2+ b14 22 865.2 2+ a15 22
pSP2 TDYALRR(S)PIKTIQIS 647.9 3+ 603.4 2+ y10-NH3 18 862.4 2+ b14 18
SP3 MISPSKKRTIL 425.1 3+ 757.5 1+ y6 15 844.4 1+ y7 15
pSP3 MI(S)PSKKRTIL 451.8 3+ 629.4 1+ y5 23 757.5 1+ y6 23
SP4 DSKQLLSPGKQFRQI 619.9 3+ 875.5 1+ y7 25 972.4 1+ y8 25
pSP4 DSKQLL(S)PGKQFRQI 646.6 3+ 875.5 1+ y7 25 972.4 1+ y8 25
SP5 SSASLLSSPSRRSRPS 558.5 3+ 706.3 2+ y13-H2O 25 741.9 2+ y14-H2O 20
pSP5 SSASLLS(S)PSRRSRPS 585.5 3+ 654.8 2+ y11 20 754.8 2+ y13 25
SP6 TDVTPESSPEKLQFGS 861.4 2+ 1305.6 1+ Y12 26 905.5 1+ y8 26
pSP6 TDVTPES(S)PEKLQFGS 901.4 2+ 1385.6 1+ Y12 28 1072.5 1+ y9 28
SP7 NNTPSSSPLKGSESK 511.6 3+ 652.8 2+ y13 6 602.3 2+ y12 6
pSP7 NNTPSS(S)PLKGSESK 538.3 3+ 692.8 2+ y13 7 642.3 2+ y12 7
SP8 ARFKNGLMSPERIQQQ 476.5 4+ 586.3 3+ b15 4 543.6 3+ b14 4
pSP8 ARFKNGLM(S)PERIQQQ 661.6 3+ 855.5 2+ b14 30 759.2 1+ a7 30
SP9 FLKPPMRISPNKTDGMK 490.7 4+ 567.3 3+ Y15 5 524.6 3+ y14 5
pSP9 FLKPPMRI(S)PNKTDGMK 510.8 4+ 777.9 2+ y13 14 588.3 3+ b15 6
SP10 KKVVRKLSFHVYEDE 626.1 3+ 865.6 2+ b14 20 661.7 2+ b11 20
GluFib EGVNDNEEGFFSAR 786 2+ 1171 1+ y10 30 684 1+ y6 30
AngII DRVYIHPF 523.8 2+ 647.2 1+ b5 15 NA NA NA NA
Ser36 DNVFVRLSMSPLRTTSQK 699.3 3+ 975.3 2+ b17 30 884.3 2+ y15 30
pSer36 DNVFVRLSM(S)PLRTTSQK 726.0 3+ 924.4 2+ y15 30 843.9 1+ b7 30
Ser54 EFLKPPMRISPNK 519.9 3+ 1039.6 1+ y9 25 942.6 1+ y8 25
pSer54 EFLKPPMRI (S)PNK 546.4 3+ 1022.6 1+ y8 25 924.7 1+ y9 25
Thr68 HSIQVTPR 469.4 2+ 713.3 1+ y7 12 600.7 1+ y15 12
pThr68 HSIQV(T)PR 509.7 2+ 793.4 1+ y6 14 880.2 1+ y7 17
Ser117 IQNSDHITNIIFPTSPTK 676.2 3+ 777.5 1+ y7 20 1136.6 1+ b10 20
pS117 IQNSDHITNIIFPT(S)PTK 702.8 3+ 1023.3 1+ b9 20 1136.6 1+ Y8 20
Std1 DAPFENDLPR 587.3 2+ 890.3 1+ Y10 16 614.7 1+ y9 16
Std2 DAPFENDLPRAK 458.4 3+ 813.5 1+ y7 15 942.6 1+ y8 15
Std3 LNSMLANEGK 538.8 2+ 963.7 1+ y9 15 849.7 1+ y8 15
Note: Phosphopeptide names begin with ‘‘p’’, and the phosphorylated amino acid is in parentheses. ‘‘SP’’ refers to synthetic peptides. Peptides with ‘‘Std’’ were internal
standards used for normalization of recombinant protein data. Trypsin-digested samples were normalized using Std1 and Std3. Lys-C-digested samples were normalized with
Std2 and Std3. GluFib and AngII peptides were used for normalization in synthetic peptide experiments. Data in Fig. 3 were normalized with GluFib, SP10, and SP5. CE,
collision energy. NA, not applicable (only one transition used).
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Use of SRM MS to measure activities towards multiple substrates in
single reactions
Because the power of SRMMS lies in its ability to quantitatively
measure many specific target molecules within a complex mixture,
we next demonstrated the simultaneous measurement of a mix-
ture of phosphopeptide substrates dephosphorylated by Cdc14
(Fig. 3). The relative rates of dephosphorylation (with each
peptide’s initial SRM signal normalized to 100%) of seven of our
synthetic phosphopeptides were measured. Note that most con-
ventional assays for phosphatase and kinase activity are not useful
for analysis of substrate mixtures and provide only global data
with multiply phosphorylated substrates because they do not dis-
tinguish between individual sites. Although the specificity of SRM
is not necessarily required for measurement of synthetic peptide
mixtures of this complexity (standard MS analyses would suffice,
particularly with high-resolution instruments), this approach
would allow rapid screening of large peptide mixtures for charac-
terization of enzyme specificity or identification of potential
enzyme substrates. Similarly, the approach can be applied to anal-
ysis of many phosphorylation sites on intact protein substrates in a
cell extract following postreaction enzymatic digest without the
need for affinity purification or fractionation steps. In these cases,
the specificity and sensitivity of SRM MS is essential.
Independent measurement of dephosphorylation rates at multiple
phosphorylation sites on an intact protein substrate
As an example of the utility of this approach, we simultaneously
monitored multiple phosphorylation sites on an intact protein sub-
strate of Cdc14, the yeast spindle stabilizing protein Fin1 [33].



































































































Fig.1. Dynamic range and dephosphorylation rate analyses. (A) SRM signal intensity as a function of peptide amount for one of the phosphopeptide substrates (pSP4) used in
this study, demonstrating the linear dynamic range of the SRM-based kinase/phosphatase assay. Axes are log scale. (B) The indicated synthetic peptides were analyzed five
independent times, and the corresponding SRM signals were plotted. The horizontal lines indicate the sample means. The percentage deviation from the mean was then
calculated for each trial. The average deviation was less than 4% for all peptides. Data from one transition are shown but were nearly identical for the second transitions. (C–E)
Dephosphorylation of the peptides pSP1 (C), pSP2 (D), and pSP4 (E) by Cdc14 as a function of time using a conventional spectrophotometric assay (N) compared with the SRM
assay (d). Each data point is the mean of three independent experiments. Error bars represent standard error of the mean. Lines are from linear regression analyses. The
average difference in rates (from regression analysis) between the two assays was 11 ± 5%.
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Cdk1 as described in Materials and Methods. Cdk phosphorylation
sites are the preferred substrates of Cdc14 phosphatases [34,35],
and previous studies have demonstrated that Fin1 is regulated by
both Cdk and Cdc14 [33]. Intact phosphorylated GST-Fin1 was re-
acted with Cdc14 and prepared for MS analysis by protease diges-
tion. The resulting peptide mixture was analyzed by SRM MS. We
monitored both the unmodified and phosphorylated forms of four
peptides containing consensus Cdk sites (S/T-P) that are known
in vivo phosphorylation sites of biological importance [33,36–38]
as well as several additional peptides lacking Cdk1 sites that were
used for normalization. Estimated initial phosphorylation stoichi-
ometry was similar for each site, and plotting relative phosphory-
lation of the individual Fin1 Cdk1 phosphorylation sites over time
after the addition of Cdc14 revealed an unexpected difference in
apparent dephosphorylation rates (Fig. 4A). These results suggest
that not all Fin1 Cdk phosphorylation sites are equivalent sub-
strates for Cdc14 and that additional specificity determinants
may exist. This type of observation can be made only by using an
assay capable of quantifying phosphorylation at individual sites
and highlights the potential of our method to study kinase and
phosphatase specificity using intact multiply phosphorylated and
physiologically relevant protein substrates, including large protein
complexes, and in the context of complex mixtures such as cell
extracts.
Measuring protein dephosphorylation in a complex mixture
With an eye toward future implementation of this strategy for
studies in vivo and in cell extracts, we analyzed our recombinant
Fin1 phosphatase reaction products again after mixing them with
a large excess of trypsin-digested yeast whole cell extract
(Fig. 4B). Even within the context of a cell extract, the SRM MS ap-
proach was specific enough (Fig. 4C and D) that we could faithfully
reproduce the relative dephosphorylation rates at all four Cdk1
phosphorylation sites (cf. Fig. 4A and B).
Protocol for an in vivo phosphatase assay
In Fig. 5, we outline a potential strategy for an in vivo phospha-
tase assay, using Cdc14 as an example, for which SRM MS could be
used to simultaneously monitor a large number of substrate sites
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Fig.2. Validation of SRM for measurement of phosphatase and kinase steady-state
kinetic parameters. (A) Dephosphorylation of peptide pSP4 by Cdc14 was plotted as
a function of substrate concentration using either the spectrophotometric (N) or
SRM (d) assay. (B) Relative phosphorylation (% of Vmax) of peptide SP1 by Cdk1 was
plotted as a function of substrate concentration for the sake of comparison using
either the spectrophotometric (N) or SRM (d) assay. In both panels, each data point
represents the mean of three independent experiments, and error bars represent
standard error of the mean. The Michaelis–Menten equation was fit to the data
using GraphPad Prism software to generate the nonlinear regression lines and
obtain the steady-state kinetic parameters KM (panels A and B) and kcat (panel A
only) reported in Table 2. Note that we did not attempt to calculate kcat values for
the kinase assays in panel B due to incomplete product recovery for technical
reasons in the radioisotope-based assay.
Table 2
Comparison of Cdc14 KM and kcat values for phosphopeptide substrates.
Peptide KM (lM) kcat (s–1)
SRM Colorimetric SRM Colorimetric
pSP2 437 ± 28 348 ± 35 4.2 ± 0.2 4.1 ± 0.2
pSP3 94 ± 8 98 ± 1 2.2 ± 0.1 2.0 ±0.1
pSP4 202 ± 51 249 ± 5 1.3 ± 0.2 1.1 ± 0.01
pSP5 350 ± 32 341 ± 44 3.8 ± 0.8 2.2 ± 0.2
Note: Steady-state kinetic parameters were determined from the experiment in
Fig. 2A, and similar experiments not shown with the other phosphopeptides, using
the procedures described in Materials and Methods and described previously [25].



















































Fig.3. Simultaneous measurement of multiple phosphatase substrates. (A) A
mixture of the phosphopeptide substrates pSP2 (j), pSP3 (d), pSP4 (N), pSP6 (.),
pSP7 (h), pSP8 (s), and pSP9 (D), each at 100 lM, was reacted with purified Cdc14
and aliquots were removed at the indicated time points for analysis by SRMMS. The
stoichiometry (% phosphorylation) at each time point was calculated as described in
Materials and Methods. Each data point represents the average of three indepen-
dent assays. For each peptide, 500 fmol was injected for the SRM MS analyses. Error
bars were omitted for clarity but were similar to those in the single peptide
phosphatase assays shown in Figs. 1 and 2. (B) Overlay of representative SRM traces
(both transitions) from the experiment in panel A for all seven phosphopeptides.
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under native physiological conditions. The yeast Cdc14 phospha-
tase is kept inactive during the majority of the cell cycle by its com-
petitive inhibitor, Net1 [39]. Because Cdk sites are preferred Cdc14
substrates, yeast cells can be arrested in early mitosis when Cdk
activity is high, for example, by chemical treatment with the
microtubule depolymerizing agent nocodazole or by expression
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Fig.4. Measuring dephosphorylation of multiple sites on an intact protein substrate. Recombinant GST-Fin1 phosphorylated in vitro with Cdk1 was treated with purified
Cdc14, and aliquots were removed over time. The protein was subjected to an in-gel digest with either Lys-C or trypsin, and resulting peptides (1 pmol) were analyzed by
SRM MS as described in Materials and Methods either alone (A) or after addition to a large excess of trypsin-digested yeast whole cell extract (B). The percentages of the
original phosphorylation remaining relative to the zero time point are plotted. Each data point is the average of three trials, and error bars are standard errors of the mean.
pThr68 is on a tryptic peptide, whereas the other sites are on Lys-C peptides. (C) SRM signals for each of the phosphopeptides plotted in panel B (both transitions) at the zero
time point are overlaid to show the specificity in the background of a whole cell extract. (D) MS scans of the trypsin-digested yeast extract with (left plot) and without (right
plot) recombinant Fin1 peptides are shown to illustrate the sample complexity.
Fig.5. Protocol for implementation of an in vivo phosphatase assay. The method described in this article can potentially be used to monitor changes in phosphorylation and
study enzyme specificity in vivo. A potential experimental procedure for studying Cdc14 specificity in vivo is outlined. Details are provided in Results and Discussion. T1, T2,
and so forth refer to time points following induction of phosphatase expression.
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of a nondegradable securin (Pds1) mutant [40]. Dephosphorylation
of Cdc14 substrates is then ‘‘initiated’’ by the addition of galactose
to the culture to ectopically express Cdc14 from the GAL1 promoter
and aliquots of the culture collected over time. Extracts are made
and proteins are digested under denaturing conditions [41], and
the phosphorylation status at a large number of specific phosphor-
ylation sites of interest is monitored by liquid chromatography
(LC)–SRM MS. SRM methods can be developed based on existing
phosphoproteomic data [37,38,42]. This approach would allow rel-
ative rates of dephosphorylation of Cdk sites on many proteins to
be determined. We expect that similar types of assays could be de-
signed for a large number of kinases and phosphatases in many dif-
ferent model systems. A current challenge is the ability to detect
modified peptides in cell extracts with the required sensitivity.
Continued improvements in triple quadrupole instrumentation
should make experiments like this more routine in the near future.
Conclusions and considerations for use of the SRM MS phosphatase/
kinase assay
This method is not useful for discovery and mapping of phos-
phorylation sites. The sites must be known or mapped initially
by standard tandem MS methods. Like other MS analyses of PTMs,
success of this method is dependent on generation of detectable
peptides by protease digestion. Certain PTMs will inevitably be dif-
ficult to detect due to lack of conveniently located digestion sites.
Although we previously demonstrated that two modification sites
on a peptide can be quantified individually using SRM MS [25], the
existence of several PTMs on a single peptide makes individual
quantification difficult. Nonetheless, we conclude from our studies
that combining SRM MS with label-free quantification methods
provides a powerful, flexible, and accurate approach for the study
and characterization of phosphatases and kinases on natural pro-
tein substrates. Although we focused here on reversible protein
phosphorylation, this method is equally applicable, in principle,
to the study of other PTMs. SRM MS also offers the potential for
high-throughput analysis of hundreds of modification sites simul-
taneously. Even with partially purified proteins or large protein
complexes, the specificity of SRM is a significant advantage be-
cause it largely avoids complications of overlapping signals from
other peptides of similar m/z. The use of label-free quantification
allows the method to be used with any experimental system, im-
proves sensitivity by eliminating additional chemical reaction or
sample processing steps, and obviates the need for costly isotope
labeling reagents when monitoring large numbers of PTMs.
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Quantification of protein and PTM abundance in biological samples is an important
component of proteomic studies. Label-free methods for quantification using MS are
attractive because they are simple to implement and applicable to any experimental system.
We demonstrate that PTM stoichiometry can be accurately measured using label-free
quantification and selected reaction monitoring. Use of selected reaction monitoring is
advantageous with complex biological samples and we show this approach can be used to
quantify multiple PTMs independently on a single peptide.
Keywords:
Label-free quantification / MS / PTM / Selected reaction monitoring / Stoichiometry /
Technology
MS-based identification of proteins and covalent PTMs has
proven to be a powerful approach for global proteome char-
acterization and the emerging field of systems biology. A
critical component of proteomic studies is the quantitative
measure of changes in the abundance of proteins and PTMs in
different experimental samples. Although simple protein MS
analyses are inherently non-quantitative due to unpredictable
differences in peptide ionization efficiencies, a number of
approaches have been developed over the past decade to allow
accurate relative and absolute quantification of proteins [1, 2].
Most quantitative MS methods rely on stable isotope
labeling. Synthetic peptides containing a heavy isotope label
and matching the sequence of sample peptides of interest can
be used as internal standards to measure absolute concen-
trations [3, 4]. Similarly, labeling of peptides either in vivo by
natural metabolic incorporation (e.g. SILAC or 15N-labeling) or
in vitro by chemical or enzymatic reactions allows relative
quantification between multiple experimental samples [5–7].
The use of stable isotopes is generally thought to provide the
most accurate quantification in MS studies because the
signals being compared are present in the same sample
thereby avoiding error associated with both parallel processing
[1] and differences in ion suppression between independent
samples. However, there are disadvantages to stable isotope-
based quantification. For global proteome studies, production
of synthetic peptide standards for all proteins or PTMs can be
impractical and in vivo isotope labeling by such methods as
SILAC is limited to certain experimental model systems.
Consequently, methods for label-free quantification have
also become popular [1, 8]. Label-free quantification neces-
sarily requires comparison of ion signals from independent
MS runs and its accuracy therefore demands extreme
precision in sample preparation and processing. In label-
free quantification, plotting ion intensity as a function of
time generates an HPLC retention peak called an extracted
ion chromatogram (XIC), integration of which provides a
measure of peptide abundance. With the appropriate stan-
dardization procedures, XICs can be compared from one
run to another to measure relative changes in abundance.
PTMs represent an additional quantitative challenge in
proteomic studies. In label-free analyses, relative abundances
of modified peptides in different samples can be determined
Abbreviations: SRM, selected reaction monitoring; XIC,
extracted ion chromatogram
Correspondence: Dr. Mark C. Hall, Department of Biochemistry,




& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2010, 10, 4301–4305 4301DOI 10.1002/pmic.201000232
146 
by the methods mentioned above. However, stoichiometry is
an important factor when evaluating function and regulation
of PTMs and is difficult to reliably measure in standard MS
analyses. Recently, a method for label-free determination of
phosphorylation stoichiometry was described based on the
principle that the signals for peptide/phosphopeptide pairs are
correlated [9]. That is, if the concentration of a peptide
modification (e.g. phosphorylation) is increased or decreased,
the concentration of the unmodified peptide must change by
the same amount. Although raw MS signals of modified and
unmodified peptide pairs cannot be directly compared due to
ionization differences, the authors showed that this correla-
tion allows the difference in ionization efficiency to be calcu-
lated from XICs from two different phosphorylation states and
applied as a correction factor. The corrected MS signals for the
peptide and phosphopeptide pairs can then be quantitatively
compared and used to calculate the fraction of the peptide
modified (stoichiometry). Since other factors in a biological
system can differentially influence the concentration of
modified and unmodified peptides, care must be taken in
calculating this correction factor (see below).
Use of XICs in proteomic experiments analyzing highly
complex biological samples is limited by insufficient specifi-
city. Steen et al. proposed that a similar quantitative approach
to PTM stoichiometry measurements would be feasible using
selected reaction monitoring (SRM) on a triple quadrupole
mass spectrometer, which has advantages of increased
specificity, sensitivity, and dynamic range [9]. However, they
did not empirically test this. The relationship between the
signal response of modified and unmodified peptide pairs in
SRM experiments is more complicated than it is for XICs
derived from peptide MS scans because SRM signal depends
on the additional parameters of peptide fragmentation
pattern and efficiency. Consequently, SRM signal responses
of modified and unmodified peptide pairs may differ by a
much greater magnitude. For these reasons, it was not clear
to us whether the same approach would be valid, or as
accurate, in practice. Because of its clear significance as an
analytical tool in proteomic studies of PTMs we directly tested
the validity of this method applied to SRM data.
All SRM experiments were performed on an Agilent 6410
triple quadrupole mass spectrometer equipped with an
HPLC-Chip nanoESI interface. A set of standard peptides
was included in all samples for normalization between runs,
essentially as described [9] and two SRM transitions were
manually optimized for each peptide. SRM transitions and
other method parameters for all peptides are listed in
Supporting Information Table 1. SRM signals for experi-
ments with synthetic peptides and recombinant protein
were validated by product ion scans of each parent ion.
Product ion scans are shown in Supporting Information
Fig. 1. Peptide mixtures were injected onto a C18 chip and
processed with a 6min gradient of increasing ACN from 3
to 35% in 0.1% formic acid. Note that the specificity of SRM
also allows for much shorter HPLC separations, even for
complex mixtures. For each SRM transition, a plot of signal
versus time was generated and peak areas integrated using
Agilent’s MassHunter software. The mean SRM signal of
each standard peptide in all samples was determined. Then,
the average percent deviation from this mean for all three
standards was determined for each sample and used to
adjust raw SRM signals. To calculate stoichiometry from the
normalized SRM data, a correction factor must be deter-
mined that allows direct quantitative comparison of signals
from unmodified and modified peptide forms. We used
equations of the same form described by Steen et al. [9] and
redefine them here in the context of SRM experiments. The
total concentration of a peptide [P0] is the sum of the
concentrations of its unmodified [uP] and modified [mP]
forms and can be related to the integrated SRM transition







where s reflects SRM signal response (a function of peptide
ionization, fragmentation, fragment ion selected, and detec-
tion). This equation can be rearranged to solve for the ratio
smP/suP, which is the SRM correction factor allowing TuP and
TmP to be directly compared. In order to determine smP/suP
for a peptide with a single modification, two samples (A and
B) must be analyzed that differ in stoichiometry by at least
10% [9]. It is important to note that for reliable determination
of correction factors, samples A and B should not be inde-
pendent biological samples because in vivo there may not be a
direct relationship between the concentration of unmodified
and the modified protein forms (e.g. due to stability differ-
ences). Instead, the modification state of a single biological
sample can be enzymatically altered at the peptide stage to
generate different modification states, as described [9]. For in
vitro experiments like those presented here, this is not as
much of a concern. The rearrangement then gives
smP
suP
¼ ðTmPB TmPBÞ=ðTuPB TuPAÞ ð2Þ
which is easily determined by plugging in the integrated
normalized SRM signals for each peptide. Once smP/suP is
calculated for any given pair of transitions, it is used to adjust
the normalized SRM signals for the unmodified and modified
forms of the peptide so the percent modified can be directly
calculated. An example of the effect of SRM signal correction
is shown in Supporting Information Fig. 2. The correction
factor is a constant for a given set of analytical conditions but
needs to be recalculated if sample type or complexity changes
or if different instrument settings, analytical conditions, or
SRM methods are used. All SRM correction factors for
peptide/phosphopeptide pairs are listed in Supporting Infor-
mation Table 2.
We first tested the approach using two synthetic peptide/
phosphopeptide pairs mixed in defined ratios. Table 1
summarizes that a broad range of defined modification stoi-
chiometries from 5 to 80% were accurately measured from
SRM data using this method (average % error5 372). We
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then analyzed the same samples in single ion monitoring
(SIM) mode to measure stoichiometry values from XICs
according to Steen et al. (average % error5 271). Clearly, the
accuracy and reproducibility of stoichiometry measurements
from SRM and SIM data were almost indistinguishable. A
paired t-test confirmed no statistically significant difference
between the two methods (p-value5 0.06).
We extended our comparative analysis using a more
biologically relevant sample, the recombinant autopho-
sphorylated cytoplasmic domain of the human EphA2
receptor (EphA2-C0) that was dephosphorylated with the
human low molecular weight protein tyrosine phosphatase
[10, 11]. EphA2-C0 was digested in solution with trypsin
before and after partial dephosphorylation. Several peptides
containing phosphotyrosine were monitored by both SIM
and SRM and stoichiometries were calculated as described
above. Consistent with results from the synthetic peptides,
the stoichiometries obtained from the SIM and SRM
analyses of EphA2 were very similar (Table 1). Note that
peptide IAYSLLGLK could not be evaluated by SIM due to
overlapping signal from an isobaric ion, highlighting a
limitation of SIM analysis, even in a relatively simple
mixture. Also, signal responses for most peptides and their
phosphorylated cognates in SRM analyses differ far more
than in SIM analyses [12, 13] due to differences in frag-
mentation. As shown from the calculated correction factors
in Supporting Information Table 2, the SRM signals for
several peptides in this study differed by more than tenfold
between the unmodified and the phosphorylated forms.
Thus, accurate quantification of stoichiometry is possible
even when large differences in SRM signal response
between modified and unmodified species exist. We also
compared SIM and SRM based label-free stoichiometry
calculation of the recombinant EphA2 phosphopeptide
VLEDDPEAT(Y)TTSGGK to absolute quantification with
stable isotope-labeled peptides. Repeated trials with isotope-
labeled standards at two different concentrations yielded an
average stoichiometry of 8871% from SIM and 9172%
from SRM for this phosphorylation site compared to
8372% from SIM and 8772% from SRM for label-free
quantification.
We next tested the approach in a complex mixture that
better represents actual samples from a proteomic experi-
ment. Phosphorylation stoichiometry of the same synthetic
peptide/phosphopeptide pairs was determined after spiking
small defined amounts into a highly complex mixture of
tryptic peptides obtained from a yeast whole cell extract. In
this experiment, specificity of SRM signals was validated by
comparing the extract with and without the synthetic
peptides (Supporting Information Fig. 3). Figure 1A shows
the total ion chromatogram from an MS scan of the spiked
extract, highlighting the complexity, and Fig. 1B shows the
Table 1. Measurement of phosphorylation stoichiometry with synthetic peptides and recombinant proteins






Peptide Set 1d) 5 671 571




Peptide Set 2d) 5 571 571





VLEDDPEAT(Y)TTSGGK – 8072 8174
QSPEDV(Y)FSK – 7075 6675
T(Y)VDPHT(Y)EDPNQAVLKf) – 47710 4278
T(Y)VDPHTYEDPNQAVLKf) – 1774 4977
TYVDPHT(Y)EDPNQAVLKf) – 2977
IA(Y)SLLGLK – 772 ND
a) Synthetic peptides were synthesized on a Prelude peptide synthesizer (Protein Technologies) and purified to apparent homogeneity by
reverse phase HPLC. Concentrations of purified peptide stocks were determined by amino acid analysis at the Purdue Proteomics
Facility.
b) All data sets are averages of three or more measurements from independent MS analyses and error values are standard deviations.
c) Identical amounts of the three standard peptides were added to all samples for normalization.
d) Phosphorylated residue is in parentheses.
e) EphA2 peptides were generated by trypsin digest of recombinant EphA2 cytoplasmic domain purified from E. coli as described [11].
f) Stoichiometry of the singly and doubly phosphorylated forms had to be calculated differently than for peptides with single
phosphorylation sites (see text). Note that SIM data only reveal the overall percentage of singly phosphorylated species and cannot
distinguish between the two forms.
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overlaid raw SRM traces for the unmodified and phos-
phorylated peptide pairs and the standard peptides in this
same mixture. After normalization (Fig. 1C) and correction
as described above, stoichiometries were calculated from the
integrated SRM traces with an error of 171%, comparable
to values obtained with pure synthetic peptides (Fig. 1D).
Thus, relatively accurate measurement of modification
stoichiometry is possible in highly complex biological
samples using this label-free approach. Note that SIM
analysis of these samples is not possible because the lower
specificity results in overlapping signals from other ions.
An additional advantage of SRM analysis of PTMs is the
ability to extract stoichiometries for two modification sites
on a single peptide, a common occurrence for phosphory-
lation and other modifications. Although XIC-based analy-
ses can determine the overall percent of doubly and singly
modified peptide forms, SRM has the potential to determine
the percentage of modification at each individual site. We
demonstrate this principle on a synthetic peptide set
consisting of an unmodified peptide and two different
phosphorylated forms mixed in defined ratios (Fig. 2). This
analysis requires that SRM transitions are selected that are
unique for each modification site (Fig. 2A) and that data
from three different modification states are collected.
Equation 1 is altered to account for the additional
species and used to solve for the different SRM correction
factors to compare unmodified and modified peptide
forms as described [9]. Again, we consistently measured
stoichiometries of individual phosphorylation sites with
high accuracy (Fig. 2C; average % error5 372). In princi-
ple, a doubly phosphorylated form of the peptide can be
included as well, as would often be the case with real
biological samples. For example, we were able to calculate
stoichiometry for all three modified forms of EphA2 peptide
T(Y)VDPHT(Y)EDPNQAVLK, which has two tyrosine
phosphorylation sites (Table 1).
As with the XIC-based quantification, there are some
limitations to this procedure. Importantly, assumptions
must be made that modification does not affect proteolytic
cleavage and that other in vivomodifications do not exist that
would complicate stoichiometry determination. These
sources of error can be circumvented by careful initial
analysis of specific target proteins but are difficult to address
in large-scale proteomic studies. In some cases, obtaining
sufficiently different modification states to calculate stoi-
chiometry requires partial enzymatic removal of the PTM,
as described [9]. Nonetheless, we conclude that label-free
SRM experiments can be used to accurately determine the
stoichiometry of PTMs as an alternative to MS scan-based
XICs in complex proteome samples and in cases where two
or more modifications reside on a single peptide. Although
our experiments here focused on phosphorylation, this
approach is applicable in principle to any PTM capable of
detection by MS. The specificity of SRM reduces the need
Figure 1. Stoichiometry measurements in whole cell extracts. (A) TIC of trypsin-digested yeast whole cell extract spiked with 200 fmol/mL
total concentration of unmodified and phosphorylated synthetic peptides. (B) SRM signals for two co-eluting transitions for each standard
(STD) and experimental synthetic peptide from the sample in (A). mP1 and uP1 are the modified and unmodified forms of peptide
MI(S)PSKKRITIL and mP2 and uP2 are the modified and unmodified forms of peptide DSKQLLL(S)PGKQFRQI where the parentheses
indicate the site of modification (phosphorylation). (C) Normalized intensities of standard peptides and the mP1 and uP1 peptide pair at
each defined mP1 stoichiometry. (D) Stoichiometries were calculated from the SRM signals and averages from three independent
analyses plotted with standard deviations.
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for purification or fractionation, an advantage for PTM
studies where artificial loss or gain of modifications during
sample processing is a problem. As SRM is becoming a
popular choice for target molecule detection and quantifi-
cation in proteomic studies, this method should prove
useful whenever PTM stoichiometries are desired.
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Figure 2. Stoichiometry measurement at two sites on a single
peptide. (A) Peptide sequence with y and b fragment ion selec-
tion for unique monitoring of two phosphorylation sites (in
parentheses) by SRM. (B) SRM traces for each of the three forms
of the peptide from (A) at two different ratios. pT represents
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Cdc14 Phosphatases Preferentially Dephosphorylate a
Subset of Cyclin-dependent kinase (Cdk) Sites Containing
Phosphoserine*□S
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Background:Cdc14 phosphatases help control mitosis by dephosphorylating sites (Ser/Thr-Pro) targeted by cyclin-depen-
dent kinases (Cdks).
Results: Cdc14 family phosphatases strongly prefer phosphoserine over phosphothreonine at Cdk sites.
Conclusion: By discriminating among Cdk sites, Cdc14 may participate in setting the order and timing of Cdk substrate
dephosphorylation.
Significance: Mechanisms governing the timing of Cdk site dephosphorylation are crucial for proper coordination of late
mitotic events.
Mitotic cell division is controlled by cyclin-dependent
kinases (Cdks), which phosphorylate hundreds of protein
substrates responsible for executing the division program.
Cdk inactivation and reversal of Cdk-catalyzed phosphoryla-
tion are universal requirements for completing and exiting
mitosis and resetting the cell cycle machinery. Mechanisms
that define the timing and order of Cdk substrate dephosp-
horylation remain poorly understood. Cdc14 phosphatases
have been implicated in Cdk inactivation and are thought to
be generally specific for Cdk-type phosphorylation sites. We
show that budding yeast Cdc14 possesses a strong and
unusual preference for phosphoserine over phosphothreo-
nine at Pro-directed sites in vitro. Using serine to threonine
substitutions in the Cdk consensus sites of the Cdc14 substrate
Acm1, we demonstrate that phosphoserine specificity exists in
vivo. Furthermore, it appears to be a conserved property of all
Cdc14 family phosphatases. An invariant active site residue was
identified that sterically restricts phosphothreonine binding and is
largely responsible for phosphoserine selectivity. Optimal Cdc14
substrates also possessed a basic residue at the3position relative
to thephosphoserine,whereas substrates lacking this basic residue
were not effectively hydrolyzed. The intrinsic selectivity of Cdc14
may help establish the order of Cdk substrate dephosphorylation
during mitotic exit and contribute to roles in other cellular
processes.
During cell division, mitosis is triggered when cyclin-depen-
dent kinases (Cdks),5 in association with mitotic cyclins, phos-
phorylate hundreds of proteins at Ser-Pro and Thr-Pro
sequences to promote chromosome condensation, nuclear
envelope breakdown, centrosome separation, and assembly of a
bipolar microtubule spindle. After chromosome segregation
initiates at anaphase, mitotic cyclin proteolysis leads to Cdk
inactivation and disassembly of the molecular machinery of
mitosis, a process called mitotic exit. Cyclin destruction and
Cdk inactivation are necessary but not sufficient formitotic exit
(1). Dephosphorylation of Cdk substrates by opposing protein
phosphatases is also required (1). In the budding yeast, Saccha-
romyces cerevisiae, the Cdc14 phosphatase is essential for Cdk
inactivation (2, 3) and is thought to be the primary phosphatase
responsible for reversing Cdk phosphorylation events to drive
mitotic exit (2). Cdc14 activity toward a limited number of sub-
strates in vitro confirms its ability to counteract Cdks (4, 5).
During interphase and early mitosis, Cdc14 is sequestered in
an inactive state in the nucleolus (2, 6). At the onset of ana-
phase, active Cdc14 is released to the nucleoplasm, where it
dephosphorylates a distinct subset of nuclear Cdk substrates to
stabilize the mitotic spindle and establish the spindle midzone,
promote the timely separation of ribosomal DNA and telom-
eres, and correctly position the nucleus (7, 8). These activities
ensure proper spindle elongation and chromosome segrega-
tion. In late anaphase, Cdc14 accumulates in the nucleus and
cytoplasm. Dephosphorylation of Cdc14 targets in the cyto-
plasm triggers mitotic cyclin destruction and Cdk inhibition,
events required for exit frommitosis (2, 3). Cdc14 also localizes
to the bud neck, where cell abscission occurs and is thought to
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tion Grant MCB 0841748 (to M. C. H.), National Institutes of Health Grant
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be involved in promoting onset of cytokinesis by unknown
mechanisms (9).
Cdc14 phosphatases are conserved in eukaryotes with the
exception of higher plants. Most vertebrates express two para-
logs typically designated Cdc14A and Cdc14B. Unlike the bud-
ding yeast enzyme, Cdc14 orthologs of most other species are
not required for mitotic exit (10). In vertebrates, there are con-
flicting reports on the functions of the Cdc14 isoforms, but
there is evidence for involvement in regulating mitotic entry,
centrosome duplication, DNA repair, and cytokinesis (10).
Cdc14 phosphatases are members of the protein-tyrosine
phosphatase superfamily (11). Based on structural and partial
sequence similarities and in vitro activity with artificial sub-
strates, Cdc14 phosphatases are classified as dual specificity
phosphatases, a subgroup of protein-tyrosine phosphatases
capable of dephosphorylating Ser/Thr as well as Tyr residues
(12, 13). However, few sites targeted by Cdc14 in vivo have been
directly identified, and the specificity of Cdc14 phosphatases
has not been defined by biochemical analyses. In this study, we
examined the substrate selectivity of Cdc14 phosphatases and
found that they possess a conserved ability to discriminate
between phosphoserine (Ser(P)) and phosphothreonine
(Thr(P)) at Cdk sites. The strong preference of Cdc14 for
Cdk sites containing Ser(P) suggests previously unrecog-
nized complexity in the regulation of Cdk targets and high-
lights a mechanism that could allow Cdk substrates and indi-
vidual Cdk sites to be differentially regulated.
EXPERIMENTAL PROCEDURES
Peptide Synthesis and Purification—Peptide synthesis and
purificationwas performed using solid-phase Fmoc (N-(9-fluo-
renyl)methoxycarbonyl) chemistry on a Prelude parallel pep-
tide synthesizer (Protein Technologies, Tucson, AZ) essentially
as described (14) with the following changes. Coupling times
for phosphorylated amino acids were increased to 3 h. Com-
pleted peptides were cleaved with 5ml of 95%TFA, 2.5%water,
and 2.5% triisopropylsilane, precipitated, and washed three
times with 35ml of diethyl ether prior to purification by reverse
phase HPLC. Purified peptides were dissolved in 50 mM Tris-
HCl (pH8.0), and concentrationswere determined as described
previously (15).
Purification of Cdc14 Phosphatases and Cdc14 Substrates—
His6-tagged budding yeast Cdc14 (wild-type and the A285G
mutant) or His6-tagged fission yeast Clp1 (fission yeast
ortholog of budding yeastCdc14)were expressed inEscherichia
coli and affinity-purified using a Ni2-chelate column. The cat-
alytic domains of the hCdc14A (residues 1–379) and hCdc14B
(residues 1–418) isoforms were expressed as N-terminally
tagged glutathione S-transferase (GST) fusion proteins in
E. coli and affinity-purified using glutathione agarose. Full-
length, recombinant forms of the budding yeast proteinsAcm1,
Cdc6, and Fin1were expressed asGST fusion proteins inE. coli,
affinity-purified on glutathione beads, and phosphorylated by
Cdk1 for use as substrates forCdc14. See supplementalmaterial
for detailed methods used for protein purification and phos-
phorylation of protein substrates.
Phosphatase Assays—Dephosphorylation of phosphopep-
tides was measured by detection of released inorganic phos-
phate with either a 2.5% (w/v) ammonium molybdate, 0.15%
(w/v)malachite green solution dissolved in 1 NHCl as described
(15) or BIOMOLGreenTM reagent (Enzo Life Sciences). Assays
were performed in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1
mM EDTA, and 0.1% -mercaptoethanol at 30 °C for varying
times. Reactions were stopped with either an equal volume of
1.2 N HCl (for malachite green assays) or the BIOMOL Green
reagent as directed by the supplier, and absorbance was mea-
sured at 620 nm. Standard curves were generated using sodium
phosphate under identical buffer conditions.Km and kcat values
were obtained by measuring initial rates at varying substrate
concentrations and fitting the Michaelis-Menten equation to
these data using non-linear regression with either Kaleida-
Graph (Synergy Software) or GraphPad Prism (GraphPad Soft-
ware) programs. For phosphopeptides exhibiting substrate
inhibition, data were fit with a modified Michaelis-Menten
equation containing a substrate inhibition (Ki) term.
Dephosphorylation of Recombinant Protein Substrates—
Cdk1-phosphorylated GST-Fin1 (3 M), GST-Acm1 (5 M), or
GST-Cdc6 (1 M) were treated with budding yeast His6-Cdc14
(200 nM) and incubated at 30 °C for the indicated times. For
Acm1 and Cdc6, aliquots were removed, added to equal vol-
umes of 2 SDS-PAGE loading dye, heated at 95 °C to stop the
reaction, and separated by SDS-PAGE. Gels were stained with
Coomassie Blue, and excised bands were subjected to in-gel
digestion with either Lys-C (for Acm1) or trypsin (for Cdc6)
and prepared for mass spectrometry (MS) analysis as described
(16). For Fin1, reactions were stopped by the addition of an
equal volume of acetonitrile. Samples were diluted to 20% ace-
tonitrile with fresh 50 mM ammonium bicarbonate, digested
with 50 ng of Lys-C (Sigma-Aldrich) overnight at 37 °C, and
analyzed by MS.
LC/MS Analysis and Label-free Quantification—Peptides
derived from recombinant proteins were analyzed by liquid
chromatography coupled to electrospray ionization MS on an
LTQ-Orbitrap Velos instrument (Thermo Scientific). Phos-
phopeptides were identified, and phosphorylation sites were
confirmed based on product ion spectra. Extracted ion chro-
matograms for all detectable parent phosphopeptides and sev-
eral non-phosphorylated peptides were generated using Xcali-
bur and integrated using GraphPad Prism. To quantify
dephosphorylation at each Cdk site, phosphopeptide signals
were first normalized using the non-phosphorylated standard
peptides and then converted to percentages of the zero time
point signals. For the Cdc6 peptides containing two Cdk sites,
the Orbitrap was operated in targeted tandem MS mode, and
extracted fragment ion chromatograms specific for each phos-
phorylation sitewere generated.Quantificationwas the same as
for the other sites. For additional details, see supplemental
Methods.
Co-immunopurification (co-IP) and Immunoblotting—The
acm1-S4T6 allele was generated using the QuikChange Multi
site-directed mutagenesis kit (Stratagene) and confirmed by
sequencing. ACM1 and acm1-S4T were integrated under con-
trol of the naturalACM1 promoter at theTRP1 locus in aW303
6 Throughout this study, Acm1-S4T indicates an Acm1 mutant in which Thr
replaces Ser at four consensus Cdk phosphorylation sites.
Substrate Specificity of Cdc14 Phosphatases
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acm1 background using the pRS404 vector. 3HA-CDC14 and
the 3HA-cdc14-C283S substrate trap mutant were integrated
under control of the GAL1 promoter at the LEU2 locus using
the pRS305 vector. To analyze the effect of Cdc14 on Acm1
phosphorylation and stability, cultures were grown to mid log
phase (A6000.4) in YP-raffinose medium, and 2% galactose
was added for two h to induce 3HA-Cdc14 expression. Soluble
protein extracts were generated by glass bead lysis in IP buffer
(50 mM sodium phosphate (pH 7.5), 100 mM NaCl, 10% glyc-
erol, 0.1%TritonX-100, and 5mMEDTA) supplementedwith 1
mMphenylmethylsulfonyl fluoride, 1Mpepstatin, 100M leu-
peptin, 20 mM sodium fluoride, and 20 mM -glycerophos-
phate. Extracts were then separated by SDS-PAGE on a 10% gel
and analyzed by immunoblotting. Acm1 and Acm1-S4T were
detected with an affinity-purified polyclonal antibody directed
against recombinant GST-Acm1 (Pacific Immunology, 0.04
g/ml working concentration). 3HA-Cdc14 was detected with
anti-HA 12CA5 (Roche Applied Science, 0.4 g/ml). Rabbit
anti-G6PD (0.2 g/ml) was from Sigma-Aldrich. Cultures for
co-IP analysis were grown and processed similarly except that
the 3HA-Cdc14-C283S substrate trapmutant was expressed by
galactose induction. Soluble whole cell extracts in IP buffer (4
mg) were incubated with 12.5 l of EZview anti-HA affinity
resin (Sigma-Aldrich) for 2 h at 4 °C with gentle mixing and
washed 4 with 1 ml of IP buffer, and bound proteins were
eluted by boiling in SDS gel loading buffer without reducing
agent. Recovered proteins were supplemented with 25 mM
dithiothreitol, reheated, and analyzed by SDS-PAGE and
immunoblotting.
RESULTS
We showed that the budding yeast Cdh1 inhibitor Acm1 is a
substrate of Cdc14 (16). In subsequent studies, a phosphopep-
tide containing the conserved Thr-161 Cdk phosphorylation
site of Acm1 could not be dephosphorylated in vitro by Cdc14,
even at high enzyme concentrations. This finding suggested
that Cdc14 might act only on a subset of Cdk sites. To test this
possibility, we synthesized over 20 phosphopeptides matching
sequences from budding yeast Cdk substrates and examined
their ability to be dephosphorylated by Cdc14 (Fig. 1, A and B,
Table 1, and supplemental Table S1). Without exception,
Cdc14 exhibited little or no detectable activity toward peptides
containing a Thr(P). In contrast, Cdc14 exhibited a broad range
of rates and catalytic efficiencies toward Ser(P)-containing pep-
tides. Acm1pS31, the most effective Ser(P)-containing pep-
tide for budding yeast Cdc14, had a catalytic efficiency (kcat/
Km) more than 3 orders of magnitude greater than the best
peptide substrate bearing Thr(P) (Table 1).
To more directly determine whether Cdc14 distinguishes
between Ser(P) and Thr(P), we replaced Ser(P) with Thr(P) in
Acm1pS31. The catalytic efficiency for Acm1pT31 was over
3,000-fold lower than Acm1pS31 (Fig. 1C and Table 1). Con-
versely, whenThr(P) in theCdc6pT7 peptidewas replacedwith
Ser(P), catalytic efficiency increased more than 1,000-fold (Fig.
1D and Table 1). Additional phosphopeptide substrates (sup-
plemental Table S2) confirmed the 1 proline specificity of
Cdc14 and its ability to dephosphorylate tyrosine (13), albeit
weakly and largely independent of a1 Pro.
The selectivity of Cdc14 for Ser(P) at Cdk sites was also
observed with full-length protein substrates. We purified
FIGURE 1. Budding yeast Cdc14 is highly selective for Ser(P) at Cdk phosphorylation sites in phosphopeptide substrates. A, time-dependent dephos-
phorylation of phosphopeptide substrates Acm1pS3 (●), Acm1pT161 (E), andCdh1pT157 (X) by budding yeast Cdc14. The concentration of all substrateswas
300 M. B, same as A showing Ser(P)-containing peptide substrates Acm1pS3 (●), Acm1pS31 (f), Acm1pS48 (Œ), Cdh1pS42 (), Cdh1pS169 (), and
Cdh1pS239 (E). All substrates were 100 M. Peptide sequences are shown in Table 1 and supplemental Table S1. C and D, the rate of dephosphorylation of
peptides Acm1pS31 (f) and Acm1pT31 (●) (C) and of peptides Cdc6pS7 (f) and Cdc6pT7 (●) (D) was measured as a function of peptide concentration. Data
are the average of three independent experiments, and using non-linear regression, data were fit with a form of the Michaelis-Menten equation containing a
substrate inhibition term. The amino acid sequence and kinetic parameters for peptides in C and D are given in Table 1 or supplemental Table S2.
TABLE 1
Catalytic efficiency (kcat/Km) of budding yeast Cdc14 for Ser(P)- and
Thr(P)-containing peptide substrates
To calculate catalytic efficiencies, steady state kinetic parameters were determined
by measuring initial velocity as a function of peptide substrate concentration at pH
8.0 and 30 °C. The kcat and Km values were determined by fitting the Michaelis-
Menten equation to the data using nonlinear regression and are given in supple-
mental Tables S1 and S2.









a The name of the parent protein from budding yeast is followed by the iden-
tity (pS for Ser(P) or pT for Thr(P)) and residue number of the phosphorylated
residue.
b Peptide sequences are given in single-letter code with phosphorylated residues
underlined in bold and are identical to those of the parent phosphoprotein with
the exception of the Acm1pT31 and Cdc6pS7 variants (asterisks) in which the
phosphoamino acid was replaced as indicated.
cND, in reactions containing from 0.2–1.0 M Cdc14 and 1–5 mM substrate, rates
were at or below the limit of detection (about 1.0 pmol min1); thus steady state
kinetic parameters were not determined.
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recombinant forms of the physiologic Cdk substrates Acm1,
Fin1, and Cdc6 and phosphorylated them in vitrowith purified
Cdk1 (Clb2-Cdc28). MS analyses of all three proteins con-
firmed the sites of phosphorylation and showed that all three
proteins contained both Ser(P) and Thr(P) residues at roughly
equivalent average stoichiometry (supplemental Table S3 and
supplemental Dataset 1). Following treatment with Cdc14, we
used proteolytic peptide MS signals to independently quantify
relative rates of dephosphorylation at each detectable Cdk
phosphorylation site in the three protein substrates. In Acm1,
Cdk sites containing Ser(P) were efficiently dephosphorylated
by Cdc14, whereas Thr(P)-161 was not significantly affected
(Fig. 2A). Similarly, in Fin1 and Cdc6 (Fig. 2, B and C and sup-
plemental Dataset 2) all Ser(P) sites were almost completely
dephosphorylated, but no significant hydrolysis of Thr(P) was
observed. Ser selectivity was manifested clearly on three pep-
tides containing both a Ser(P) and a Thr(P) Cdk site. In all three
cases, signal for the Ser(P) form decreased during the reaction,
whereas the Thr(P) form accumulated due to Ser(P) dephos-
phorylation from the doubly phosphorylated substrate popula-
tion (Fig. 2, B and C and supplemental Dataset 2).
We next considered the source of the wide variation in cata-
lytic efficiencies among Ser(P) peptide substrates. Activity of
Cdc14 toward Ser(P) substrates correlated strongly with the
number of basic residues C-terminal to Ser(P) (supplemental
Table S1). The best Cdc14 substrates contained 3 basic residues
occupying the 3 to 5 positions relative to Ser(P), whereas
peptides with no basic residues in this region were virtually
unreactive. We synthesized peptide variants of an efficient
(Acm1pS31) and poor (Cdh1pS169) Ser(P) substrate that had 0,
1, 2, or 3 basic residues occupying the3 to5 positions (Fig.
3 and supplemental Table S2). For both, the dephosphorylation
rate was very low in the absence of basic residues. The rate
increased dramatically with a single basic residue at the 3
position and was further increased by additional basic residues
at 4 and 5 (Fig. 3). Preliminary analyses of a larger peptide
library revealed that3 was the only position in the2 to6
FIGURE 2. Budding yeast Cdc14 preferentially dephosphorylates Ser(P)-containing Cdk phosphorylation sites in physiologic protein substrates. A–C,
dephosphorylationof the indicated residues fromfull-length recombinantGST-Acm1 (A), GST-Fin1 (B), andGST-Cdc6 (C) bybuddingyeastCdc14wasmeasuredover
time(blackbars, 0min;whitebars, 5min;graybars, 30min)usingaquantitativemassspectralassay.Single-lettercodeswereusedto indicateaminoacidresidues inthis
panel. Data are means of three trials with standard errors. Remaining phosphorylation at each site is plotted relative to 0 min, which was set at 100%.
FIGURE 3. Activity of Cdc14 phosphatases is dependent on basic residues
C-terminal to Ser(P) at Cdk sites.A andC, the complete sequences of the wild-
type Acm1pS31 (A) and Cdh1pS169 (C) peptides are shown in black on the first
line with the residues of the 3 to 5 region (relative to Ser(P) (pS)) in each
variant shown below in red. B and D, rates of dephosphorylation of Acm1pS31
and its variants (B) andofCdh1pS169and its variants (D) bybuddingyeastCdc14
were compared at a single substrate concentration of 300 M. The amino acid
sequenceof the3 to5 region ineachpeptide is shownbelow the xaxis.Data
represent the mean of three independent experiments with standard errors.
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region where a single basic amino acid conferred high catalytic
efficiency to a Ser(P)-containing substrate peptide (data not
shown).
To test the physiological importance of Cdc14 Ser(P) selec-
tivity, we overexpressed Cdc14 from the GAL1 promoter and
monitored the phosphorylation status and stability of wild-type
Acm1 and an Acm1 mutant in which its four Ser-containing
consensus Cdk phosphorylation sites were changed to Thr
(Acm1-S4T, Fig. 4A). Our previous work demonstrated that
Cdk phosphorylation stabilizes Acm1 and reduces its SDS-
PAGE mobility, whereas Cdc14-catalyzed dephosphorylation
triggers Acm1 proteolysis (16). Consistent with our prior work,
the slow mobility form of Acm1 was lost upon Cdc14 overex-
pression, and the overall level of Acm1 was strongly reduced
(Fig. 4B). In contrast, the level and SDS-PAGE mobility of
Acm1-S4T were unaffected by Cdc14 overexpression.
We also examined the ability of an active site Cdc14 mutant
(Cdc14-C283S) that binds substrates tightly (16) but is catalyt-
ically inactive to associate with Acm1 and Acm1-S4T by co-IP
analysis. Consistent with our previous work (16), wild-type
Acm1 was efficiently recovered in an IP of 3HA-Cdc14-C283S
(Fig. 4C). Acm1-S4T was completely absent from the 3HA-
Cdc14-C283S IP samples, indicating thatCdc14 has low affinity
for Acm1 if its Ser Cdk sites are converted to Thr Cdk sites. The
overall phosphorylation status of Acm1 and Acm1-S4T
appeared similar based on their identical SDS-PAGE mobility
pattern. Together, the resistance of Acm1-S4T to dephosphor-
ylation by wild-type Cdc14 and lack of binding to the Cdc14-
C283S substrate trap mutant clearly demonstrate that Cdc14
distinguishes between Ser(P) and Thr(P) Cdk sites in vivo.
To determine whether specificity for Ser(P) was evolution-
arily conserved, we purified several Cdc14 orthologs and tested
their activities on a subset of the synthetic phosphopeptide sub-
strates. The catalytic domain of human Cdc14A (residues
1–379) exhibited efficient dephosphorylation of Ser(P) pep-
tides and poor activity toward Thr(P) peptides (Fig. 5A). The
difference in catalytic efficiency between the best Ser(P) and
Thr(P) substrates was 625-fold (supplemental Table S1). The
catalytic domain of human Cdc14B (residues 1–418) and fis-
sion yeast Clp1 showed a similar preference for Ser(P) peptide
substrates (Fig. 5,B andC). The strong preference for a3 basic
residuewas also conserved in hCdc14A and hCdc14B, although
the human enzymes appeared less sensitive to additional basic
residues (supplemental Fig. S1). We conclude that intrinsic
selectivity for Ser(P)-Pro-X-Lys/Arg sites is a conserved prop-
erty of the Cdc14 phosphatase family.
The structure of hCdc14B bound to a short Ser(P) peptide
substrate (17) provided insight into the molecular basis for
Ser(P) selectivity. Without altering the conformation of
hCdc14B or the backbone of the bound peptide, the Ser(P) res-
idue of the peptide was replaced with Thr(P) in the model (Fig.
6A). This change revealed a steric clash between methyl side
chains on Thr(P) of the peptide substrate and Ala-316 of
hCdc14B, an invariant active site residue among Cdc14 phos-
phatases (supplemental Fig. S2 and Table S5). The structure of
the KAP phosphatase (18) is similar to that of the catalytic sub-
domain of hCdc14B (17). This similarity is particularly strong
within a 54-amino acid region encompassing the active site
where residues 292–345 of hCdc14B could be superimposed on
the corresponding segment of the KAP phosphatase, residues
115–172, with a rootmean square deviation of 1.1 Å for aligned
C atoms. KAP dephosphorylates a Thr(P) in the activation
segment of Cdks (19), and interestingly, has Gly at the posi-
tion corresponding to Ala-316 in hCdc14B (supplemental
Fig. S2 and Table S5). Consistent with these observations,
further analysis of the structural model of hCdc14B sug-
gested that replacement of Ala-316 by Glymight alleviate the
steric interference with the Thr(P) side chain and permit
efficient Thr(P) binding and hydrolysis (Fig. 6A). To test this,
we replaced the homologous Ala-285 in budding yeast
Cdc14 with Gly, generating a Cdc14 A285G mutant that
exhibited a net 100-fold decrease in selectivity for Ser(P)
when compared with Thr(P) (Fig. 6, B and C). This result
suggests the Ser(P) selectivity in Cdc14 enzymes arises
largely from steric occlusion of Thr(P) from the active site
but indicates that additional features of the enzyme must
FIGURE 4. Cdc14 Ser(P) selectivity exists in vivo. A, schematic of Acm1 pro-
tein showing the location and sequence of the four Ser(P)-containing Cdk
consensus sites and the corresponding amino acid substitutions made to
create the Acm1-S4T mutant. B, extracts from asynchronous cultures of cells
expressing Acm1 or Acm1-S4T from the natural ACM1 promoter before and
after galactose-inducedoverexpressionof 3HA-Cdc14were analyzedby SDS-
PAGE and immunoblotting. G6PD is a loading control. pAcm1 represents a
slow mobility Cdk-phosphorylated form of Acm1. C, anti-HA antibody resin
was used to isolate 3HA-Cdc14-C283S and interacting proteins from soluble
extracts of asynchronous cultures expressingeitherwild-typeAcm1orAcm1-
S4T fromthenaturalACM1promoter. Immunoblottingwasused todetect the
indicated proteins in the initial extracts and after anti-HA IP.G6PD is a loading
control.
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also confer Ser(P) specificity because the catalytic efficiency
of Cdc14 A285G toward Thr(P)-containing peptides is sig-
nificantly lower than that for peptides containing Ser(P).
DISCUSSION
Cdc14 substrate specificity has previously been assumed to
include either Ser(P) or Thr(P) residues located within Ser/
Thr-Pro consensus sequences recognized by Cdks. Our work
provides crucial refinements in our understanding of sites tar-
geted by the Cdc14 phosphatases. We show that efficient
dephosphorylation by Cdc14 phosphatases not only requires
Pro at the 1 position but also requires Ser as the phospho-
amino acid and a basic amino acid at 3. At least with the
budding yeast enzyme, additional adjacent basic residues fur-
ther enhance activity. Importantly, mutational analysis of Cdk
phosphorylation sites in Acm1 clearly demonstrated that the
phosphoserine selectivity detected in vitrowas observed in cells
and is physiologically relevant.
An invariant active site Ala residue and adjacent acidic
groove of Cdc14 phosphatases are major determinants of sub-
strate specificity and function. The methyl group of an Ala res-
idue located at the edge of the active site cleft restricts access to
Thr(P) residues, bestowing the ability to discriminate between
Ser(P) and Thr(P). Gray et al. (17) described a negatively
charged groove extending from the active site of hCdc14B that
contains 3 acidic residues conserved in Cdc14 phosphatases
from diverse species (supplemental Fig. S2 and Table S5). The
negative effect of mutating residues Glu-168, Glu-171, and
Asp-177 on the activity of budding yeast Cdc14 toward human
Cdh1 (20) and our results revealing the importance of basic
residues at3 to5 positions in substrates confirm the impor-
tance of this acidic channel in substrate recognition.
The unexpected specificity of Cdc14 phosphatases for
Ser(P)-Pro-X-Lys/Arg sequences has broad implications for the
mechanisms by which Cdk site phosphorylation is reversed
during cell cycle progression and for understanding functions
of Cdc14 enzymes in other cellular processes. Selectivity for
Ser(P) within Cdk sites is biologically relevant because a sub-
stantial fraction of physiologic Cdk phosphorylation sites con-
tains Thr(P). Cdks do not appear to distinguish between Ser or
Thr (21, 22), and large-scale phosphoproteomic data suggest
that 22% of in vivo budding yeast Cdk sites contain Thr(P) (23).
In HeLa cells, 27% of Cdk-like sites up-regulated in mitosis
contain Thr(P), whereas 21% of total proline-directed phos-
phosites are Thr(P) (24).
Our results imply that Cdc14 phosphatases are restricted
in their capacity to oppose Cdks and may therefore play spe-
cialized roles in reversal of Cdk phosphorylation. Cdk sub-
strates are dephosphorylated at different times during mito-
sis (25) to ensure that events such as chromosome
segregation, exit from mitosis, and cytokinesis are properly
orchestrated, and the intrinsic specificity of Cdc14 could
contribute to this timing. For example, budding yeast Cdc14
is transiently activated in early anaphase to target a small set
of substrates important for anaphase spindle function (7, 8).
As predicted by our data, the known early anaphase Cdc14
substrates have significantly higher Ser-Pro to Thr-Pro
ratios and frequencies of Ser-Pro sites with a 3 basic resi-
due than the average yeast protein and known Cdk sub-
strates (supplemental Table S4). The different specificities of
S phase and mitotic Cdks combined with the differential
timing of cyclin degradation during mitosis have also been
proposed to contribute to the temporal dephosphorylation
of Cdk substrates in yeast (26), a mechanism that is not
mutually exclusive with the Cdc14 specificity reported here.
FIGURE 5. Human Cdc14A, human Cdc14B, and fission yeast Clp1 phos-
phatases exhibit selectivity for Ser(P). A, the rate of dephosphorylation of
the indicatedphosphopeptidesby thehCdc14A(1–379) catalytic domainwas
compared at single substrate concentrations (250M for Ser(P) peptides and
for Acm1pT31 and Cdc6pT7; 1 mM for all other Thr(P)-containing peptides).
pS, Ser(P); pT, Thr(P). B, the rate of dephosphorylation of the indicated phos-
phopeptides by the hCdc14B(1–418) catalytic domain was compared at sin-
gle substrate concentrations (500 M for Acm1pS3 and Acm1pS31, 1 mM for
all others). Data in A and B are averages of four trials with standard errors.
C, dephosphorylation of Acm1pS31 (●) and Acm1pT31 (f) by fission yeast
Clp1 was measured as a function of peptide concentration. Data were fit with
the Michaelis-Menten equation containing a substrate inhibition term. Rates
are expressed per pmol of Cdc14.
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Cdk sites containing Thr(P) could allow proteins to avoid
premature dephosphorylation by Cdc14 in early anaphase. One
example in budding yeast is the Cdc14 inhibitor, Net1 or Cfi1,
which sequesters Cdc14 in an inactive state in the nucleolus for
most of the cell cycle (2, 6). Cdk1-mediated phosphorylation of
an N-terminal region of Net1 at the onset of anaphase is
required for the initial transient release of Cdc14 from the
nucleolus (27). Four of the six Cdk sites in this region are Thr,
and the two Ser sites lack3 basic residues (27), suggesting that
they are all poor Cdc14 substrates that could have evolved to
prevent Cdc14 from inhibiting its own release. Before the onset
of anaphase, there may be an active pool of Cdc14 in the nucle-
olus (28, 29); thus Ser(P) selectivity may be particularly impor-
tant in preserving the interaction of Cdc14 with Net1 in
interphase and early mitosis and sustaining normal Cdc14
regulation.
In budding yeast, Cdc14 is thought to be responsible for
dephosphorylating most mitotic Cdk substrates during mitotic
exit. Our results imply that at least one other protein phospha-
tase is likely required to oppose Cdks. The Ser/Thr protein
phosphatases PP2A and PP1 are involved in mitotic regulation
and are good candidates for targeting Thr(P)-Pro sites (6). The
involvement of multiple phosphatases permits diversity in the
mechanisms governing reversal ofmitotic phosphorylation and
may allowmore refined temporal and spatial control of mitotic
exit.
More specialized roles for Cdc14 in opposing Cdks are also
consistent with the fact that Cdc14 is not required for mitotic
exit in most eukaryotes (10). Currently, the functions of verte-
brate Cdc14 enzymes during cell division are not clear (10).
Although the functions and substrates of Cdc14 orthologs, and
the specific kinases they oppose, may have diverged substan-
tially during evolution, our findings clearly show that their
enzymatic specificity has been conserved. The strict selectivity
of Cdc14 may be useful in identifying novel substrates and
thereby elucidating biological functions in humans and other
eukaryotes, including defining and clarifying roles in regulating
cell division.
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Abstract
The protein kinase Bcr-Abl plays a major role in the pathogenesis of chronic myelogenous leukemia (CML), and is the target
of the breakthrough drug imatinib (GleevecTM). While most patients respond well to imatinib, approximately 30% never
achieve remission or develop resistance within 1–5 years of starting imatinib treatment. Evidence from clinical studies
suggests that achieving at least 50% inhibition of a patient’s Bcr-Abl kinase activity (relative to their level at diagnosis) is
associated with improved patient outcomes, including reduced occurrence of resistance and longer maintenance of
remission. Accordingly, sensitive assays for detecting Bcr-Abl kinase activity compatible with small amounts of patient
material are desirable as potential companion diagnostics for imatinib. Here we report the detection of Bcr-Abl activity and
inhibition by imatinib in the human CML cell line K562 using a cell-penetrating peptide biosensor and multiple reaction
monitoring (MRM) on a triple quadrupole mass spectrometer. MRM enabled reproducible, selective detection of the peptide
biosensor at fmol levels from aliquots of cell lysate equivalent to ,15,000 cells. This degree of sensitivity will facilitate the
miniaturization of the entire assay procedure down to cell numbers approaching 15,000, making it practical for translational
applications in patient cells in which the limited amount of available patient material often presents a major challenge.
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Introduction
Kinase inhibitor drugs represent an approximately $10 billion
market in the pharmaceutical industry, and this is anticipated to
expand even further over the coming decade. [1] The classic
example and breakthrough drug for this therapeutic strategy is
GleevecH (imatinib). Imatinib inhibits the Bcr-Abl kinase, an
oncogene encoded on the Philadelphia chromosome (a transloca-
tion of chromosomes 9 and 22; tumor cells with this translocation
are known as Ph+) on which the disease process of chronic
myelogenous leukemia (CML) depends. Approximately 90% of
CML patients achieve initial remission with imatinib, and for
,70% of patients, that remission remains stable for a long period
of time; however, a significant proportion (,30%) either never
respond or develop recurrent and/or resistant disease and
experience relapse within a few years. [2,3] Evidence from
monitoring the relative inhibition of Bcr-Abl in CML patients
beginning therapy suggests that failure to achieve at least 50%
relative inhibition of the kinase’s activity is associated with poorer
short- and long-term outcomes. [4] A similar relationship has been
observed for other promising kinase inhibitor drugs. [5] Relatedly,
failure of clinical trials for inhibitors targeted at other kinases due
to heterogeneity of patient response (unlike the relatively
homogenous response of CML patients to imatinib) is a major
risk in kinase inhibitor drug development, and often arises due to a
lack of pharmacodynamic assessment of the response of the drug
target and downstream signaling pathways. [5,6] The Food and
Drug Administration has become increasingly involved in efforts
to include companion diagnostics as a part of the drug approval
process. [7] Kinase assays developed as companion diagnostics
could assist with earlier decision making on the potential for a drug
to be successful. This could also enable more effective selection of
patients who are likely to benefit, refining the population for
defining successful response in a clinical trial. [5] Additionally, the
patent on Gleevec has recently expired; however, imatinib is
currently first-line therapy for CML, and still holds the biggest
market. [8] The still-branded inhibitors TasignaH (nilotinib) and
SprycelH (dasatinib) are being promoted as first-line therapies for
newly-diagnosed CML patients, but may not be necessary in most
cases where imatinib is effective but just not reaching the relative
inhibition required for the best clincial outcomes. Accordingly,
stakeholders including patients, doctors and insurance companies
would benefit from information on whether less costly, generic
imatinib could be effective for a given individual. Pharmaceutical
companies may also find methods to detect sensitivity to branded
drugs useful to support the need for their branded drugs, for
example in cases where imatinib is found to be ineffective
regardless of dose.
A relevant companion diagnostic for kinase inhibitor pharma-
codynamics needs to measure enzymatic activity, and thus
substrate phosphorylation, for a targeted kinase. Protein and
peptide phosphorylation by kinases has traditionally been detected
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using 32 P-radiolabeled ATP or antibody-based methods (such as
ELISA and Western blot). These methods are reliable and well-
characterized, but often are limited by concerns over waste
generation (radiolabeled assays) or the requirement for phospho-
site-specific antibodies, which are not always available at the scales
necessary for clinical tests at a reasonable cost. To overcome these
limitations, several approaches (e.g. microarray, bead-based and
targeted mass spectrometry (MS) methods) have been described
that detect kinase activity from relatively small amounts of cell
lysate (down to ,10 mg). [9–15] The number of Ph+, Bcr-Abl
expressing CML cells per ml of blood is highly variable from
patient to patient, reaching several hundreds of millions during
chronic phase (during which diagnosis typically occurs) and
dropping to 0.15–56106 upon hematological remission (when
patients would likely benefit from monitoring for maintenance of
kinase inhibition and potential for disease recurrence). Typical
total protein yields from CML model cells such as K562 average
approximately 50–250 mg per 106 cells, so assays that can achieve
reproducible signal with ,10 mg of sample would potentially be
appropriate for translational assays on patient material. However,
kinase signaling is highly dependent on factors such as subcellular
localization and scaffolding–therefore, assays that can measure
kinase activity in intact cells are desirable for achieving the most
biologically-relevant measurements of activation and inhibition.
Furthermore, there is evidence from proteomic studies that
downstream phosphorylation sites (such as Y207 of CrkL) may
not be accurate reporters of drug sensitivity and pharmacody-
namics in leukemias including CML. [16] Accordingly, exogenous
sensors that report kinase activation states (rather than the
phosphorylation of downstream substrates) with high sensitivity
may provide useful information about individual patient response
to kinase inhibitors and facilitate personalized therapeutic
decisions in the clinic.
Genetically-engineered Fo¨rster resonance energy transfer
(FRET) protein constructs for detecting Bcr-Abl activity in intact
cells have been reported, however transfecting patient cells with
sensor constructs for clinical assays is very challenging and not
practical for a typical clinical laboratory. We previously reported a
cell-permeable peptide biosensor for Abl kinase and its application
for detecting DNA damage-related Abl kinase activation in intact
cells (Fig. 1). [17,18] Because it can be applied in a relatively
simple workflow (involving straightforward, reproducible incuba-
tion and lysis steps), this peptide biosensor strategy has the
potential to be compatible with clinical laboratories. Our previous
applications of the assay used Western blot and MALDI-TOF MS
to detect peptide phosphorylation and required 2–56106 cells per
experiment, which corresponds to 6–156106 cells for triplicate
analyses. While these cell numbers are trivial to achieve in cultured
cell lines and may be available from patient material in some cases
at diagnosis, they are not optimal for application to a clinical
setting in which the yield of CML cells per ml of whole blood is
typically lower than those levels once treatment with imatinib is
initiated. Moreover, our previous demonstrations of the assay
technology were performed in model cell lines genetically
engineered to overexpress constructs of Abl kinase that were not
necessarily relevant to the CML disease model. Accordingly, we
set out to establish an assay that would provide higher sensitivity
for detecting Bcr-Abl kinase activity using the peptide biosensor
and also demonstrate the method in a more clinically relevant
model (the human CML cell line K562). We chose LC/MS with
multiple reaction monitoring (MRM) as an analysis strategy based
on its excellent sensitivity and signal to noise. Lower detection
limits for MRM can reach the fmol-amol range depending on the
specific analytes and instrumentation involved. We and oth-
ers[9,19–21] have successfully detected and quantified peptides
and their phosphorylated derivatives using this technique. Here we
describe the development of the MRM method and demonstrate
that the biosensor/MRM strategy can be employed to detect Bcr-
Abl activity and inhibition in CML cells as a model for monitoring
drug sensitivity in human leukemia.
Materials and Supplies
Peptide Synthesis
Fmoc-protected amino acid monomers were purchased from
Peptides International (Louisville, KY, USA). Fmoc–biotinylated
lysine was obtained from Akaal Organics (Long Beach, CA, USA).
The photocleavable residue (3-(2-nitrophenyl)-3-aminopropionic
acid) was obtained from Lancaster Synthesis and Fmoc-protected
by J. Thomas Ippoliti’s lab at the University of St. Thomas (St.
Paul, MN). Other reagents were purchased from Sigma-Aldrich if
not specified.
Cell Culture
K562 cells were obtained from ATCC (Rockville, MD). Cells
were routinely maintained in RPMI-1640 supplemented with 10%
fetal bovine serum, 1% penicillin/streptomycin, and 1% L-
glutamine in a 5% CO2 humidified environment at 37uC.
Experimental Procedures
Peptide synthesis, purification and
characterization. Peptides were synthesized via solid phase
Fmoc chemistry on 50 mmol CLEAR-Amide resin using a Prelude
Peptide Synthesizer (Protein Technologies, Tucson, AZ, USA)
Figure 1. Peptide-based biosensor for Abl kinase. The ‘reporter’ sequence, called ‘Abltide,’ [28] is an efficient Abl kinase substrate. The
‘targeting’ sequence binds to the Abl kinase SH3 domain [29] (a protein-protein interaction domain important for Abl kinase regulation). The
‘transduction’ sequence is the TAT peptide from the HIV-TAT protein that helps the virus deliver its contents to host cells. Glycine linkers allow flexible
spacing of active modules. A UV cleavable linker (b-Npa) allows release of the short reporter segment from the larger peptide if desired (but is not
relevant to the application described here) and a biotin tag on the reporter enables detection or enrichment of the peptide via streptavidin.
doi:10.1371/journal.pone.0056627.g001
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with a double coupling cycle (22 min deprotection with 20%
piperidine in DMF, 661 ml DMF wash, 2610 min coupling with
100 mM amino acid, 90 mM HCTU/0.4 M NMM in DMF,
361 mL DMF wash). After synthesis, peptides were deprotected
and cleaved using TFA/Water/EDT/TIS 94.5%/2.5%/2.5%/
1%. After cleavage, peptides were purified to at least 90% purity
using an Agilent Technologies 1200 Series HPLC system (Santa
Clara, CA, USA) with a C18 reverse phase column (1625 cm).
Characterization of peptide identity and purity was performed by
LC/MS (Accela/LTQ, Thermo Finnigan) with a Hypersil GOLD
column (2.1650 mm) and MALDI-TOF/TOF MS (Voyager
4800, Applied Biosystems, Foster City, CA, USA). Peptides were
lyophilized and stored at 220uC before use.
Cell-based biosensor assay. Three independent replicate
experiments were performed for the time course with Western blot
detection. Three side-by-side replicate experiments with just one
time point (5 min) were performed for the MRM analysis. K562
cells were cultured to log phase growth and seeded to 56106 cells/
ml in a six-well plate (3 mL per well). When necessary, cells were
pre-incubated with imatinib (10 mM) for 1 h at 37uC followed by
incubation with three treatments: 25 mM peptide (dissolved in
PBS), 25 mM peptide +10 mM imatinib, and 25 mM peptide
+1 mM pervanadate (prepared by reacting a solution of sodium
orthovanadate with H2O2, followed by heating at 95uC to degrade
excess H2O2). At the indicated time points (5, 30, 60 min), aliquots
(1 mL) were collected and centrifuged (2200 rcf, 1 min, 4uC) to
remove excess media. To collect any remaining cells in the wells
Figure 2. Bcr-Abl activity detection using Abl substrate peptide in the human CML cell line K562. Bcr-Abl activity was detected using the
biosensor peptide in K562 cells at 5, 30 and 60 min (N= 3). Peptide and phosphopeptide were detected below the 15 kD molecular weight marker by
overlaid signal from IR-dye-labeled streptavidin (showing biotinylated peptide) and Western blot for antiphosphotyrosine (4G10). Phosphorylated
endogenous proteins Abl, STAT5 and CrkL, as well as b-tubulin as a loading control, were detected as described in the Materials and Methods.
Additional replicate blots shown in the supporting information. Quantification of total peptide (streptavidin bands) and phosphopeptide (4G10
bands) via raw data from integration of fluorescence intensity at the MW observed for the biosensor (without background subtraction) is shown (B) to
illustrate degradation of the peptide in the presence of phosphatase inhibitor, which may have contributed to the decrease in phosphopeptide signal
over time (C). White = peptide alone, grey = inhibition by Gleevec (imatinib/IM), black = phosphatase inhibitor sodium pervanadate (PV). Error bars
represent SEM from three independent experiments.
doi:10.1371/journal.pone.0056627.g002
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from the final aliquot, all wells were washed with phosphate
buffered saline (PBS, 400 ml) and these washes were combined
with the collected cells. Cells were suspended in PBS (1 ml) to
wash away excess peptide, centrifuged again (2200 rcf, 1 min,
4uC), and lysed using Phosphosafe Extraction Reagent (Novagen)
supplemented with EDTA and protease inhibitor cocktail (Roche).
Cells were immediately flash-frozen in liquid nitrogen, thawed on
ice for 15 min, vortex mixed, and centrifuged to clarify
(16,000 rcf, 15 min, 4uC). The supernatant was collected,
measured for total protein concentration using the BCA assay
(ThermoFisher Pierce, Rockford, IL), flash frozen again and stored
at 280uC until use.
Figure 3. Degradation of the Abl biosensor in K562 cells. After just 5 min of incubation with cells and ,2–3 min sample handling time, no
intact peptide biosensor (Mw: 4753.5) remains. Detected ions suggest that the biosensor peptide underwent C-terminal degradation in K562 cells,
leaving the N-terminal ‘‘reporter’’ region unperturbed. Representative degradation products are listed in the sequence table (C) and highlighted in
the MALDI-TOF spectrum (B). M/z values listed in the table refer to each degradation product and its photocleavable linker photolysis-related
derivative. Derivatives exhibiting net losses of 16 and 34 amu were also observed in the MALDI-TOF (but not ESI) MS spectra for the intact peptide.
These were likely due to laser-induced fragmentation of the nitro group on the photocleavable linker as described in the supporting information;
MALDI-TOF and ESI data for the intact peptide are also provided in the supporting information. A mock enrichment with K562 cell lysate alone is
shown for comparison (A). MS/MS analysis of a representative degradation product (1) is shown in the supporting information.
doi:10.1371/journal.pone.0056627.g003
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Enrichment and MALDI-TOF/TOF analysis. Biosensor
peptide from samples generated as described above (in the Cell-
based biosensor assay section) was captured using streptavidin-
coated MagneSpheres (Promega Corporation, Madison, WI). The
beads (20 ml) were prepared by washing with 0.1% Octyl-b-
glucoside/PBS (36150 ml). K562 cell lysates (200 mg total protein)
were incubated with the beads on a shaker (600 rpm, 60 min).
Beads were captured using a MagnaBot 96-well magnetic capture
device (Promega) and washed with 0.1% Octyl-b-glucoside/PBS
(36150 ml) and deionized water (36150 ml). Peptide was eluted
using 15 mL sample buffer (ACN/H2O/TFA, 50%/50%/0.1%).
0.5 mL from each sample was co-spotted with a-cyano-4-hydro-
xycinnamic acid (10% w/v) containing ammonium dihydrogen
phosphate (5 mg/ml), [22] dried and analyzed on a 4800 MALDI-
TOF/TOF Analyzer (ABSciex). Selected ions were analyzed by
MS/MS (specifying the parent ion mass for selection and CID)
and sequenced de novo.
Western blot analysis. Samples of equal protein content
(100 mg/lane) were diluted into Laemmli buffer and subjected to
SDS-PAGE. Proteins were transferred to nitrocellulose membrane
and analyzed by Western blotting. Membranes were split at the
15 kD mark and blocked in 3% milk in TBS-T overnight at 4uC,
followed by blotting with the indicated antibodies in 3% milk/
TBS-T. The bottom membrane was blotted with: DyLight-649
labeled Streptavidin (1:1000, ThermoFisher Pierce) to detect total
biosensor; 4G10 a-phosphotyrosine antibody to detect the
phosphorylated biosensor. Upper section of the membrane was
blotted with: a-phospho-Abl (Y245) (1:1000, Cell Signaling), a-
phospho-STAT5 (Y694) (1:5000, Abcam) and a-phospho-CrkL
(Y207) (1:1000, Abcam) to detect phosphorylation of endogenous
sites in the Bcr-Abl signaling pathway. a-b-tubulin (1:100,000,
Millipore) was used as a loading control. Blots were incubated with
IR-dye-labeled secondary antibodies (Rockland Immunochemical)
in 3% milk/TBS-T (1:10,000). Signals of immunoblots were
visualized using the Odyssey system (LiCOR Biosciences, Lincoln,
NE), quantified using densitometry with Quantity One (Bio-Rad),
and analyzed with GraphPad Prism software.
Sample preparation and digestion. Aliquots (18 mg each)
of cell lysate samples were processed to separate proteins from
lipids. [23] Chloroform/methanol/water (2:2:1.8 v/v/v) was
added to the samples and the mixture vortex mixed, followed by
centrifugation (5 min at 3000 rpm) to separate the chloroform and
aqueous layers. The aqueous layer was retained and extracted
again in the same manner, after which the chloroform layers
containing lipids were discarded. The extracted protein in the
aqueous layer was then precipitated with cold acetone prior to the
digestion protocol, in which the samples were taken up in
ammonium bicarbonate buffer (50 mM) containing 0.1% (w/v)
RapiGest SF (Waters Corporation, Milford, MA) to give protein
concentrations of 1 mg/ml. Dithiothreitol (DTT, 10 mM) was
added (1:1 per volume, for a final concentration of 5 mM) and the
sample incubated at 60uC for 30 min to denature the proteins.
After cooling to room temperature, samples were incubated in the
dark with iodoacetamide (final concentration 15 mM from
55 mM stock) for 30 min. Trypsin was added (0.5 mg) and the
samples incubated at 37uC for 18 h. Following digestion, samples
were treated with TFA (10% stock to give final concentration
0.2% w/v) at 37uC for 30 min. Samples were diluted with 0.01%
TFA to 0.5 mg/ml, centrifuged to clarify, and the supernatant
injected directly onto the triple quadrupole LC/MS system
(described below) for analysis (2 ml per sample, for a total protein
loading of ,1 mg). For calibration standards, Abl biosensor
peptide and synthetic reporter segment were added into lysate at
appropriate concentrations to result in 5–250 fmol per 2 ml
injection, then digested and prepared as described above.
LC-MS/MS analysis. Tryptic peptides were separated on a
nano-LC/MS system which included Agilent 1100 Series capillary
and nano flow pumps, micro-well plate sampler with thermostat,
and Chip Cube MS interface on the Agilent 6410 Triple
Quadrupole mass spectrometer (Agilent Technologies, Santa
Clara, CA). The peptides were loaded at 3 ml/min on an Agilent
chip containing a 40 nl enrichment column packed with Zorbax
300SB-C18 5 mm material. The enrichment column was switched
into the nano flow path after 5 min, and peptides were separated
with an analytical column (0.75 mm6150 mm) packed with C18
Figure 4. Calibration curve for detecting unphosphorylated and phosphorylated peptide using MRM. Synthetic versions of each
peptide were added into trypsin-digested K562 cell lysate and analyzed by MRM. Extracted ion chromatograms for each were generated (A),
integrated and plotted against input peptide to establish the calibration curve (B). Solid lines represent the 540604 transition from the
unphosphorylated peptide EAIYAAPFAK; dashed lines represent the 580480 transition from the phosphorylated derivative EAIpYAAPFAK. Error bars
(which are too small to be visible on the graph) represent standard deviation (SD) of two replicate analyses.
doi:10.1371/journal.pone.0056627.g004
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reverse phase ZORBAX 300SB-C18 5 mm material at a flow rate
of 0.3 ml/min. The chip is coupled to the electrospray ionization
(ESI) source of the triple quadrupole mass spectrometer. The
peptides were eluted from the column using a linear gradient of
increasing acetonitrile. For the first 5 min, the column was
equilibrated with 5% acetonitrile/95% water/0.1% formic acid
(mobile phase A) followed by a linear gradient of 5%–15% B
(100% acetonitrile/0.1% formic acid) in 10 min, 15–22% B in
30 min, and 22–100% B in 35 min. The column was washed with
100% B and then equilibrated with A before the next sample was
injected. Blank injections were run between samples to avoid
carryover.
Product ion scans were run on the triple quadrupole instrument
and analyzed using Skyline software [24] (MacCoss Labs, WA) to
develop a method to monitor transitions from each peptide of
interest. Quadrupole 1 and 3 were run at unit resolution with a
minimum dwell time of 30 msec. Using this method, peptides of
interest were analyzed by multiple reaction monitoring mass
spectrometry (MRM-MS). Standard peptides were synthesized
and diluted into stock solutions in deionized water (using dry
weight as measured by analytical microbalance) and concentration
curves (in fmol) were used for quantitation of the peptides in the
cell lysate samples.
Results and Discussion
Characterization of Biosensor Uptake and
Phosphorylation
We based the peptide biosensor assay for Bcr-Abl/Abl kinase
activity on our previously reported methodology, [17,18] applied
here to the disease-relevant, patient-derived CML model cell line
K562. We first characterized the uptake and phosphorylation of
the biosensor peptide in these cells using Western blot. To confirm
that intracellular Abl signaling was not disrupted in our system, we
probed cell lysates to examine the phosphorylation status of Bcr-
Abl’s autophosphorylation site and the endogenous Abl substrates
STAT5 and CrkL. Cells were cultured to log phase growth then
treated with the peptide EAIYAAPFAKKK(c-biotin)G-bNpa-
GCGGAPTYSPPPPPGGRKKRRQRRRLL in the presence or
absence of either imatinib or the phosphatase inhibitor pervana-
date for 5, 30 or 60 minutes. Then cells were harvested and lysed
in detergent buffer containing EDTA (to quench and prevent post-
lysis kinase activity), phosphatase inhibitors (to inhibit post-lysis
dephosphorylation of the biosensor) and protease inhibitors (to
inhibit post-lysis degradation) before being flash frozen in liquid
nitrogen. Lysates were processed as described in the Experimental
Procedures, separated by SDS-PAGE and analyzed by Western
blot using a two-color LiCOR scanner for quantitative detection of
IR-dye labeled secondary antibodies and streptavidin (to measure
total peptide signal via the biotinylated residue). As shown in Fig. 2
and blots from additional replicates provided in the supporting
information, the peptide was readily taken up into K562 cells and
phosphorylated, and the presence of EDTA (quenching kinase
activity) and phosphatase inhibitors (preventing dephosphorylation
of the peptide) in the lysis buffer indicated that the observed
phosphorylation of the biosensor was occurring in the cell before
lysis. As expected, phosphorylation was inhibited in the presence
of imatinib and stabilized in the presence of pervanadate. In the
presence of pervanadate, observed peptide levels decreased over
time (as shown in Fig. 2B and 2C, plotted from raw integration of
band intensities with no background subtraction). Since the lysis
buffer contained a cocktail of protease inhibitors, it was unlikely
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previous reports, [25] we found that this was due to degradation of
the peptide once it enters the intracellular environment.
To test this, we exploited the biotin affinity tag to capture
peptide from lysate generated after 5 min incubation and analyzed
it by MALDI-TOF/TOF mass spectrometry. Within just 5 min of
exposure to cells (as well as approximately 2–3 min additional
processing time for cell harvesting), essentially no intact peptide
was observed, even for samples treated with peptide alone (Fig. 3).
Several fragments were detected (along with photo-induced ion
chemistry intermediates arising from the UV laser ionization
inherent in MALDI-TOF analysis, also observed with the intact
peptide as further discussed in the supporting information) and
identified by MS/MS analysis to arise from C-terminal degrada-
tion. In particular, the cell permeability tag, TAT, was almost
completely removed from the C-terminus. However, the N-
terminal ‘‘reporter’’ sequence (which contains the phosphorylation
site for Bcr-Abl, see Fig. 1) was still intact–that is, no
corresponding N-terminally truncated fragments were observed.
Accordingly, the bands detected by streptavidin/4G10 in Fig. 2
likely represent these degradation products. Peptide in lysates was
enriched using streptavidin-coated magnetic nanoparticles
through the peptide’s biotinylated reporter segment. From this
Figure 5. Representative extracted transition chromatograms for each treatment condition. Full chromatograms are shown in row (A).
Expanded chromatograms for the region in which EAIYAAPFAK and EAIpYAAPFAK are expected to elute (based on the calibration curve) are shown in
row (B), and show that the relevant peaks had signal for both transitions from each analyte.
doi:10.1371/journal.pone.0056627.g005
Figure 6. Quantification of peptide amounts and percent phosphorylation. Total peptide detected is represented by each full bar in (A),
with the white portion representing the fraction of phosphopeptide and the gray fraction representing the fraction of unphosphorylated peptide. %
phosphorylation is shown in (B). Error bars in both represent SEM from three replicate biological experiments.
doi:10.1371/journal.pone.0056627.g006
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workflow, phosphorylated and unphosphorylated peptides could
be detected by MALDI-TOF in linear positive and negative mode,
however reproducibility and signal to noise were poor (example
spectra provided in the supporting information)–a problem we had
not previously encountered when working with engineered cell
lines. [18] Accordingly, a more sensitive detection strategy was
needed to robustly quantify the degree of biosensor peptide
phosphorylation by Bcr-Abl. In future work, it may be possible to
improve sensitivity and reduce ambiguity by eliminating the
photocleavable linker and stabilizing the peptide biosensor via the
incorporation of residues resistant to proteolysis; [25,26] however,
our first goal was to establish an optimized detection technology.
Development of the MRM Method for Quantitative
Analysis
We pursued MRM as a strategy to achieve better sensitivity in
the context of trypsin-digested whole cell lysate from cells
incubated with the biosensor peptide. A key advantage of MRM
is the ability to detect and reproducibly quantify targeted peptides
and phosphopeptides [19,20] with exquisite selectivity and
sensitivity. A further advantage for the peptide biosensor assay
was that the tryptic fragment arising from the ‘‘reporter’’ module
sequence is unnatural, and thus not subject to confounding
background from the native proteins in the cell lysate. Two
transitions for each peptide were included in the development of
the MRM method, to increase confidence in peptide identity. A
calibration curve was established for quantitation of the MRM
signal from the tryptic fragments of the biosensor peptide and its
synthetically phosphorylated derivative, which were added 1:1 at
various concentrations into trypsin-digested K562 lysate (1 mg/ml).
Signals for both the modified and unmodified form of the Abl
biosensor peptide were robust and linear between 5 and 250 fmol
(Fig. 4). Analytical coefficients of variation (CV) were between 1–
26% (depending on the transition). One transition from each
peptide was chosen for quantitative analysis based on its signal to
noise and CV across the calibration range (Table 1). Based on the
ratios of these transitions, the ratio of signals for the phosphor-
ylated and unphosphorylated peptides was approximately 1:1,
with a CV of 4.3% across the entire concentration range, giving us
confidence in the analytical reproducibility for quantifying the
percent phosphopeptide in a sample.
Analysis of Biosensor Phosphorylation
To analyze biosensor phosphorylation, K562 cells were
incubated with the biosensor for 5 minutes either alone or in the
presence of Bcr-Abl inhibitor (imatinib) or phosphatase inhibitor
(pervanadate) as described above. 1 mg of each cell lysate was
analyzed using the MRM method described above. MRM signal
data were extracted as chromatograms and the substrate peptide
and its phosphorylated derivative were identified by the presence
of both transitions in their respective peaks at the retention time
expected for these analytes from the calibration curve analyses.
Some background peaks were observed in each extracted
chromatogram (Fig. 5A), however none of these exhibited signal
for both transitions and the expected retention time. Because the
intensities of the total ion chromatograms (TICs) for each analysis
were not completely uniform, a characteristic, invariable peak in
the TIC was integrated and used to calculate a correction factor
for each MRM chromatogram. After this correction was applied,
the peaks specific to the unphosphorylated and phosphorylated
peptides were integrated and interpolated to determine the
amount of unphosphorylated and phosphorylated peptides in
each sample. As expected, both unphosphorylated and phosphor-
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alone (Figs. 5B and 6). No phosphorylated peptide was detected in
the samples pre-treated with imatinib, and higher levels (relative to
peptide alone) of phosphorylated peptide were detected in the
samples treated with phosphatase inhibitor. Differences between
% phosphorylation observed in the peptide only and peptide+-
pervanadate samples were statistically significant (p,0.05, one-
way ANOVA with Tukey post-test), as well as being significantly
different compared to the absence of phosphopeptide seen in the
peptide+imatinib samples (p = 0.044 and 0.025, respectively, one
sample t-test).
All peptides were detected at levels above both their LOD and
LOQ (Table 2). The fmol-scale levels of peptide detected here may
represent the entirety of material taken up into cells and isolated
by lysis, or it may represent the remaining reporter segment
present after some degree of degradation. MALDI-TOF analysis
of degradation indicated that N-terminal degradation did not
appear to be taking place, however it is still possible that the
fragments were just not observable. Future work to better
understand biosensor stability will address this. Nonetheless,
MRM-based detection of the N-terminal tryptic fragment was
for the most part reproducible: CVs for analyte quantification
were acceptable (20% for unphosphorylated and 23% for
phosphorylated species) for the samples treated with peptide
alone. CVs for the imatinib and pervanadate treated samples were
somewhat higher (,42% for total peptide detection, unpho-
sphorylated plus phosphorylated, from each) and considerably
higher (71%) for the amount of phosphopeptide detected in the
pervanadate treated samples. Comparing these results to the
Western blot detection described in Fig. 2, the CVs for
streptavidin band intensities from the experiment described in
Fig. 2 were lower for the peptide only and imatinib treated samples
(11% each) but comparable (32%) for the pervanadate treated
sample. CVs for the 4G10 signals of the peptide only (12%) and
pervanadate (68%) samples were more similar to the CVs from
MRM. For imatinib treated samples, 4G10 Western blot CVs
were much higher due to the background intensity which was not
a factor in the MRM analysis. While these two experiments and
methods cannot necessarily be directly compared (for example, the
analytical variabilities may be different between the two
techniques, and the ratio of 4G10/streptavidin signal is uncali-
brated and thus cannot give a % phosphopeptide), this at least
shows that the results from MRM analysis are correlated with
those observed using the traditional Western blot analysis. Based
on the excellent analytical CVs obtained from the MRM
calibration curve experiments, the higher CVs observed for the
imatinib and pervanadate treated samples most likely reflect
biological or sample processing and handling variability (e.g.
peptide uptake, the enzymatic reaction taking place, level of
phosphatase inhibition, and small differences in e.g. lysis and/or
handling) rather than analytical variability. When self-normalized
to represent the % phosphopeptide compared to total (Fig. 6B),
CVs were within an acceptable range (20–40%) for all samples,
given the biological variability involved in a cell-based enzyme
activity assay. [27].
Taken together, these results demonstrate that we can
accurately and reproducibly detect Bcr-Abl biosensor peptide
phosphorylation and inhibition in an intracellular assay. Using
K562 cells as a human CML model system, we showed substantial
improvements in the lower detection limits for the assay read-out
compared to our previous detection strategies. The amount of total
sample analyzed (1 mg) is equivalent to approximately 15,000 cells,
indicating that we can achieve several orders of magnitude
improvement in sensitivity compared to Western blot or MALDI-
TOF detection. [17,18] While the total number of cells processed
as demonstrated in this manuscript was .250,000, this level of
sensitivity and technical reproducibility for the detection method
should enable future miniaturization of the assay procedure and
application to clinical material.
Concluding Remarks
In this method development work, we demonstrated a peptide
biosensor-based assay for monitoring Bcr-Abl kinase activity and
inhibition in intact, live cells using MRM detection with
femtomole sensitivity and good reproducibility. SRM and MRM
have long been established as clinical tools for monitoring small
molecule metabolites, and are becoming more and more popular
for analysis of protein biomarkers from blood samples. Peripheral
blood mononuclear cell (PBMC) and serum samples are routinely
prepared by pathology laboratories and can either be sent to
contract facilities for MRM/SRM analysis or even analyzed in-
house, since many hospital labs now have the necessary
instrumentation and expertise. Therefore, it should be possible
to establish MRM-based biosensor assays as companion diagnos-
tics for kinase inhibitor therapy. Since mass spectrometry is also
capable of detecting many analytes simultaneously, expansion of
the suite of peptide biosensors to additional kinase targets for
multiplexed analysis in CML and other leukemias may allow this
strategy to be used in the future to analyze signaling profiles and
drug sensitivity for individual patients, enabling personalized
assessment of the therapeutic options from available kinase
inhibitors.
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containing additional data is available in PDF format.
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